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“Everything on Earth has a purpose, every disease an herb to cure it, and every person a mission….” 
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Neutrophils are short-lived leukocytes that migrate to sites of infection where they 
phagocytose, degranulate, and form Neutrophil Extracellular Traps (NETs). During NET formation, 
the nuclear lobules of neutrophils disappear, the chromatin expands and, decorated with 
neutrophilic granule proteins are expelled.  NET formation requires the generation of reactive 
oxygen species (ROS) by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is 
activated by the protein kinase C (PKC) activator phorbol-12-myristat-13-acetate (PMA). Bacteria, 
fungi, viruses, and microbial components and other immune cells are the physiological stimuli of 
NETs. NETs can be pathogenic, for example in sepsis, cancer, autoimmune and cardiovascular 
diseases. Therefore, the identification of NET formation inhibitors is of high interest. The focus of 
the project is the application of chemical biology techniques to study NET formation and identify 
small molecule inhibitors. 
A semi-automated high content phenotypic screen was developed using human neutrophils 
that can identify inhibitors of NET formation. For this purpose, established small molecule 
compound libraries were screened. The identified small molecule hit compounds were grouped into 
four categories based on their influence on nuclear morphology and cell viability. These groups are: 
group 1: viable cells with small nuclei; group 2: viable cells with large nuclei; group 3: dead cells 
with small nuclei; and group 4: dead cells and NET formation. Since this is the first assay of 
NETosis to be reported, it was patented.   
After the screening of commercial compound libraries, GW5074, a c-Raf kinase inhibitor that 
stopped NET formation with group 1 characteristics was identified. To investigate if the Raf-MEK-
ERK pathway is involved in NET formation, specific kinase inhibitors, GW5074 (c-Raf), U0126 
(MEK), Staurosporine (PKC) kinase inhibitors and the ERK inhibitory peptide (ERK) were tested. 
They were all identified as group 1 phenotype inhibitors. Ras, an upstream protein from Raf, was 
excluded as a key protein involved in the NET formation mechanism after testing indirect Ras 
inhibitors. Additionally, the involvement of the ERK pathway upstream of NADPH oxidase was 
proven. It was shown that anti-apoptotic proteins are expressed to allow NETosis to occur and are 
regulated by MAPK signaling pathway. The neutrophils phagocytic and degranulation functions 
were shown to be  uneffected in the presence of inhibitors. This work was published in Nature 
Chemical Biology (Hakkim et al., 2011). 
In addition to the ERK signaling pathway, the involvement of the eicosanoid pathway in NET 
formation was established. Arachidonic acid, diaglycerol and platelet activation factor, known 
activators of the eicosanoid pathway, were identified as triggers of NET formation. Furthermore, it 
was demonstrated that lipoxygenase (LOX) is required for NETosis by using specific LOX inhibitors 
that blocks NET formation. The COX signaling pathway was excluded due to the lack of inhibitory 
activity of the COX specific compounds. Traditionally in innate immunology, lipid signalling is known 
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to be involved in cell-to-cell communication. For NETosis, the involvment of this role it was 
confirmed by the identification of lipid bodies present on the NETs. It is hypothesized that the lipid 
bodies are composed of a signaling lipid. This work needs to be further established and is beyond 
the scope of this thesis. Our results elucidated a new function in leukocytes, leading to possibilities 
to develop a novel field in neutrophil biology. 
After screening the MPI Dortmund in-house-compound library, tetrahydroisoquinolines 
(THIQs) were identified as a novel class of NET formation inhibitors. THIQs inhibit NETosis at low 
micromolar concentration independent of the NET formation stimulus and at different stages of NET 
formation. Cells treated with THIQ 1 displayed decondensed nuclei and the phenotype was 
assigned to group 2, making this an inhibitor with a unique profile. As before, the influence of THIQs 
on the oxidative burst was studied. THIQs do not affect ROS formation suggesting that they act 
downstream of ROS formation. Next, the THIQs were biochemically tested on proteins that are 
involved in the mechanism of NET formation. Interestingly, none of these proteins were shown to be 
direct targets for the THIQs. Based on the structure activity relationship (SAR) of 100 THIQs, tool 
compounds suited for target identification were designed and synthesized. With these compounds, 
affinity-based proteomic experiments were performed on human neutrophil lysates. Unfortunately, 
no proteins were identified that were selectively enriched with the active probe in comparison to the 
control. The cellular target of the THIQs might not be a cytosolic soluble protein and is yet to be 
identified. 
A hallmark of many immune disorders is the overproduction and lack of degradation of 
NETs. NET formation inhibitors are considered promising candidates for the treatment of one 
autoimmune disease, systematic lupus erythematosus (SLE). Therefore, SLE patient-derived 
neutrophils were used to evaluate the ability of THIQs to inhibit NET formation in a physiologically 
highly relevant setting. THIQs inhibited NET formation efficiently in non-activated and PMA-
activated SLE patient neutrophils. These results clearly indicate that THIQs have great potential as 
tool compounds and as a starting point for the development of novel small molecule therapeutics. 
The study of the neutrophil NET formation enigma is a perfect example wherein a chemical 
biology approach can be applied successfully. A robust assay protocol was established allowing 
NET formation to be studied quickly and could be scaled up to a high throughput setup. Two novel 
signalling mechanisms were identified and added to the overall mechanism of NETosis. A novel 
small molecule NET inhibitor compound class was identified and added to the general toolbox 
developed by us and others to study NETs. 
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Neutrophile sind kurzlebige Leukozyten, die zu Infektionsorten wandern, wo sie 
phagoyztieren, degranulieren und  sogenannte Neutrophil Extracellular Traps (NETs, deutsch: 
Neutrophile Extrazelluläre Fallen) bilden. Während der NET-Formation lösen sich die nuklearen 
Lobuli der Neutrophilen auf, das Chromatin dehnt sich aus und wird zusammen mit neutrophilen 
Granulaproteinen in den extrazellulären Raum ausgestoßen. Bakterien, mikrobielle Komponenten, 
Pilze, Viren und andere Immunzellen gehören zu den physiologischen Aktivatoren der NET-
Formation. Die Bildung von NETs kann außerdem durch den Proteinkinase C (PKC) Aktivator 
Phorbol-12-myristat-13-acetat (PMA) induziert werden, der die Nicotinamid-Adenin-
Dinukleotidphosphat (NADPH) -Oxidase katalysierte Bildung von reaktiven Sauerstoffspezies 
(ROS) und so letztlich NET-Formation bewirkt. Die Formation von NETs kann auch in Krankheiten 
involviert sein, unter anderem in Sepsis, Krebs und Autoimmun- sowie Herz-Kreislaufkrankheiten. 
Aus diesem Grund ist die Identifizierung von NET-Bildungsinhibitoren von großem Interesse. Der 
Schwerpunkt dieses Projektes ist es kleine Moleküle, welche die NET-Formation inhibieren zu 
identifizieren und diese im Sinne eines Chemischen Biologie basierten Ansatzes zu nutzen um die 
Formation von NETs zu genauer zu untersuchen.  
Ein semi-automatisierter, multiparametrischer phenotypischer Screen zur Identifizierung von 
Inhibitoren der NET-Formation in humanen Neutrophilen wurde entwickelt und mehrere 
Substanzbibliotheken wurden in dem neuartigen Assay getestet. Die aktiven Substanzen wurden 
dann, basierend auf dem von ihnen induzierten Phänotypen in eine von vier Kategorien eingeteilt. 
Diese Kategorien waren: 1) Lebende Zellen mit kleinem Nucleus, 2) Lebende Zellen mit großem 
Nucleus, 3) Tote Zellen mit kleinem Nucleus, und 4)Tote Zellen die NETs gebildet haben. Dieser 
Assay war der erste seiner Art und wurde daher patentiert. 
In dem Screening von kommerziellen Substanzbibliotheken wurde GW5074, ein bekannter 
c-Raf Kinase Inhibitor, als Inhibitor der NET-Formation der Kategorie 1 identifiziert. Daher wurden 
weitere Inhibitoren des Raf-MEK-ERK Signalwegs auf ihren Effekt auf die NET-Formation hin 
untersucht. Die getesteten Substanzen GW5074 (c-Raf Inhibitor), U0126 (MEK-Inhibitor), 
Staurosporin (PKC Inhibitor) und das ERK inhibitory peptide (ERK Inhibitor) induzierten alle einen 
Kategorie 1 Phänotyp. Direkte Inhibitoren von Ras, einem dem Raf-MEK-ERK Signalweg 
vorgeschaltetem Protein, zeigten keinen Effekt, somit konnte eine Schlüsselfunktion von Ras in der 
NET-Bildung ausgeschlossen werden. Darüber hinaus wurde die Beteiligung des ERK-Weges 
upstream der NADPH-Oxidase nachgewiesen. Es wurde gezeigt, dass die Expression von anti-
apoptotischen Proteinen zur NET-Formation notwendig ist und dass dies durch den MAPK 
Signalweg kontrolliert wird. Die phagozytotische Aktivität und die Degranulierung von Neutrophilen 
bleibt durch die Inhibitoren der NET-Formation unberührt. Diese Ergebnisse wurden in Nature 
Chemical Biology veröffentlicht (Hakkim et al., 2011). 
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Neben dem ERK-Signalweg wurde die Beteiligung des Eicosanoid-Weges in der NET-
Bildung etabliert. Arachidonsäure, Diacylglycerin und Thrombozytenaktivierungsfaktor, bekannte 
Aktivatoren des Eicosanoidwegs, wurden als Auslöser der NET-Bildung identifiziert. Durch die 
Verwendung spezifischer Lipoxygenase (LOX) Inhibitoren konnte darüber hinaus gezeigt werden, 
dass LOX-Aktivität für die NET-Formation notwendig ist. Cyclooxigenase (COX) konnte unter 
Verwendung des selben Ansatzes als Schlüsselprotein ausgeschlossen werden. Aus der 
klassischen Immunolgie ist bekannt, dass Lipid-Signalling in der Zell-zu-Zell-Kommunikation eine 
wichtige Rolle spielt. Dies konnte in diesem Projekt durch den Nachweis von Lipid Bodies auf NETs 
auch für die NET-Formation bestätigt werden. Die genaue Rolle und Zusammensetzung dieser 
Lipid Bodies in NETs benötigt weitere Forschung und liegt außerhalb des Rahmens dieser Arbeit. 
Unsere Ergebnisse zeigen eine neue Funktion von Leukozyten, was zu Möglichkeiten der 
Entwicklung eines neuartigen Feldes in der Biologie der Neutrophilen führt. 
In dem Screening der internen Substanzbiblitohek des MPI Dortmund wurden 
Tetrahydroisoquinoline (THIQs) als ein neuartige Klasse von Inhibitoren der NET-Formation 
identifiziert. THIQs sind wirksam in Konzentrationen im niedirgen millilmolaren Bereich und 
inhibieren die Bildung von NETs unabhängig vom Stimulus der NET-Formation und in 
verschiedenen Stadien. THIQ 1 ist der einzige Inhibitor, der einen Kategorie 2 Phänotyp mit 
dekondensierten Nuclei bewirkt.  THIQs haben keinen Effekt auf die Bildung von ROS und in 
weiteren biochemischen Experimenten konnte kein direkter Einfluß auf bekannte, in die Bildung von 
NETs involvierte Proteine beobachtet werden. Basierend auf Untersuchungen bezüglich der 
Struktur-Wirkungsbeziehung von 100 THIQs wurden daraufhin Sonden zur 
Affinätschromatographie-basierten Identifikation der THIQ-Zielproteine entworfen und synthetisiert. 
Die in den anschließenden Pulldown-Experimenten konnten jedoch keine potentiellen Zielproteine 
identifiziert werden und somit ist das zelluläre Ziel der THIQs, be idem es sich eventuell um ein 
nicht-zytosolisches Protein handeln könnte, noch offen. 
Die Überproduktion und mangelhafte Degradation von NETs ist ein Kennzeichen vieler 
Autoimmunerkrankungen, insbesondere von Systemischen Lupus erythematodes (SLE). Inhibitoren 
der NET-Formation stellen daher ein vielversprechendes Ziel für dessen Behandlung dar. Die 
Wirksamkeit der THIQs auf nicht-aktivierte und PMA-stimulierte NET-Formation konnte in diesem 
Projekt erfolgreich an Neutrophilen von SLE-Patienten gezeigt werden. Die Wirksamkeit dieser 
Substanzen in einem physiologisch relevanten Modell unterstreicht das Potential dieser neuartigen 
Klasse von Inhibitoren der NET-Formation als funktionelles Molekül zur Erforschung der NET-
Formation und als Startpunkt für Entwicklung neuartiger Medikamente.  
Die Erforschung der NET-Formation in Neutrophilen ist ein perfektes Beispiel in dem ein 
chemisch-biologischer Ansatz erfolgreich angewendet werden kann. In diesem Projekt wurde ein 
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robustes Assayprotokoll zur Evaluation der NET-Formation etabliert und in ein 
Hochdurchsatzformat übertragen. Dadurch konnte eine Rolle von zwei Signalwegen in der 
Formation von NETs gefunden werden. Außerdem wurde eine neuartige Klasse von kleinen 
Molekülen mit der Fähigkeit die Formation von NETs zu inhibieren identifiziert, die auch 
Wirksamkeit in SLE-Patientenzellen Wirksamkeit zeigt. 
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1.1 Chemical biology and disease  
In science, the objective is to investigate natural phenomena and part of the challenge is to 
create solutions to problems that arise during the process. The development of new tools and new 
technologies is essential. Chemical biology is the division of science where chemical tools, usually 
small molecule probes, are used to study biological systems and events (Altmann et al., 2009). The 
possibilities and flexibility that they provide are diverse and in particular small molecules derived 
from nature – in essence natural products - have proven their value since the beginning of 
chemistry and biology (Doweyko and Doweyko, 2009; Eder et al., 2014; Wetzel et al., 2011).  The 
use of small molecules provides the possibility for full control over concentration, duration of 
exposure, protein modulation and phenotype manipulation. Another advantage is that these tools 
allow for rapid effect recording of effect and swift clearance. Being able to remove the tool 
compound quickly is a great advantage over permanent modifications such as gene knock-out or 
knock-downs, if these are even possible. Such genetic modifications are often lethal to the host 
limiting their use (Ziegler et al., 2013).  
Today, the focus for chemical biology is on finding solutions to problems such as better 
treatment for cancer; overcoming antibiotic resistance; engineering microbes that can function as 
small molecule factories; shortening the drug development pipeline or using technology for smarter, 
accurate and painless diagnostics (Kostic et al., 2016b). In order to study such complex processes, 
collaboration between many different scientific fields are required. Different disciplines that 
collaborate in a chemical biology project range from synthetic organic chemistry to immunology, 
from molecular biology and pharmacology, to biochemistry and bioorganic chemistry (Bucci et al., 
2010; Kostic et al., 2016a, b). A good example of a chemical biology approach is the application of 
“click” chemistry. The organic chemistry process of a click reaction is a diverse procedure that 
allows the generation of complex conjugated molecules performed in-situ in biological systems. 
Whether it is copper catalyzed or by Staudinger ligation, it has been applied in several fields such 
as bioconjugation, drug discovery, and materials science (Nwe and Brechbiel, 2009; Thirumurugan 
et al., 2013). The Bertozzi’s group successfully performed an in vivo biorthogonal chemistry click 
reaction in live cells, mice, and in zebrafish. This work provides labeling tools for imaging and target 
validation (Agarwal et al., 2015; Chang et al., 2010; Cohen et al., 2010). 
 Besides chemical biology approaches with specifically designed tools, nature has always 
been a good source of inspiration for small molecule probe design. Natural products are highly 
optimized for their purpose through evolution, making them excellent starting points for novel 
biological active compounds. Wetzel et.al. has depicted a natural compound scaffold tree to 
categorize scaffolds of interest with high potential of biological activity (Wetzel et al., 2009).  Large 
numbers of libraries have been synthesized based on these scaffolds (Doweyko and Doweyko, 
2009). A good example where such small molecules are used is in the study of reactive oxygen 
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species (ROS) (Dickinson and Chang, 2011). The generation of ROS is a fast complicated process 
making it challenging to study. Several small molecule tool compounds have been developed such 
as diphenyleneiodonium chloride (DPI), apronin, and pyrocatechol respectively an inhibitor, a 
scavenger and an activator of ROS formation. A common application of well-established 
compounds, inhibitors or activators, is use as controls. In research performed in ROS generation, 
small molecules are used as controls. These molecules allow for rapid manipulation of ROS 
formation unlike gene knockouts (Bolt et al., 2009; Saladino et al., 2008). 
As the scientific challenges increase in difficulty so do the complexity of the tools that are 
required. Studying a complex autoimmune disease or cancer requires the use of biological systems 
that result in complicated readouts. The use of stem cells and primary human cells for screening 
clearly fits these criteria, since it is far from simple. As it will be described in this thesis, we are the 
first to apply a combination of novel proposed (i.e. primary cell screens, new techniques of 
proteomics) and traditional solutions to a physiological problem, the study of neutrophil extracellular 
traps. 
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Neutrophil Extracellular Trap (NET) formation is a recently discovered response carried out by 
neutrophils in order to trap pathogens as part of the native immune response. Many details 
concerning the mechanism of action of this newly discovered type of cell death are still unknown. 
Their properties make neutrophils complicated cells to handle and there is no permanent cell line 
that can mimic NET formation. This means conventional procedures are not feasible and therefore 
we required the development of novel techniques and assays to study the phenomena. We 
postulated that chemical inhibitors of NET formation would allow us to identify key regulators of 
NETosis. Furthermore this work will lead to a better understanding of NET formation. 
The focus of this project is to identify small molecule modulators of NET formation and their 
molecular targets. These small molecule tools will be used to investigate the mechanisms and 
proteins involved in the generation of NETs. The study of NETs requires a collaboration of 
specialized biology and chemistry groups and consequently we started a collaboration between the 
Zychlinsky’s group (Max Planck Institute for Infection Biology in Berlin) and the Waldmann’s group 
(Max Planck Institute of Molecular Physiology in Dortmund). The work described in this thesis has 
been performed both in Berlin and in Dortmund.  
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White blood cells are the first cells that protect the human body against invading pathogens 
and are equipped with various defense mechanisms, sometimes at the cost of their own existence 
(Nathan, 2006). White blood cell is the colloquial name for the leukocytes. If the white cells are 
classified according to their cell structure they are named granulocytes. The most abundant type of 
granulocytes are neutrophils. Granulocytes consist of neutrophils, eosinophils and basophils and 
are part of the innate immune system. All granulocytes contain many lysosomes and secretory 
vesicles and are classified based on their chemical differences and function (Rivera et al., 2016). 
Neutrophils constitute more than ninety percent of the granulocytes in circulation and according to 
early studies the bone marrow produces 9x108 neutrophils/kg of body weight per day (Dancey et al., 
1976; Gunzer, 2014). Many of the immune cells are terminal cells, i.e cells that will not undergo cell 
division. These terminal cells, neutrophils, reside in the blood for approximately eight hours.  
3.1 Morphology  
Neutrophils were first named by Paul Ehrlich in the late nineteenth century (Amulic et al., 2012) 
for their capacity to retain neutral dyes. Their main physical characteristic is their lobulated nuclei 
giving them the name of “polymorphous nucleus” which caused them to be classified as 
polymorphonuclear cells (PMNs) by Elie Metchnikoff in 1893. The terms neutrophil and PMN are 
used interchangeably in this dissertation.  
Why do neutrophils have lobulated nuclei? To this day, there is no definite explanation (Figure 
1). One of the earlier theories was postulated by Metchnikoff and states that the lobulated nucleus 
facilitates passage to different sites in the body through blood vessels and small pores. No definite 
proof has been found to support this (Chou et al., 2010) and the notion may be incorrect because 
some experiments using human promyelocytic leukemia cells (HL60) cells, with the Pelger-Hüet 
anomaly (PHA) round nuclei phenotype, show the unaffected ability to cross membranes (Olins and 
Olins, 2004, 2005). Another possible explanation for the lobulated nuclei is the enhancement of 
phagocytosis since it provides more space in the cytoplasm for accepting pathogens (Carvalho et 
al., 2015). Notably, there has been no real evidence dictating an evolutionary need for 
polymorphonucleus. 
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Figure 1. Transition electron microscopy image of a neutrophil (Fuchs et al., 2007).  
 
3.2 Neutrophils source 
Neutrophils differentiate from precursor cells named hematopoetic stem cells in a process 
called myelopoiesis. This differentiation is a stepwise process starting with division into a 
multipotent precursor which further divides into a myeloid or a lymphoid progenitor. Subsequently, 
most of the differentiated myeloid cells become part of the innate immune response. Alternatively, 
those cells that differentiated from the common myeloid progenitors become part of the adaptive 
immune system (Bardoel et al., 2014; Borregaard, 2010). In the case of neutrophils their common 
progenitor is the myeloid cell or myeloblast, specifically, the granulocyte/macrophage progenitor cell 
and this differentiation process is termed granulopoiesis (Figure 2). Granulopoiesis is highly 
regulated by cytokine release (Bugl et al., 2012). The main cytokine involved are the granulocyte 
colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) 
(Mayadas et al., 2014). Inter-leukins (IL) regulate G-CSF production in peripheral tissues triggered 
with IL-23, IL-17, and the levels of G-CSF known as the G-CSF feedback loop. IL-23 is produced by 
macrophages and dendritic cells (DC) and induces the production of IL-17 by T helper cells, T 
lymphocytes and natural killer cells. This results in the neutrophil differentiation followed by the 
expression of G-CSF. Macrophages produce IL-23 after the clearing of apoptotic neutrophils, hence 
this process depends on the amount of neutrophils in circulation (Bardoel et al., 2014; Mayadas et 
al., 2014; Stark et al., 2005). An additional means of generating neutrophils is via emergency 
granulopoiesis (Basu et al., 2000) which is a reaction to the presence of foreign pathogens. The 
pathway is dependent on the particular pathogen. For example in the case of Listeria 
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monocytogenes GCSF is required for a neutrophil rapid response (Bardoel et al., 2014; 
Papayannopoulos and Zychlinsky, 2009b). However, it is not the case for Candida albicans where 
interleukin-1 (IL-1) is used (Altmeier et al., 2016; Basu et al., 2000). It is certain that when it comes 
to maintenance, the neutrophil numbers are controlled by constant exposure to pathogens.  For 
instance, germ-free mice suffer from serious neutropenia (low number of neutrophils) (Bugl et al., 
2013). In brief, homeostasis of neutrophils is regulated by the amount of available neutrophils. The 
number of available PMNs is dependent on phagocytosis, PMNs numbers in bone marrow, or 
external pathogens that trigger inflammatory responses. 
 
 
Figure 2. Neutrophil Granulopoiesis. The transition of the myeloid cell in the bone marrow to full maturation in 
the blood stream. Image modified from Kruger, et. al. (Kruger et al., 2015). 
 
3.3 Neutrophil Response 
After maturation, neutrophils migrate to sites of inflammation. PMNs are the first cells to 
infiltrate infected tissue and compose more than sixty percent of cells at the site of infection 
(Brinkmann and Zychlinsky, 2007; Papayannopoulos and Zychlinsky, 2009a). They are terminal 
cells and do not undergo cell division and as a result, as “ready-to-go” cells, they have to be able to 
pass through different environments and tissues to the target locations. In doing so they have 
alternative ways to use and re-use their weapons. The role that the neutrophil will perform is 
completely dependant on the activation, i.e. stimulus.  Stimulants include bacterial derived 
pathogen-associated molecular patterns (PAMPs), i.e. lipopolysaccharide (LPS) and N-
Formylmethionyl-leucyl-phenylalanine (fMLP). Also, chemoattractants and cytokines, i.e. tumor 
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necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, and IL-17; adhesion molecules produced by 
endothelial cells, i.e. P-selectins and E-selectins and the integrin superfamily intercellular adhesion 
molecules (ICAMs) can recruit neutrophils (Figure 2 and 3) (Borregaard, 2010; Kruger et al., 2015; 
Mayadas et al., 2014).   
 
3.3.1 How does the Neutrophil Response Work? 
Neutrophils are abundant and widely distributed throughout the body. Primary chemokines 
coordinate the equilibrium of the neutrophil release and retention. PMNs are released from bone 
marrow by stromal cells that produce C-X-C motif chemokine ligand (CXCL)-12 which is recognized 
by the C-X-C-motif chemokine receptor (CXCR)-4 on PMNs and induces neutrophil mobilization 
(Figure 2). The two main chemokines receptors expressed in neutrophils are CXCR1 and CXCR2 
which are responsible for retention and release of cytokines, respectively (Kruger et al., 2015; 
Martin et al., 2003). CXCR2 is the receptor for CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and 
CXCL8, all of which chemokines are responsible for neutrophil homeostasis in response to 
neutrophil number by releasing myeloid cells (Nauseef and Borregaard, 2014).  
 Myeloid cells (pre-neutrophil cells) are released from bone marrow when a disease state is 
detected. These cells are capable of recognizing a series of signals that lead directly to employment 
of their “attack” mechanisms and then on to maturation into neutrophils.  
The steps of the traditional adhesion cascade are (Figure 3):  
a) Capture: the initial attachment of the neutrophil to the endothelium close to inflammatory 
sites and performed by selectins; 
b) Rolling: neutrophils roll along the endothelium mediated by selectins; 
c) Firm adhesion: integrin-mediated rolling is stopped, adhesion and spreading of the 
 cells occurs; 
d) Crawling/transmigration: mediated by integrin’s and in which the neutrophil crawls through 
the endothelial space or tissue reaching the site of infection/inflammation.  
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Figure 3. Neutrophil recruitment and function. Once the neutrophil gets released, it captures, rolls and goes 
through the epithelial layer. Here it performs its function of phagocytosis, degranulation or NETosis. Image 
based on images from Amulic, et. al and Mayadas, et. al. (Amulic et al., 2012; Mayadas et al., 2014).  
 
3.4 Neutrophils Components 
Since neutrophils are the first line of defense against the invading pathogens, the chemical 
weapons used by neutrophils to kill bacteria substances are highly toxic. These substances are 
located, transported, and used by the neutrophil in a controlled manner to avoid unnecessary 
damage to healthy tissue. PMNs have developed special organelle-based storage and transport 
system and these organelles are called granules.  
3.4.1 Granules 
The neutrophil’s arsenal is composed of granular proteins, secretory vesicles, antimicrobial 
peptides, and antimicrobial proteins. The granules can be divided in three major types, azurophilic 
(primary), specific (secondary) and gelatinase (tertiary) granules. The secretory vesicles are usually 
referred to as a type of granule; and usually classified as the fourth group (Amulic et al., 2012; 
Borregaard, 2010). 
 Azurophilic granules are also known as primary or peroxidase-positive granules, named 
after their ability to take up dye azure A (Amulic et al., 2012).  They are the first type of granule upon 
maturation and are the largest in size (~0.3 µm in diameter) but also the last to mobilize. Some of 
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these primary granules include the following proteases: myeloperoxidase (MPO), lysozyme, 
inducible nitric oxidase synthase (iNOS), β-glucoronidase, bactericidal/permeability-increasing 
protein (BPI), and the serine containing proteases: neutrophil elastase (NE), cathepsin G (CG), 
proteinase 3 (PR3) (Faurschou and Borregaard, 2003).The secondary granules or specific granules 
are smaller (~0.1 µm in diameter) and are the second ones to mature. Their main component is the 
glycoprotein lactoferrin and they contain a wide range of antimicrobial proteins including neutrophil 
gelatinase-associated lipocalin (NGAL), human cathelicidin (hCAP-18) and lysozyme. The tertiary 
type of granule, or gelatinase granules, are the smallest and the last to be formed during 
maturation. They are composed of a few antimicrobials and used mainly for storage of 
metalloproteases, i.e. gelatinase and, leukolysin. The last class of organelles are the secretary 
vesicles. These are not granules by definition, though they are often classified in the granules 
(Figure 4). They are formed during endocytosis at the last stage of neutrophil maturation. Secretory 
vesicles are a reservoir for the membrane molecules and are used during neutrophil migration. 
3.4.2 Antimicrobial peptides and proteins 
An additional component of the neutrophil’s arsenal are the antimicrobial peptides and proteins, 
which are relatively small, <10 kDa, and produced in abundance.  Over 800 have been identified 
(Reddy et al., 2004). These peptides have become the focus of many studies and, most of the work 
performed with these peptides is based on in vitro experiments. The identification of neutrophilic 
antimicrobial proteins allowed their classification into three main categories: cationic, enzymatic, 
and the class of ‘depriving’ proteins (Amulic et al., 2012; Brogden, 2005). 
Cationic peptides comprise the main group of peptides in neutrophils and usually bind to 
negatively charged microbial cell membranes producing pores, thereby causing membrane 
permeabilization. Cationic peptides can also inhibit DNA and RNA biosynthesis or can disrupt 
bacterial biofilms. These peptides include defensins, mainly α-defensins, and cathelicidins. 
Defensins have multiple disulfide bonds that under physiological conditions change structure and 
become more active (Schroeder et al., 2011). Their main function is to permeabilize the bacterial 
wall via formation of pores and to inhibit RNA and DNA synthesis. LL-37 is the most intensively 
researched of all the cathelicidins. LL-37 stimulates neutrophil chemotaxis, increases chemokine 
receptor expression, induces cytokine production, decreases apoptosis as well as potentiating other 
immune cells, for example dendritic cells (Lande et al., 2011; Lande et al., 2007; Mayadas et al., 
2014).  The other class of neutrophil components are antimicrobial proteins which are categorized 
as either cationic proteins, proteolytic enzymes or metal chelator proteins. The cationic proteins 
include bactericidal, or permeability-increasing protein (BPI), that binds to lipopolysaccharide (LPS) 
resulting in an increase in cell permeability and hydrolysis of bacterial phospholipids (Canny and 
Levy, 2008), and histones, which besides their major role in DNA packaging are excellent 
antimicrobials. The second class of antimicrobial proteins are the proteolytic enzymes that 
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participate in the dismantling of the bacterial cell wall. Important proteins in this group include 
lysozyme, serine proteases, and azurocidin. The serine proteases Proteinase 3 (PR3), neutrophil 
elastase (NE) and Capthepsin G (CG) are highly regulated by serpins and only released under 
specific conditions (Campanelli et al., 1990; Weinrauch et al., 2002). Finally, metal chelator proteins 
function as antimicrobial proteins by chelating the pathogen metal load and thereby limiting bacterial 
growth. As examples lactoferrin binds iron while calprotectin is active in binding zinc (Amulic et al., 
2012). 
 
Figure 4. Neutrophil components. Neutrophils have a polymorphous nucleus; azurphilic, specific and tertiary 
granules and phagosomes. Phagosomes are equipped with proteases that release ROS. Neutrophils also 
express receptors for cytokines and chemokines that enables the communication to other cells.   
 
3.4.3 Reactive Oxygen Species 
Reactive oxygen species (ROS) are a collection of oxygen-based reactive molecules which 
include radical species (O2•-, and OH•), non-radical hydrogen peroxide (H2O2) and hypochlorous 
acid (HOCl) (Hayyan et al., 2016). ROS generation in neutrophils is a cascade starting with a 
respiratory burst, or other increase in oxygen consumption, to produce superoxide (O2•-) by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. This enzyme reduces oxygen into 
superoxide (O2-) (Mayadas et al., 2014). In turn, superoxide dismutase (SOD) converts O2- into 
(H2O2) (Fuchs et al., 2007; Metzler et al., 2011) and myeloperoxidase (MPO) converts H2O2 to 
(HOCl) (Hampton et al., 1998). NADPH oxidase complex is composed of p47phox, p67phox, and 
p40phox that migrate to the membrane and form the complex by binding with membrane proteins 
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gp91phox (NOX2) gp22phox and GTPase Rac (Rac1 and Rac2) (Kleniewska et al., 2012). Besides 
ROS generation, NAPDH oxidase regulates inflammation by activating redox cascades that signal 
to other cells (Seger, 2010). Superoxide is involved with the change in ionic flux in the phagosome 
(Reeves et al., 2002) (Figure 4). 
The main function of ROS is eliminating antimicrobial activity through decarboxylation, 
deamination or peroxidation (Bardoel et al., 2014). Indirectly ROS can kill pathogens by modulation 
of phagocyte proteinase activity (Williams, 2006). ROS is involved in signaling via the oxidation of 
cysteine residues of several proteins, change in the ionic influx and signaling to host molecules 
(Amulic et al., 2012; Winterbourn et al., 2006). Another important ROS species is nitric oxide (NO), 
a short-lived and highly reactive molecule produced by inducible nitric oxidase synthase (iNOS) and 
found in primary granules of neutrophils (Evans et al., 1996). Additionally, superoxide reacts with 
NO thereby producing high levels of peroxynitrite. 
Regulation is a highly sensible step in ROS generation, since an overproduction will result in 
uncontrollable oxidation and high damage to regular tissue. On the other hand, inhibiting ROS 
production in neutrophils can be dangerous, for example in the case of chronic granulomatous 
disease (CGD) which is caused by a mutation in the NADPH oxidase complex. These patients 
cannot produce ROS and are consequently very inefficient in killing pathogens leading to severe 
infections (Kuhns et al., 2010; Winkelstein et al., 2000). 
3.5 Neutrophil Defense Mechanisms 
PMNs can interact with other cells, both immune and non-immune. Neutrophils communicate 
with macrophages, B and T lymphocytes, mesenchymal stem, dendritic and natural killer cells, and 
platelets. As mentioned previously, PMNs communicate with endothelial cells when translocating 
throughout the body (Scapini and Cassatella, 2014). In the following section, the mechanisms in 
which the neutrophil responds in a sites of infection. This will include the secretion of cytokines, 
degranulation, phagocytosis, and generation of neutrophil extracellular traps. 
3.5.1 Phagocytosis 
Phagocytosis is the process of pathogen ingestion by the neutrophil. It takes place in a vacuole 
in the neutrophil called a phagosome. Phagocytosis is the major mechanism that neutrophils 
employ to fight infections. Phagocytosis is a very fast process, considering it includes such major 
changes as physical uptake of particle, intracellular signaling cascades, and major cytoskeletal 
rearrangements (Figure 3) (Amulic et al., 2012; Vieira et al., 2002). For example, it takes as little as 
20 seconds for IgG-opsonized particles to be phagocytosed by neutrophils (Segal et al., 1980). 
Phagocytosis is triggered by the pattern-recognition receptors of microorganisms, or by opsonic 
receptors, i.e. FcɣRs, C-type lectin receptors, or complement receptors. After activation, the particle 
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or pathogen is taken up while the phagosome granules fuse and NADPH oxidase complex is 
assembled and becomes active (Lee et al., 2003). 
This process called phagosome maturation is an extremely toxic combination for bacteria. 
Compared to the phagosome of macrophages, the neutrophil phagosome is neutral, with alkaline 
periods during which serine proteases, i.e. NE and CG, are activated (Jankowski et al., 2002).  Ion 
channels play a major role in phagosomal maturation, in which cytosolic calcium ions are essential. 
Potassium (K+) channels activate, in response to the NADPH oxidase, the release of granular 
proteases. Phagocytic receptors are triggered by immune complexes or by tissue damage (Amulic 
et al., 2012; Lee et al., 2003; Mayadas et al., 2014). 
3.5.2 Degranulation 
Degranulation is the release of antimicrobial molecules (previously described in Section 3.4) in 
response to a stimulus. Many immune cells are capable of degranulation, for example granulocytes, 
mast cells, T- cells and natural killer (NK) cells (Figure 3). In human neutrophils, granules are more 
than just storage-units that become activated during inflammation. Granules mobilize once the cell 
has activated in response to pathogen invasion or an inflammatory response. The secretory 
vesicles are the particles that take most advantage of the degranulation process compared to the 
azurophilic granules or gelatinase granules since they are harder to mobilize and more likely to be 
expelled via exocytosis (Faurschou and Borregaard, 2003; Lominadze et al., 2005). 
In section 3.3.1, the main steps of the neutrophil recruitment and maturation were described. 
During capture, when the neutrophil interacts with the endothelium, in response to the selectin and 
chemoattractant interaction, the secretory vesicles mobilize (Figure 3). The merging of the 
secretory vesicles with the plasma membrane exposes the components to the external environment 
resulting in the step known as firm adhesion. Once the PMNs start to travel through the endothelial 
space, a process called transmigration or crawling (both terms are used interchangeably in the 
literature). Signaling leads to the mobilization of gelatinase granules. The metalloproteases released 
during this process aid the traverse movement of the neutrophil. Once the PMN reaches the site of 
infection, oxidative burst occurs and the azurophilic and specific granules mobilize and kill 
pathogens (Amulic et al., 2012; Faurschou and Borregaard, 2003; Mayadas et al., 2014). 
 
 
 
 
- 20 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 21 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 22 - 
 
1 
2 
3 
4 
5 
6 
7 
Chapter 4: Neutrophils Extracellular Traps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 23 - 
 
In 2004, Zychlinsky and colleagues reported the first visual recording by microscopy of the 
release of extracellular chromatin fibers decorated with cytoplasmic granules and histones produced 
by a neutrophil. This is the official discovery of the neutrophil extracellular trap (NET) (Brinkmann et 
al., 2004). For quite some time, scientists have described extracellular fiber like structures present 
in their samples. Due to the lack of advanced microscopy techniques they were considered as 
artifacts. Since then, the process of NET formation was coined NETosis. NEtosis describes a new 
form for neutrophils to confine infections that results in expulsion of extracellular DNA traps 
(Brinkmann et al., 2004; Fuchs et al., 2007; Steinberg and Grinstein, 2007). 
Neutrophils are not the only cells that can undergo extracellular trap formation. Cells like are 
eosinophils (Yousefi et al., 2008), mast cells (von Kockritz-Blickwede and Nizet, 2009), monocytes 
and macrophages (Chow et al., 2010) all share similarities in molecular mechanism. Upon 
activation, neutrophils undergo drastic nuclear changes, i.e., chromatin decondensation and nuclear 
envelop disintegration, cytoskeleton rearrangement and release DNA extracellularly (Brinkmann et 
al., 2004; Fuchs et al., 2007; Hakkim et al., 2011; Urban et al., 2009) (Figure 5). 
 
 
Figure 5. Morphological changes during Neutrophil extracellular trap (NET) formation. Upon stimulation with 
PMA, neutrophils undergo a series of drastic changes, specifically in the nucleus. In the first 20 minutes ROS 
are released and azurophilic granules migrate to the nucleus where the nucleus gets delobulated followed by 
chromatin decondensation. Finally, the chromatin is released extracellularly.  
 
4.1 How do NETs work? 
NET formation is a programmed cell death mechanism that can be monitored via three methods: 
quantification of extracellular DNA using a dye that binds double stranded DNA, such as Picogreen 
after deoxyribonuclease (DNase) treatment; morphologically, i.e. monitoring DNA using DNA-
binding dyes with a microscope; molecular mechanisms, using known processes involved in NET 
formation like oxidative burst or cell death.   
The unique neutrophil nuclear morphology was introduced in the previous chapter and the focal 
peculiarity was the multi-lobulated shape. Undoubtedly, transformation in nuclear morphology will 
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be the most dramatic change to be monitored in the phenomenon of NET formation (Carvalho et al., 
2015; Fuchs et al., 2007). During NETosis the nucleus rearranges and the nuclear lobules are lost, 
accompanied by chromatin decondensation, a detachment of the inner from the outer nuclear 
membrane and a simultaneous disintegration of the granules. This is followed by disintegration of 
the nuclear envelope causing the cytoplasm and nucleoplasm to mix homogenously. The final step 
is the ejection of the cellular content into the extracellular space (Fuchs et al., 2007). 
Recently, thanks to modern microscopic techniques, several proteins and processes have been 
connected to NETosis. Three main classes of NET formation mechanisms were described in 
literature: ROS-dependent, ROS-independent and the non-cell death mechanism. B. Yipp and P. 
Kubes introduced the terms of suicidal vs. vital NETosis (Yipp and Kubes, 2013). The main 
characteristic of suicidal NETosis is the activation of Protein Kinase C that results in cell death. 
During vital NETosis which is activated by direct microbe exposure, rupture of the outer cell 
membrane does not occur. Another difference is the timeframe, in suicidal NETs occur between 90 
and 180 min. In the case of vital NETs occur in 5 to 60 min (Yipp and Kubes, 2013). Many other 
research groups have generated their own interpretation of the formation of NETs. Yousefi et. al. 
differentiates between NET formation vs NETosis which correlates to the difference between 
suicidal and vital NETosis (Yousefi and Simon, 2016). The terms NETosis, NET formation and NET 
generation will be used interchangeably in this thesis. 
4.1.1 Mechanisms of NET formation 
The ROS dependent mechanism was the first type of NETosis described. This ROS dependent 
mechanism was studied by activating neutrophils with PMA. NADPH oxidase catalyzes the 
conversion of O2 to O2
-.  Followed by conversion of O2
- to H2O2 by SOD catalysis, which inturn is 
catalyzed by MPO catalyzes to producing HOCl from H2O2 (Patel et al., 2010; Urban et al., 2009). 
These redox reactions have two main purposes: cell signaling and bacterial killing. The ROS cell 
signaling is for the mobilization and maturation of granules. Simultaneously, ROS production 
recruits other immune cells (Campos et al., 2007; van der Linden and Meyaard, 2016).   
While studying NETosis, Remijsen observed vacuolization in CGD patient cells and 
hypothesized that the vacuolization was caused by autophagy (Remijsen et al., 2011) which is the 
lysosome-regulated disintegration of intracellular components allowing organelle and protein 
regeneration for maintenance of cytoplasmic homeostasis (Rubinsztein et al., 2012). Remijsen and 
colleagues proved that autophagy plays a role in NETosis by monitoring the distribution of the 
microtubule-associated protein light chain 3 (LC3) which is transfered into the vacuoles in a pattern 
typical for autophagy. Also, they were able to stop the process by using traditional autophagy 
inhibitors such as wortmanin. They postulate that vacuolization typical for autophagy is necessary to 
allow the mixing of the chromatin with the granules before being expelled outside of the cell.  
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Epigenetics plays a role in NETosis. Reported in literature is the histone hypercitrullination which 
mediates the chromatin unfolding via deamination of the histones through conversion of the arginine 
side chains in histones to citrullines. The hypercitrullination is regulated via the peptidyl arginine 
deiminase-4 (PAD4). PAD4 replaces the arginines, which are positively charged, with an uncharged 
citrulline and directly affects the rapid nuclear decondensation (Cooper et al., 2013).  
ROS generation releases granules such as NE and MPO, where NE migrates to the nucleus 60 
minutes after stimulation. Once in the nucleus NE digests histones, specifically degrading histones 
H2B and H4 leading to DNA decondensation (Papayannopoulos et al., 2010). Slower than NE, 
MPO migrates to the nucleus after 120 min stimulation and also aids in DNA decondensation 
(Metzler et al., 2011; Papayannopoulos et al., 2010). Additionally MPO was found to be required for 
the release of NE from the granules in the cytosol during NET formation (Metzler et al., 2014). 
Hypercitrullination together with the NE histone degradation have been identified as required for 
chromatin decondensation. 
The suicidal part of the NETosis has been the topic of much controversy. Many immunologists 
have stated that the cell sacrifice is a high price to pay and seems extreme, especially in 
combination with the complications related to release of cell contents into the tissue environment. 
Non-cell death ETosis, also known as vital NETosis, has been reported (Clark et al., 2007). 
Here an extracellular DNA release was observed while the cell membrane of the PMNs remained 
complete. A detailed mechanism of this ETosis was described by Kubes and colleagues who 
reported that vesicles with DNA are passed though the cytoplasm, merged with the plasma 
membrane and expelled out of the cell with no membrane perforation (Pilsczek et al., 2010; Yipp 
and Kubes, 2013). The non-cell death NETosis does employ ROS, although the role of this 
compound has not been specified its involvement has been proven to be essential for granular 
mobilization, cellular response and inflammation. Other cells were also found to perform ETosis. 
Yousefi and colleagues reported a “catapult-like” expulsion of mitochondrial DNA by eosinophils 
keeping the cells viable. This cell death has also been termed as vital NETosis. This ETosis can be 
stimulated by IL-5 and LPS and is inhibited by the NADPH oxidase inhibitor DPI (Yousefi et al., 
2009). The mayor activators are bacteria, in particular gram-positive bacteria, such as 
Staphylococcus aureus (Pilsczek et al., 2010). 
The last NET formation mechanism that has been reported is ROS-independent NET formation. 
This is by far the most controversial mechanism since it is the most occult of all three mechanisms. 
There has been no experimental proof that supports the exclusion of ROS. This ROS- independent 
NETosis mechanism is based on calcium-influx and the activation of calcium- influenced pathways. 
This is a huge contradiction to well-established data reported in the literature for years. The finfings 
in the literature state that stimulating cells, including PMNs, with ionomycin causes ROS generation 
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(Walker et al., 1991). They activated NET formation with ionomycin in differentiated human 
promyelocytic leukemia (HL-60) cells and neutrophils (Parker et al., 2012). Using the same cell 
system, Douda et. al. later demonstrated that calcium induced NETosis requires mitochondrial ROS 
and the involvement of the SK3 ion channel. They proved that different kinase mechanisms are 
involved. When NETosis is activated by PMA, ERK is required while when activated by calcium 
ionophore A23187, AKT is the required kinase. They changed the name of the mechanism to 
NADPH-oxidase-independent NETosis rather than ROS-independent (Douda et al., 2015). 
4.2 What are NETs composed of?  
NETs are composed of DNA, serving as a backbone, decorated with antibacterial proteins. 
The chromatin fibers were studied via high resolution scanning electron microscopy and were 
described as smooth fibers that are approximately 15 nm in diameter with globular structures of 30 
to 50nm. The globular structures are conformed of antibacterial neutrophil proteins (Brinkmann and 
Zychlinsky, 2007). Urban and colleagues performed a proteomic study of NETs. As the interest in 
NETs has grown so has the list of identified NET proteins. Table 2 displays the proteins that 
compose NETs (Urban et al., 2009). 
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Table 2. Summary of the protein composition of NETs. 
 
*Most abundant proteins found on NETs. 
a 
Proteins identified via proteomic approach by Urban, C. et.al. 
(Urban et al., 2009). 
 
 
Granules Neutrophil elastase*
a ELA2/P08246
Lactotransferrin
 a LTF/P02788
Azurocidin
 a AZU1/P20160
Cathepsin G
 a CTSG/P08311
Myeloperoxidase
 a MPO/P05164
Leukocyte proteinase 3
 a PR3/P24158
Lysozyme C
 a LYZ/P61626
DEFA-1 and -3
P59665, P59666
Nucleus Histone 1 H1F0/P07305
Histone H2A *
 a H2A/Q9NV63+
Histone H2B
 a
: H2B/Q16778+
 a) Histone H2B*
 a 
 b) Histone H2B-like 
a
Histone H3*
 a H3/Q71DI3+
Histone H4*
 a H4/P62805+
Cytoplasm S100 calcium-binding protein A8*
 a S100A8/P05109
S100 calcium binding protein A9
 a S100A9/P06702
S100 calcium-binding protein A12 
a S100A12/P80511
ACTB, ACTG1 
P60709, P63261
Myosin-9
 a MYH-9/P35579
ACTN1, ACTN4
P12814, O43707
Plastin-2
 a LCP1/P13796
Cytokeratin-10 
a KRT-10/P13645
Fibronectin FN1/P02751
Peroxisomal Catalase
 a CAT/P04040
Glycolytic enzymes Alpha-enolase 
a ENO1/P06733+
Transketolase
 a TKT/P29401
Cathelicidin CAMP CAP18 FALL39
LL-37 P49913 
Membrane/Secreted
Gene name 
Swissprot/TREMBL
Protein nameCellular localization
BPI/P17213
H2B/Q3KP43,Q6GMR5
MNDA/P41218
Alpha-actinin (1 and/or -4)
 a 
Cytoskeleton Actin (P and/or R)
 a 
Myeloid cell nuclear differentiation 
antigen
 a 
Bactericidal permeability-increasing 
protein
Neutrophil defensin 1 and 3
 a 
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4.2.1 Neutrophil Elastase 
In earlier chapters neutrophil elastase (NE) was introduced as a neutrophil-specific protein. 
Consequently it is of high interest to study the role of NE in the context of NETosis (Bardoel et al., 
2014).  NE cleaves a variety of proteins, i.e. enterobacterial virulence factors, quite specifically, and 
protects against both gram-positive and gram-negative bacteria and fungal infections (Weinrauch et 
al., 2002). Papayanoupolous et al. demonstrated that NE is required in the formation of NETs via 
histone degradation. NE antibodies are used as the main marker for the identification of NETs 
together with a nuclear dye in all microscopy experiments. Interestingly, NE knock out mice are 
hardly used as a direct proof for NET mechanistic studies since humans with NE mutations suffer 
strong infections and NE knockout in mice leads to neutropenia. Neutropenia leads to a separate 
series of defects in mice and therefore introduces issues that might not be linked directly to the 
effects of NE on NET mechanisms (Amulic et al., 2012). 
4.2.2 Myeloperoxidase 
Myeloperoxidase (MPO), like NE, is a very abundant neutrophil protein stored in azurophilic 
granules (Schultz and Kaminker, 1962). MPO is an important component in the oxygen-dependent 
killing by neutrophils through the production of oxidants. MPO catalyses the conversion of hydrogen 
peroxide to hypochlorous acid (H2O2 to HOCl) which is a very potent antimicrobial agent (Klebanoff, 
2005). Unlike NE, MPO-deficiency is not common in humans and has minor effects with regard to 
the overall health of the patient. Infections are the main concern for MPO-deficient patients since 
they have defective intercellular killing. The most common infection is caused by Candida albicans 
that can occasionally cause serious health effects. This stability has led to the use of MPO-deficient 
human patients and MPO-deficient mice for NETosis studies. The MPO work was led by Metzler et. 
al. where joint studies of NE and MPO were addressed and led to the finding that both proteins 
translocate to the nucleus and aid in DNA decondensation (Metzler et al., 2014; Petrides and 
Nauseef, 1998).  
4.3 What triggers NETs? 
Neutrophil mechanisms were discussed in section 3.5 and activators of those mechanisms 
were briefly mentioned. It is no coincidence that NET formation is triggered by similar stimuli. Often 
NETosis is seen as the last resort of the cell and the stimuli are often presented in high 
concentrations or in combination with other stimuli. NETosis is activated by PAMPs of a wide range 
of microbes including bacteria, fungi, virii and eukaryotes. Table 3 summarizes the known 
pathogenic stimuli of NET formation and table 4 summarizes the known molecular, non-bacterial 
stimuli for NETosis.  
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Table 3. Known pathogens that induce NET formation.   
 
 
 
Microorganism Name Type NETosis Type
Fungus
Aspergillus 
fumigatus
Suicidal (Bruns, lung 2010) 
Candida albicans Yeast
Suicidal, Vital (Urban et al., 
2009)
Cryptococcus gatti Yeast Suicidal (Springer et al., 2010)
Cryptocococuss 
neoformans
Yeast Suicidal (Urban et al., 2009)
Bacteria
Enterococcus 
faecalis
Gram positive Suicidal (Lippolis et al., 2006)
Listeria 
monocytogenes
Gram positive
Vital, Suicidal (Ermert et al., 
2009) 
Mycobacterium 
canetti
Gram positive Vital (Ramos-Kichik et al., 2009) 
Mycobacterium 
tuberculosis
Gram positive Vital (Ramos-Kichik et al., 2009) 
Staphylococcus 
aureus
Gram positive
Vital, Suicidal (Brinkmann et al., 
2004; von Kockritz-Blickwede and 
Nizet, 2009)
Streptococcus 
dysgalactiae
Gram positive Vital (Lippolis et al., 2006)
Streptococcus 
pneumoniae
Gram positive
Vital, Suicidal (Beiter et al., 2006; 
Crotty Alexander et al., 2010) 
Streptococcus 
pyogenes
Gram positive
Vital (Buchanan et al., 2006; von 
Kockritz-Blickwede and Nizet, 2009) 
Escherichia coli Gram negative
Suicidal (Lippolis et al., 2006; 
Webster et al., 2010) 
Haemophilus 
influenza
Gram negative Suicidal (Hong et al., 2009) 
Helibactor pylori Gram negative Suicidal (Hakkim et al., 2011) 
Klebsiella 
pneumonia
Gram negative
Suicidal (Papayannopoulos et al., 
2010)
Pseudomonas 
aeruginosa
Gram negative
Suicidal (von Kockritz-Blickwede 
and Nizet, 2009)
Serratia 
marcescens
Gram negative Suicidal (Lippolis et al., 2006)
Shigella flexneri Gram negative
Suicidal  (Brinkmann et al., 
2004)
Virus
Human 
Immunodeficiency 
Virus-1 (HIV-1)
(Saitoh et al., 2012)
Eukaryota Eimeria bovis Parasite (Behrendt et al., 2010)
Leishmania 
amazonensis
Trypanosoma (Guimaraes-Costa et al., 2009)
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Table 4. Known non-bacterial stimuli of Neutrophil Extracellullar Traps   
 
 
 
Stimuli Pathway / Component NETosis Type Reference
Single
PKC 
ERK 
ROS
Histone citrullination
NE and MPO relocation
Actin (Guimaraes-Costa 2009)
PKC
ERK
ROS 
PKC
ERK 
ROS
ROS
PAD4
Histone citrullination
Actin
ROS
PAD4
Glucose oxidase (GO) ROS Suicidal
(Fuchs et al., 2007; 
Oehmcke et al., 2009) 
Nitric oxide donors ROS Suicidal (Patel et al., 2010)
ROS
PAD4
Histone citrullination 
PAD4
Actin
Leukotoxin CD18 NA
Histone citrullination
PAD
ROS 
Cathelicidin
ROS
Histones
Panton-Valentin leukocidin ROS Viable (Pilsczek et al., 2010)
Uric acid ROS Viable (Arai et al., 2014)
Mixtures
ROS
Mitochondrial DNA
ROS
Mitochondrial DNA
Cells
ROS
TXA2 
ERK 
Calcium ionophore NA (Wang et al., 2009)
Phorbol 12-myristate 13-
acetate (PMA)
Suicidal
(Brinkmann et al., 2004; 
Hakkim et al., 2011)
Platelet activation factor 
(PAF)
Suicidal (Hakkim et al., 2011)
1-2-dioctanoyl-sn-gylcerol 
(diacylglycerol (DAG) 
analog)
Suicidal (Hakkim et al., 2011)
Lipopolysaccharide (LPS) NA
(Li et al., 2010; Ramos-
Kichik et al., 2009) 
Hydrogen peroxide Suicidal (Li et al., 2010)
Interleukin-8 (IL-8) NA
(Ramos-Kichik et al., 
2009)
Tumor necrosis factor 
(TNF) α
NA (Wang et al., 2009)
M1-protein-fibrinogen 
complex
NA 
(Lauth et al., 2009; 
Oehmcke et al., 2009) 
Statins NA (Chow et al., 2010)
Granulocyte macrophage 
colony stimulating factor 
(GM-CSF) + C5a
Viable (Yousefi et al., 2009)
GM-CSF + LPS Viable (Yousefi et al., 2009)
Thrombin receptor 
activated peptide (TRAP) 
activated platelets
Viable (Caudrillier et al., 2012)
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4.4 NETs purpose 
Neutrophils are filled with many antimicrobial proteins to eradicate infections (section 3.4). 
NETs additionally assist antimicrobial activity by pathogen trapping, immobilization and exposure of 
antimicrobial components to trapped pathogens (Brinkmann et al., 2004). Whether this effort is 
enough to kill bacteria directly is much up for debate.  Proof of trapping has been tested with several 
bacterial strains and mutated bacteria, monitored by electron microscope, immunofluorescence 
microscopy, and flow chambers with microscopy (Goldmann and Medina, 2012). Several bacterial 
strains such as Staphylococcus aureus, Shigella flexneri, Salmonella typhimurium and Escherichia 
Coli bind to extracellular DNA in vitro (Beiter et al., 2006; Brinkmann et al., 2004). The ultimate proof 
of NETs biological relevance is their effect on the evolution of bacterial organisms, either by, the 
evolution of processes of evasion or the evolution of other specific defense mechanisms in an effort 
to avoid capture within NETs. Streptococcus strains, i.e. S. pyogenes, S. pneumonie, (Beiter et al., 
2006) S. aureus, have evolved to produce DNases that dismantle the NETs DNA backbone 
(Buchanan et al., 2006; Walker et al., 2007).  Pseudomonas aeruginosa uses the DNA to form 
biofilms and repurposes the granular proteins (Mulcahy et al., 2008; Walker et al., 2005). Trapping 
is not exclusive to bacteria as Saitoh et. al. showed via super-resolution structured illumination 
microscopy that HIV activates NETs via toll-like receptors (TLR) 7 and TLR8. They also found HIV 
particles trapped in the NETs that were released upon DNase treatment (Saitoh et al., 2012).  To 
strengthen the NET antimicrobial purpose, ROS generation is prolonged when neutrophils undergo 
NETosis compared to when they undergo regular apoptosis (Mayadas et al., 2014). 
4.5 The dark side of NETs 
In recent decades, life expectancy has increased significantly. However therapeutic and 
disease-treatment challenges remain in the fields of chronic diseases like cardiovascular diseases, 
obesity, diabetes, chronic pain, persistent inflammation and autoimmune diseases. For many of 
these chronic illnesses no reliable diagnosis and treatments are available due to the complexity of 
the disease. Discoveries such as NET formation gave new mechanistic insights for cardiovascular, 
inflammatory and autoimmune diseases.  
Many diseases arise when there is a fault in homeostasis maintenance, such as uncontrolled 
NET formation. The role of NETs in disease and their physiological relevance are exploratory. In 
infectious diseases, NETosis is thought to be beneficial due to their antibacterial components and 
ability to trap bacteria. There are other benefits. In the case of chronic granulomatous disease 
(CGD) patients suffer from a genetic deficiency in NADPH oxidase and cannot effectively fight 
infections and CGD patients suffering from chronic Aspergillus nidulans infections where able to 
clear the infection when NET formation was restored via gene therapy (Bianchi et al., 2009). 
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However, for many autoimmune and inflammatory diseases, NET formation is detrimental as 
NET components contribute to the pathology of the disease and in many cases increase the 
severity of inflammation.  
When NET formation increases in an uncontrolled manner, its components lead to auto-antibody 
generation, large amounts of ROS release, artery and vein clogging due to chromatin’s sticky 
nature, and recruitment of immune cells. In chronic obstructive pulmonary disease (COPD) patients’ 
sputum is highly viscous and decreases lung function due to NET components (Porto and Stein, 
2016). Another example is cystic fibrosis patients with from chronic lung infections. Here, NET 
components serve as biofilms building blocks for P. aeruginosa  (Hoiby et al., 2010).  Table 5 
summarizes the NET’s involvement in diseases. 
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Table 5. Role of NETs in disease 
 
Note: ↑ = Increase 
 
Disease NET Effect Reference
Autoimmune
? NETs
No NET clearance
? Immune cell recruitments
? Immune response
? NETs
Damaging NET components
? Immune cell recruitments
? Immune response
? NETs
Damaging NET components
? Immune cell recruitments
? Immune response
? NETs
Damaging NET components
? Immune cell recruitments
? Immune response
Venous and cardiological disease
? Immune cell recruitments
? Immune response
? NETs
? NETs
? Blockage/viscosity
? Immune cell recruitments
? Immune response
Lung disease
? NETs
Bacterial trapping (S. pneumoniae)
Bacterial biofilms  (H. influenzae)
Damaging NET components
? NETs
Damaging NET components
? Blockage/viscosity
? Immune cell recruitments
? Immune response
? NETs
? Blockage/viscosity
Damaging NET components
? NETs
? Blockage/viscosity
? Immune cell recruitments
Bacterial trapping
? Immune cell recruitments
Damaging NET components
? NETs
? Blockage/viscosity
Bacterial biofilms
? Immune response
? Blockage/viscosity
Other disease
Chronic granulomatosus disease (CGD) No NETs (Bianchi et al., 2009)
? NETs
? Immune response
? Blockage/viscosity
? NETs
? Blockage/viscosity
? Immune cell recruitments
? Immune response
? NETs
? Immune response
Damaging NET components
(Dwyer et al., 2014; Papayannopoulos et al., 2011)
Sepsis (Clark et al., 2007)
Preeclampsia (Hahn et al., 2012)
Kidney injury (Jansen et al., 2017)
(Dworski,R. allergic 2011)
Respiratory syncytial virus bronchiolitis (Cortjens, B. airway 2015)
Tuberculosis (Ramos-Kichik, V. extracellular 2009)
Transfusion-related acute lung injury (TRALI) (Caudrillier, A. transfusion 2012)
(Knight et al., 2014; Warnatsch et al., 2015)
Thrombosis (Fuchs et al., 2010)
Pneumonia (Hong et al., 2009; Wartha et al., 2007)
Chronic obstructive pulmonary disease (COPD) (Obermayer et al., 2014; Qiu et al., 2003)
(Garcia-Romo et al., 2011; Hakkim et al., 2011; Lood et al., 2016) 
Vasiculitis (Kessenbrock et al., 2009)
Rheumatoid arthritis (Dwivedi et al., 2012; Khandpur et al., 2013)
Colitis (Bennike et al., 2015)
Cystic fibrosis
Asthma
Atherosclerosis
Systematic lupus erythematosus (SLE)
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4.5.1 NETs and autoimmune diseases  
It has been a long time since Paul Ehrlich described autoimmunity as “horror autotoxicus”. In 
autoimmune disease, homeostasis is disrupted by the immune system attacking the body because 
it is unable to differentiate between self-molecules and foreign molecules. Specifically, antibodies 
and T-cells attack the host causing inflammation and organ failure. A common identifier of 
autoimmune disease is anti-neutrophil cytoplasmic antibodies (ANCAs) directed at intracellular 
proteins such as C-ANCA proteinase 3(PR3), C-ANCA atypical (BPI, MPO, CG), P-ANCA (MPO) 
and atypical ANCA (multiple specificities). The multiple specificities include catalase, enolase, actin, 
lactorefferrin, lysozyme, defensing, cathepsin G and elastase (Savige et al., 2000).  Neutrophils 
have been implicated in many autoimmune diseases and their involvements vary as much as their 
multifaceted responsibilities. Consequently, titers of ANCA antibodies vary in each autoimmune 
disease. For instance, in Wegener’s granulomatosis the titers of the ANCA antibodies are 80-90% 
C-ANCA; for cystic fibrosis (not an autoimmune disease) 80% C-ANCA atypical; microscopic 
polyangiitis  50% P-ANCA and for more complicated diseases such as rheumatoid arthritis is it 
identified by a collection of atypical ANCAs (Savige et al., 2000). These convoluted diagnostic 
parameters illustrate the complexity of autoimmune diseases. Therefore, new insights, such as the 
discovery of NET formation and their role in the autoimmune diseases, are highly valuable in 
designing and formulating improved treatments.  
4.5.1.1 Vasculitis 
Vasculitis is the name for a collection of diseases where blood vessels are affected by necrotic 
inflammation. The organs that suffer damage are mainly the lungs and kidneys, with to a lesser 
extent the skin, upper airways, brain and heart. In the case of small vessel vasculitis, MPO and PR3 
ANCA-antibodies are used for the diagnosis (Nemeth and Mocsai, 2012). Kessenbrock et. al. 
showed that NETs are involved in small vessel vasiculitis. MPO and PR3, both components of 
NETs, are the main drivers of this disease. As NET formation is increased uncontrollably, so are the 
numbers of MPO and PR3, resulting in an increasing of the titers of ANCA-antibodies. These 
increased ANCA-antibodies titers activate the immune response which results in inflammation and 
cell debri released from NETosis. ANCA-activated NETosis further activates other immune cells 
such as myeloid dendritic cells which further contribute to the illness (Bardoel et al., 2014; 
Kessenbrock et al., 2009). 
In the case of atherosclerosis, another venous disease where the arterial vessels are damaged, 
cholesterol crystals were found to induce NETosis. Here, NETs are found to primarily recruit 
macrophages. In the case where the NETosis was inhibited, the vesicular damage was reduced 
(Warnatsch et al., 2015). 
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4.5.1.2 Systematic lupus erythematosus (SLE) 
Systematic lupus erymatosus (SLE), also known as Lupus, is an autoimmune multi-symptomatic 
disease typically affecting several vital organs in the body and with a disease progress 
characterised by flares’ in which the patient experiences increased malady. In SLE, the immune 
system fails to regulate antibody generation and starts attacking several organs and tissues. SLE is 
frequently a diagnostic nightmare and is often misdiagnosed because symptoms can be so varied 
and similar to other diseases. There is no conclusive test that can unmistakably identify SLE (Yu 
and Su, 2013). The severity of the disease is not taken lightly since patients with SLE can have 
symptoms that range from the unthreatening, skin rashes, all the way to life threatening nephritis 
(kidney inflammation).  
In recent years, more attention has been given to cell types and antibody titers used to diagnose 
lupus. SLE patients produce high levels of autoantibodies against nuclear antigens. Additional to the 
ANCA antibodies, frequently used to detect autoimmune diseases, antibodies against double 
stranded DNA (anti-dsDNA) are detected. High titers in anti-dsDNA have been directly correlated 
with nephritis and SLE disease activity. Other antibodies that are present in the serum of lupus 
patients are anti-histones, antibodies against single stranded DNA (anti-ssDNA), ribonucleoprotein 
(anti-ribonucleoprotein) and ribosomes (anti-ribosomal) (Wu and Mohan, 2007). Pascual and 
colleagues have created a SLE genetic signature of 1564 transcripts of specific upregulated gene 
expression (Garcia-Romo et al., 2011). Moreover, they identified low-density neutrophils that 
express anti-ribonucleoprotein (anti-RNP), cathelicidin (LL-37), high-mobility group protein 1 
(HMGB1) and histone markers and are abundant in the population of SLE patients (Bennett et al., 
2003). 
For many years medical doctors have diagnosed and treated SLE patients with very little 
success and with generally a low understanding of the disease itself. However after the discovery of 
NETs, the similarities between the disease symptoms of SLE and the components of NETs, i.e. the 
extracellular chromatin and anti-dsDNA, appeared to be more than just coincidental and in a few 
short years several research groups identified the link between SLE and NETosis. They identified 
that SLE patients make more NETs compared to healthy people and display spontaneous NET 
formation (without a stimuli) (Jorch and Kubes, 2017; Lood et al., 2016). The DNA of these NETs 
triggers dendritic cells to produce type I interferon which results in increased NET production 
(Garcia-Romo et al., 2011; Lande et al., 2011). Not only do SLE patients make more NETs, they 
are also not able to degrade them efficiently due to the antigens present in the SLE patient sera and 
DNase I deficiencies (Hakkim et al., 2010). Over-production of NETs and impaired clearance of 
NET component are now part of the etiology of SLE. Other components of the NETs mechanism 
are currently being studied with a view to improving the treatment of SLE. For example, PAD4 Cl-
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amidine was used to decrease autoantibodies in lupus- prone mice (Knight et al., 2013). After years 
of research, SLE has become the leading NET-associated disease.  
4.5.1.3 Rheumatoid Arthritis  
Rheumatoid arthritis (RA) is a progressive destructive autoimmune disease targeting joints. 
In RA patients joint synovial lining is changed to pannus, which is a combination of synovial 
fibroblast and immune cells (Shelef et al., 2013).  For many years, the main factor of RA was IgG 
that recognizes self IgM antibodies. Only recently has the presence of anti-citrullinated protein 
autoantibodies (ACPA) been identified as a major factor involved in RA onset. ACPA is a specific 
marker for RA and NETs have been identified as a source of these auto-antigens. In the NET 
formation mechanism citrullization is essential for decondensation of the chromatin. During this 
process neighboring or passing cells can take up the citrullinated proteins generating the 
autoantibodies and immune complexes. In addition, serum from RA patients has been identified 
with NETosis triggers in vitro (Dwivedi et al., 2012; Khandpur et al., 2013). Taking everything into 
consideration these factors create an inflammatory cycle since these immune complexes trigger 
NET formation and neutrophil recruitment. 
4.6 What makes NETs difficult to study? 
In previous chapters, all the different aspects of neutrophils and NETs have been addressed. 
Since 2004, when NET formation was discovered, there has been a large amount of research 
focused on the biological relevance of NETosis. What makes these studies difficult is that cells 
undergoing NETosis, especially neutrophils, are sensitive, terminal and short-lived (Gunzer, 2014). 
In literature, it is well documented that ex vivo treatment and behavior of PMNs differs from their in 
vivo behavior. These issues also apply when investigating NET formation.  
Over the last years, molecular biology has seen major steps in the development of new genetic 
techniques i.e. RNA interference (RNAi), and CRISPR-based interference (Adamson et al., 2016). 
Nevertheless, these techniques are useless when it comes to mimicking the diverse function that 
neutrophils have in vivo (Nathan, 2006). Neutrophil-like cell lines, i.e. HL-60 and NB4, can be 
differentiated to closely resemble neutrophils although they lack certain neutrophil specific 
cytokines. Specifically, when it comes to NET formation there is no cell line that can undergo 
NETosis. Regarding mice models, NADPH oxidase and neutrophil elastase knockout mice have 
been bred, but these mice are challenged with serious infections (Amulic et al., 2012).  
Altogether, chemical biology provides an excellent solution when it comes to addressing 
neutrophils and NETosis. Ideally, the identification of a small molecule NET formation inhibitor can 
be a great tool to further study neutrophil function and more specifically NET formation. An 
additional important use for the NET inhibitor would be a pharmaceutical application aimed at NET-
dependent diseases. 
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5.1 Introduction to screening 
For more than two decades, screening has been the main technique for the identification of 
small molecules in pharma. In the early 2000s, high-throughput screening (HTS) was introduced 
and companies spend millions of dollars on building extended compound libraries (Erlanson et al., 
2016). These screening campaigns led to many pharmaceutical leads; nevertheless, it also resulted 
in many failed projects based on false positives. Ideally, in search of leads nature inspired and 
derived chemical scaffold should also be screened (Sundberg, 2000). These issues have been 
recognized in recent years. Scaffold variety has been introduced with fragment-based drug 
discovery (FBDD), natural product-inspired libraries (Biology-oriented synthesis, BIOS), and 
computational predictions (Erlanson et al., 2016; Wetzel et al., 2011). In addition, screening has 
evolved from simple biochemical assays to complex high-content cell-based and whole organism 
screening. By changing the traditional approach disrupting the purified protein-compound to primary 
cells, permanent cell cultures, and whole organism made screens more predictive and closer to in 
vivo settings. 
 Steven A. Haney describes high-content screening (HCS) as the application of biochemical 
and/or morphological parameters to study cells in a desired manner resulting in an improved drug 
discovery pipeline, both in speed as in quality (Haney et al., 2006). HCS is ideal for hit identification 
beyond small molecules, e.g. peptides or RNAi. A typical HTS protocol consists of exposing cells to 
substances and collecting the simple readout usually involving single-fluorescence readout. In HCS, 
the analysis is more sophisticated due to automated image fluorescence analysis. In recent years, 
there has been a constant improvement in screening techniques. For instance, high-throughput 
fluorescence microscopy combined with flow cytometry provides single cell resolution. This single-
cell measurement can be 2 or more parameters for one cell and it can be easily applied to a 
population of cells resulting in a qualitative and quantitative readout (Horvath et al., 2016). In 
previous screens, cell-sub-populations were completely dismissed due to the yes-or-no readouts for 
the entire cell. The HCS screens allow sub-cellular localization with multichannel fluorescence 
readouts that provide relevant information of certain cell organelles or they target genetically 
modified proteins affected by active small molecule (Kapoor et al., 2016). The challenge of HCS 
screens is the data analysis. Caie et. al. developed an automated high-content analysis where a 
multivariate clustering generated a fingerprint signature profile for compounds with biological 
similarity for different mechanistic classes (Caie et al., 2010). This chemical biology-driven 
advancement for the pursuit of biological active molecules has allowed more complex targets to be 
successfully pursued with small molecules. 
This chapter addresses the establishment of the first cell-based screen to obtain novel small 
molecule NET inhibitors. The NET assay can be considered an early version a high-content screen 
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due to the complexity of the microscopy readout. The elegance of the screen relies on its simplicity 
where one dye produces two different readouts.  
5.2 Development of an assay to detect inhibitors of NET formation.  
This is the first chemical screen to study neutrophil extracellular trap (NET) formation. This work 
was pioneered by Abdul Hakkim and Tobias Fuchs. Consequently, many optimizations were 
performed during the development of a robust assay. NET formation is a novel biological 
phenomenon and many aspects are still unknown. As previously mentioned, there is no model cell 
line that mimics neutrophil NET formation, except for purified neutrophils. Due to the short-life and 
nature of the neutrophils the assay needs to be performed uninterrupted until the cells are fixed. 
The assay starts with neutrophil gradient purification from fresh human blood. This purification was 
established in the Zychlinsky lab by Tobias Fuchs and Abdul Hakkim using Histopaque 1119 and 
Percol where neutrophils were obtained in the >95% purification by flow cytometer quantification 
(Aga et al., 2002).  
The NET assay is constructed on the morphological changes of the nuclei undergoing NET 
formation which was previously reported in 2007 (Fuchs et al., 2007). The assay detects the 
formation of four main neutrophil nuclear morphologies. The first is the lobulated nuclei, which is the 
natural state of the neutrophil (Figure 6 A and E). Upon activation, the nucleus rearranges within 
the first 60 minutes leading to the second stage which is delobulation. In this stage chromatin 
concentrates into a small circle (Figure 6 B and F). The third stage (called decondensation) is 
characterized by enlarged nuclei and internal mixing of granules and cellular components occurs 
(Figure 6 C and G). The final stage is the release of the chromatin to the extracellular space, which 
is labeled NETs (Figure 6 D and H). This sequence of nuclear morphologies was confirmed by 
detailed microscopy, see Figure 6 E-H. It is to be noted that each stage has a particular set of 
physiological parameters such as size, intensity and circularity that can be measured. The nuclear 
changes such as size and shape are quantified after the image analysis of the collected images 
from the automatic microscope. By employing this method, the exact stage in which the NET 
inhibitors stop NET formation can be determined. This will provide an insight into the cellular 
process that a particular compound targets and can narrow down the search for its protein target. 
There is an advantage if a vital DNA dye is employed, i.e. non-cell permeable dye, since it is 
possible to obtain a second readout such as cell death. 
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Figure 6. Different nuclear morphologies in NET formation. (A-D) Cartoon representations of different 
morphologies present during NET formation during time course. (E-H) Transmission electron microscope 
images of neutrophils upon activation with PMA and fixed at different times. At 0 minutes neutrophils have a 
small and lobulated nuclei (A and E). After 60 minutes the nuclei delobulate and display small and rounded 
morphology (B and F). At 120 minutes the nuclei continue to expand and are large and rounded illustrated by 
black arrows (C and G). At 180 minutes the nuclei are very large and of an irregular shape as in NETs (D and 
H) (Fuchs et al., 2007). 
 
The chosen dye is SYTOX Green. SYTOX Green intercalates with DNA and it is membrane 
impermeable so it is excluded from live cells. The half-life of neutrophils is short, although it is 
important to know the exact period of time when the cells are viable and can be used. Neutrophils 
from two healthy donors were purified at the same time and stored under the same medium 
conditions. The cell populations were compared under unstimulated and PMA stimulated conditions 
and at different times after activation and temperatures. SYTOX green was used to determine cell 
death (Figure 7). The results show that for both donors storing the cells at 4oC increased cell death 
compared to those stored at 25oC. Neutrophils of both donors showed increased cell death on 
average by 10% upon PMA stimulation. From this experiment, it can be concluded that the cells can 
be stored for up to six hours at room temperature without cell death. 
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Figure 7. Optimization of neutrophil storage shows similar trends regardless of the donor. Neutrophils 
were obtained by two different donors in parallel and stored in complete medium at 4
o
C or 25
o
C, donor 1 (A) 
and donor 2 (B). Cells were left unstimulated or were stimulated with 40 nM PMA for the indicated times. Cell 
death was measured with SYTOX Green. 
 
To validate if indeed SYTOX Green is only entering dead cells upon fixation with 
paraformaldehyde (PFA), cells were fixed with 2% PFA and incubated for 10min and 60min with 
and with and without detergent (0.1% of Triton-X). Unstimulated cells with no fixation were used as 
a negative control and cells exposed to detergent served as a positive control. Detergent-exposed 
cells have compromised cell membranes allowing the dye to enter the cell easily. After SYTOX 
Green staining, cells that were only fixed with PFA were not stained with SYTOX Green, whereas 
cells showed high fluorescence in presence of detergent (Figure 8 A).  
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Figure 8. Methodology for NET formation assay quantification of cell viability and nuclear 
morphology. (A) PFA fixation does not effect SYTOX Green staining. Cells were untreated, fixed with or 
without Triton-X. Cells were incubated for 10 to 60 min, stained with SYTOX Green and fluorescence was 
measured. (B) Quantification of neutrophil cell death with SYTOX Green. Different numbers of neutrophils 
were seeded and activated with PMA for 240 min or incubated with the nonionic detergent NP-40. (C) 
Analysis of distinct nuclear morphologies during NET formation. Neutrophils were activated with PMA for 15 
(A), 60 (B), 150 (C), and 300 min (D), fixed, permeabilized with Triton X-100 and stained with SYTOX Green. 
(A), delobulated at <100 pixels (B), decondensed at 2000 pixels (C), and NETs at 2000 pixels, respectively. 
(D-E) Graphical phenotype representation using the Heywood circularity factor. The neutrophil nuclei images 
obtained in (C) were analyzed using a dot plot graph analysis of perimeter versus Heywood circularity factor. 
Each dot represents a nucleus. Gates were set to distinguish lobulated and delobulated nuclei, and diffused 
and spread NETs. (D) Nuclear morphology 15 minutes after activation with PMA. (E) Nuclear morphology 15 
minutes 240 minutes after activation with PMA (Hakkim et al., 2011) .  
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To test if the method was quantitative, neutrophils were seeded at different concentrations. 
Cells were exposed to the non-ionic detergent NP-40 to permeabilize the cells, resulting in cell 
death. Another set of cells was activated with PMA, also resulting in cell death. Both conditions 
resulted in similar dose-dependent responses after 240 min of PMA addition (Figure 8 B). The 
fluorescence measured is proportional to the amount of cells that were plated confirming that the 
fluorescent readout is indeed quantitative.  
Next, the quantification of the morphologies was addressed based on the four main 
morphologies discussed above (Figure 6). The first parameter is the size of the nuclear area at 
different time points that corresponded to the main morphologies. After the cells were activated with 
PMA and incubated for a given time cells were fixed with PFA, permeabilized with 0.1% Triton-X 
and stained with SYTOX Green. Microscopy pictures were obtained with a 10X objective using a 
Scan^R automated microscope. Hakkim established an algorithm on the Scan^R image analysis 
software was applied and optimized for the SYTOX Green signal and the elaborate thresholds for 
the nuclear size of each morphology. To obtain images corresponding to the naïve state, cells were 
activated for 15 min with 40 nM of PMA to guarantee adhesion and these nuclei showed the 
lobulated morphology (Figure 8 C). Analysis showed that the prominent size of a lobulated nucleus 
is 1000 pixels, (Figure 8C). The second nuclear morphology, delobuated, comes after 60 min of 
activation (Figure 8 C). In the image the nuclei appear to be rounded and nuclear size 
corresponding to 800 pixels. The cells seem to have reduced the nuclear size by 200 pixels while 
displaying increased circularity. The following two nuclear morphologies are decondensed at 120 
min and NETs at 300 min. The size of the nuclei was increased significantly to 2000 pixels and 
NETs are the same in pixel size. The nuclear change in the circularity is quite drastic.  At 120 min 
the nucleus is round and large and at 300 min the nucleus is completely has been expelled and the 
circularity is lost. Size is not the only parameter that was taken into consideration, the perimeter of 
the nuclei was analysed using the Heywood circularity factor (HCF). HCF designates the ratio of the 
perimeter to the circularity of a given area. Round nuclei will have a HCF of 1, where a larger and 
more irregular shape, i.e. NETs, is expected to have a higher HCF (Figure 8 D-E). The final 
algorithm classified the images as follows: nuclei with a pixel size from 100 to 200 pixels and a HCF 
of 1 to 2 were classified as lobulated (Figure 8C A). Nuclei with the size of <100 pixels and a HCF 
of 1 classified as delobulated (Figure 8C B). Nuclei with 2000 pixels and a larger HCF were termed 
decondensed. Finally, the nuclei with 2000 pixels or higher and a very large HCF were classified as 
NETs (Figure 8C C and D). The algorithm was verified manually to confirm that the quantification 
represented the images. 
  The analysis was performed using the Scan^R image analysis algorithm as developed by 
Abdul Hakkim and Tobias Fuchs. Later, I developed another algorithm using free software Cell 
Profiler and Cell Analyst. The same parameters were taken into account in the pipeline developed 
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with the initial training of Marc Bickle from the screening facility Max Planck Institute of Molecular 
Cell Biology and Genetics in Dresden. Cell Profiler is a self-learning program and improves its 
algorithm based on the image input. Consequently, the algorithm becomes increasingly accurate by 
as more test images are added. Based on the previous experience, NET formation was halted by 
using NET inhibitors at the same stages mentioned in previous paragraphs. This facilitated the 
generation of the pipelines. Cell Profiler is strongly dependant on the images. A pipeline was 
created for each microscope that was used and in some instances modifications were performed 
per experiment.  
Many additional issues were addressed such as the optimal conditions in which to obtain 
and maintain the cells, time, automatization of the microscopy and the scale up to a full high-
throughput screen. Finally, a robust NET screening cascade was obtained for evaluation and 
medium-sized small molecule libraries were screened. Figure 9 shows the workflow of the NET 
screen as it was performed either manually, semi-automatically or automatically. The workflow 
starts with fresh human blood and finishes with the screening plates fixed and ready for microscopy 
analysis. The entire workflow must be performed within a single day due to the nature of the cells. 
The isolation of the neutrophils requires around 2 hours (Figure 9 Step 1). The plating of the 
compounds and seeding of the cells, including the 30 min compound pre-incubation, requires the 
subsequent hour to 3 hours depending on the number of compound to be tested (Figure 9 Step 2-
4).  Upon PMA activation, a 4 hours incubation time at 37oC is required to allow NET formation. 
Finally, the cells are stained with SYTOX green and fixed with PFA. 
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Figure 9. Screening protocol and morphology classification. (1) Neutrophils were isolated from Human 
peripheral blood using a density gradient (2). 1x10
4 
neutrophils were seeded (3). Cells were activated with 
PMA (40 nM) for 240 min (4). Neutrophils were fixed with PFA (2% (w/v)) and stained with the cell-
impermeable DNA dye SYTOX Green (5 and 6, respectively). At this step only dead neutrophils were stained. 
Fluorescence was determined to assess cell viability (7). Neutrophils were permeabilized to allow 
homogenous staining of all cells (8). Pictures of nuclear morphologies were taken by an automated 
microscopy system and classified into four distinctive morphologies (9 a-d). The compounds were grouped 
(10) based on both readouts (steps 7 and 9). Compounds yielding viable cells with small nuclei (lobulated or 
rounded) were in group 1, and those producing cells with large nuclei were in group 2. Non-inhibitors were in 
group 3, and dead cells with small nuclei were in group 4. Final step is hit validation (11). Figure modified from  
Nature Chemical Biology 2011 (Hakkim et al., 2011). 
With a working assay established, commercial libraries of annotated compounds were then 
screened. The libraries were obtained from Sigma Aldrich, the library of 1280 pharmacologically 
active compounds (LOPAC), and MicroSource, a US drug compound collection composed of 1380 
FDA approved drugs. The hits from these libraries of compounds with known targets can give 
insights into which enzymes and receptors are involved in the mechanisms responsible for NET 
formation. 
 
- 47 - 
 
5.3 First hit evaluation 
The LOPAC library of 1280 compounds was screened using the protocol described in the 
previous paragraph in a semi-automated manner. The compounds were pipetted in 384-well plates 
so that the final concentration was 100µM using an automated pipetting device and subsequent 
steps were performed manually (Figure 9), with 104 neutrophils plated per well and activated with 
40 nM PMA and then incubated for 240 min at 37oC. The complete library was screened twice and 
the compounds were analyzed as previously established. The main interest is in compounds that 
fall in group 1 and 2. Since there are five readouts (cell death and four morphologies), screening 
large number of compounds generates vast amounts of data and simplification is required. It was 
decided to reduce the five readouts to a two number system (one for cell death and one for 
morphology). The morphology readout was simplified by combining the lobulated and delobuted 
percentages in one number that indicate the percentage of small nuclei. Compounds with higher 
than 50 % small nuclei were classified as group 1 compounds and those with a less than 50 % 
small nuclei are classified as group 2. All compounds causing cell death in more than 50 % of cells 
were immediately discarded as toxic compounds. The screening campaign resulted in 38 
compounds that showed cell death in less than 50 % of cases, coupled with NET formation 
inhibition. This corresponds to a hit rate of 3 %. 
The next step was investigating the known biological activity and the potential involvement of the 
hit compounds in the NET formation mechanism. Indeed, it was observed that compounds with 
known modes of action, related to NET formation, were among the set of hits. Once classified 
according to activity, three main target groups could be distinguished (Figure 10). First, inhibitors of 
fatty acid metabolism were identified as NET formation inhibitors, e.g. resveratrol (B135, Figure 
10), a known COX inhibitor. COX inhibitors are powerful anti-inflammatory drugs and are often used 
in the treatment of autoimmune diseases. However, a direct link between COX inhibitors and NETs 
had not been reported. Unexpectedly, GPCR and cell cycle kinase inhibitors were identified. GPCR 
pharmacology in neutrophil biology is a so far unexplored subject in the relative new field of 
neuroimmunology. The most intriguing set of hits were the kinase inhibitors that target kinases 
involved in the oncogenic signaling pathways. Much is known about these kinases in other cell 
types linking them to cell death and cell division. Neutrophils are terminal cells and the cell division 
mechanisms are considered to be deactivated. The identification of these kinase inhibitors as NET 
formation inhibitors shows how much neutrophil and NET biology is to be explored.  
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Figure 10. Evaluation of screening hits. Hit compounds were classified according to their biological activity 
and three main inhibitor groups stood out GPCRs, fatty acid and cell cycle (A). Neutrophils were pre-
incubated with 100 µM of the compounds for 20 min at 37
o
C followed by stimulation with 40 nM PMA and 
further incubation for 240 min to allow NET formation. Cells were stained with SYTOX Green to detect death 
cells Data are mean values ± s.d. (N=1, n=2). US: unstimulated cells.  
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6.1 Hypothesis 
After the identification of kinase inhibitors as NET formation inhibitors, we set out to investigate 
the involvement of the ERK pathway in NETosis. The kinase inhibitors involved in the ERK signaling 
pathway showed a group 1 NET inhibitor phenotype. Since group 1 inhibitor is likely to arrest NET 
formation at an early stage based on our knowledge of the NET mechanism. The involvement of the 
ERK signaling pathway is hypothesized that it will be in the early stages of NETosis.  
6.2 Inhibitors of the ERK Pathway inhibit NET formation 
Experiments described in this section were performed alongside with Abdul Hakkim.  
Resulting from the LOPAC library screening, kinase inhibitors involved in oncogenic signaling 
pathways were found to inhibit NET formation effectively. The RAF protein, also known as mitogen 
activated protein (MAP) kinase kinase kinase, is a member of the MAP kinase cascade together 
with MAP kinase kinase (MEK) and extracelullar-signalling regulated kinases (ERK) proteins. This 
pathway is linked to the regulation guanosine nucleotide binding (G) protein, Ras. Ras is involved in 
cell proliferation, growth, and differentiation and has been known as a powerful oncogene for many 
years (Roberts and Der, 2007). Therefore, all MAP kinases in the pathway have been investigated 
as drug targets. The mechanisms activating this pathway are a series of phosphorylations, i.e. Ras 
indirectly activates the kinase activity of Raf by phosphorylation. Next, Raf phosphorylates and 
thereby activates MEK resulting in activation of ERK which relocates to the nucleus. Activated ERK 
regulates many crucial biological processes for example it increases cell survival by activating anti-
apoptotic proteins such as Bcl-XL and Mcl-1 which regulate the negative feedback loop to Ras-Raf-
MEK kinases, and cell vacuolization in autophagy (Cagnol and Chambard, 2010). The research on 
the effect of the kinases on the regulation of cell survival and apoptosis has produced several 
efficient and specific inhibitors that were introduced in the previous paragraph. In Figure 11, the 
sequential Ras-Raf-MEK-ERK pathway is depicted together with the structures of each inhibitor. All 
this work has been performed in mammalian cells that undergo cell division, posing the obvious 
question of the role of RAS-Raf-MEK-ERK signaling in terminal cells such as neutrophils. Although, 
there is not much research performed on the subject, the ERK ability to lengthening cell lifespan can 
be the reason for using upregulating this signaling pathway. For an activated neutrophil, with a life 
span of only a few hours, a continuous signal for cell survival can be vital in keeping the PMN alive 
until the source of infection is found.  
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Figure 11. Investigation of the involvement of the Raf-MEK-ERK pathway in NET formation. (A) 
Ras/MEK/ERK pathway and known inhibitors. MEK pathway inhibitors stop NETosis. (B and C) Neutrophils 
were pre-incubated with 100 µM of the compounds for 20 min at 37
o
C followed by stimulation with 40 nM PMA 
and further incubation for 240 min to allow NET formation. Cells were stained with SYTOX Green to detect 
dead cells (B). Data are mean values ± s.d. (N=3, n=3, *P < 0.05 unpaired two tailed Student t-test). US: 
unstimulated cells. Nuclear morphology was analyzed after fixation and permeabilization using automated 
microscopy (C).  
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To test this hypothesis, neutrophils were exposed to the different MAPK inhibitors and were 
activated to undergo NETosis by using PMA. One of the interesting hits was the cRaf-1 inhibitor 
GW5074 (LOPAC code 6416) produced a  11 % cell death and 84 % small nuclei (Figure 10) 
corresponding to a group 1-type NET inhibitors (Lackey et al., 2000). To investigate the relevance of 
the Ras-Raf-MEK-ERK pathway in the context of NET formation mechanism, the following kinase 
inhibitors were subjected to experiments that validate their inhibitory role on NETosis; U0126, a 
MEK inhibitor, and an ERK2 inhibitory peptide (Favata et al., 1998). DPI was used as a positive 
control since NADPH oxidase is involved in the NET formation pathway and is downstream of ERK 
(O'Donnell et al., 1993). Staurosporine, a potent PKC inhibitor, was used as a control (Tamaoki et 
al., 1986). 
NET formation was inhibited quite efficiently resulting in a group 1 morphology for all 
compounds, except for the ERK inhibitory peptide which showed a group 2 morphology (Figure 
11B and 11C). This data clearly shows that the Raf-MEK-ERK pathway is involved in NETosis. 
Next, Ras protein was investigated, which is upstream of Raf, as a disruptor of NETosis. At the time 
there was no direct Ras inhibitor known and several indirect strategies to disrupt Ras oncogene 
signaling had been used. The Waldmann group has developed palmostatin B, an acyl protein 
thioesterase (APT1/2) inhibitor, and BMS3 and ABT, inhibitors of RabGGTase. Palmostatin B 
inhibits APT resulting in interference with Ras intracellular localization (Dekker et al., 2010). BMS3 
is a dual inhibitor of FTase and RabGGTase and ABT inhibits RabGGTase (Bon et al., 2011; Stigter 
et al., 2012). The three inhibitors disrupt the post-translational modifications of Ras. The indirect 
Ras inhibitors failed to inhibit NET formation at all concentrations tested (Figure 12B).This data 
discards the direct involvement of Ras in NETosis and it can postulated that the mechanism 
bypasses Ras (Figure 12A). PKC is known to activate Raf directly without the participation of Ras. 
The involvement of PKC was validated by inhibiting NET formation with staurosporine (Figure 11B 
and 11C).  
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  Figure 12. Ras does not participate in NET formation. (A) Canonical Ras-Raf-MEK-ERK pathway 
sequence and the structures of inhibitors non-direct inhibitors of Ras palmostatin B, BMS3, and ABT. (A) 
Palmostatin B, BMS3 and ABT failed to inhibit NETosis at several concentrations. Neutrophils were pre-
incubated with a serial dilution of the compounds for 20 min at 37
o
C followed by stimulation with 40 nM PMA 
and further incubation for 240 min to allow NET formation. Cells were stained with SYTOX Green to detect 
death cells (B). Data are mean values ± s.d. (N=3, n=2).   
 
Plant-derived phorbol esters, such as PMA, mimic the activity of diacylglycerol (DAG) in cells 
by activating protein kinase C (PKC) (Emerit and Cerutti, 1981; Niedel et al., 1983). Since PMA is a 
non-physiological PKC activator, the ability of the physiologically occurring PKC activators such as 
the lipophilic second messenger diacylglycerol (DAG) or platelet activation factor (PAF) to generate 
NETs was investigated. Upon stimulation with the lipids DAG analog and PAF, NETosis was 
observed at a concentration of 3 μM (Figure 13A and 13B). When working with lipids, delivery to 
the cell must be optimized. It is well documented that lipids are not soluble and the use of fatty acid-
free bovine serum albumin and solvents other than DMSO such as alcohols are required. The 
delivery system to the neutrophils, concentration of the lipids, and incubation time were optimized to 
generate NETs (data not shown). After the optimization it was observed that PAF was not as 
effective as DAG as a NET formation activator. Interestingly, both activated NET formation at a 
concentration of 3 μM or higher. Showed a cell death up to 80 % (or higher) compared to the 
unstimulated control. Lower concentrations were found to be less effective. Once the optimal 
conditions were found, the cells were pre-treated with GW5074, U0126, Staurosporine kinase 
inhibitors and the ERK inhibitory peptide. These compounds successfully suppressed NET 
formation as detected by a decrease in cell death (Figure 13C and 13E) and increase in cells with 
lobulated nuclei (Figure 13D and 13F). Similarly, activation of NET formation by PAF was inhibited 
by the compounds and cells displayed the group 1 phenotype (Figure 13C and 13D). GW5074 and 
- 55 - 
 
U0126 inhibited NET formation upon activation with DAG, and cells exhibited similar phenotype as 
well (Figure 13E and 13F). In both cases, upon activation with PAF and DAG, MEK inhibitor cells 
maintained their inhibitory properties and exhibited the small nuclei phenotype. These results 
demonstrate the efficient inhibition of NET formation by the ERK pathway kinase inhibitor 
compounds induced by naturally occurring PKC activators.   
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Figure 13. MAPK inhibitors respond to physiological PKC activators. DAG and PAF activate NET 
formation.  Neutrophils were stimulated with 3 µM DAG or 3 µM PAF for 240 min (A-B). Neutrophils were pre-
treated with 100 µM of the compounds for 20 min at 37
o
C prior to stimulation with 3 µM PAF for 240 min (C-D) 
or 3 µM DAG (E-F). In all cases, cells were stained with SYTOX Green to detect dead cells (A, C and E) 
followed by fixation and permeabilization. The detailed nuclear morphology was quantified using automated 
microscopy (B, D and E). Data are mean values ± s.d. (N=3, n=3, *P < 0.05 unpaired two tailed Student t-
test). US: unstimulated cells, DAG: Diaglycerol analog: 1–2-dioctanoyl-sn-glycerol, PAF: Platelet Activating 
Factor. 
 
As mentioned in the introduction, the neutrophil’s main function is to control infection by invading 
pathogens. To confirm, the neutrophils were exposed to Helicobacter pylori (H. pylori) to activate 
NETosis. H. pylori is a gastric gram negative bacterium known to make biofilms and have an outer 
layer consisting of lipopolysaccharide (LPS) and phospholipids (Kusters et al., 2006). Both LPS and 
phospholipids are known to activate NET formation (Brinkmann and Zychlinsky, 2007). In Figure 
14A and 14B, for the first time it was shown that this gastric bacteria indeed produces NETs to a 
20% above basal level. H. pylori is not as effective as PMA. Once the cells were pre-incubated with 
the MAPK signaling inhibitors, NET formation was inhibited and cells displayed group 1 phenotype 
(Figure 14C and 14D). With these experiments it was demonstrated that the Raf-MEK-ERK kinase 
inhibitors are efficient NET inhibitors, regardless of the employed stimuli. 
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Figure 14. MAPK inhibitors block H. pylori NETs. Helicobacter pylori type 1 strain P12 was grown on Brain 
Heart infusion agar plates incubated for 37
o
C microaerophilic atmosphere. Neutrophils were stimulated with 
40 nM of PMA or MOI of 100 of Helicobacter pylori  for 240 min (A-B. Neutrophils were pre-treated with 100 
µM of the compounds for 20 min at 37
o
C to stimulation MOI of 100 of H. pylori for 240 min (C-D). In all cases, 
cells were stained with SYTOX Green to detect dead cells (A and C) The detailed nuclear morphology was 
quantified using automated microscopy (B and D). Data are mean values ± s.d. (N=3, n=3, *P < 0.05 unpaired 
two tailed Student t-test). US: unstimulated cells.  
 
6.3 Raf/ERK/MEK pathway is upstream of NADPH oxidase during NET formation 
The Raf-MEK-ERK signaling pathway was proven to be part of NET formation using a chemical 
biology approach. Small molecule kinase inhibitors were used to disrupt NETosis and the inhibitors 
were efficient regardless of the stimuli. Therefore, the next step was to investigate the placement of 
the Raf-MEK-ERK signaling pathway in the overall NET formation mechanism. Reactive oxygen 
species (ROS) are essential in cell signaling and are fundamental for NET formation. ROS 
production is measured using an insitu peroxidase/luminol assay. Neutrophils were activated with 
PMA and after fifteen minutes the amount of ROS produced was detected. Staurosporine, GW5074, 
U0126 and ERK peptide inhibitor blocked ROS generation comparable to DPI, a known NADPH 
oxidase inhibitor (Figure 15A). These data demonstrate that the Raf-MEK-ERK pathway is 
upstream of NADPH oxidase. This finding is in line with earlier reports where a direct link was 
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established between phosphorylation of p47phox, a NADPH oxidase component, by ERK (El Benna 
et al., 1996).  Next, the involvement of the ERK pathway in NETosis was assessed by detection of 
phosphorylated-ERK (p-ERK) 1 and 2 by means of immunoblotting, which is the conventional proof 
of activated ERK pathway. When neutrophils were activated with PMA there was an increase in p-
ERK compared to lack of phosphorylation when the cells were unstimulated. Staurosphorine, 
GW5074 and U0126 blocked the phosphorylation of ERK 1 and 2. The ERK peptide inhibitor only 
decreased ERK 1 phosphorylation as expected. DPI failed to block phosphorylation of ERK 1 and 2, 
proving that PMA-based NETosis is upstream of NADPH oxidase. When the cells were activated 
with H. pylori the immunoblotting results showed that the mechanism of H. pylori is independent of 
PKC (Figure 15B). Earlier in the chapter it was mentioned that there have been several studies 
linking the oncogenic potential of the MAPK signaling pathway to cancer cell survival by promotion 
of expression anti-apoptotic proteins such as Bcl-2, Bcl-XL, Mcl-1 and IAP. MAPK signaling not only 
increases the survival in cancerous cells, but also in immune cells. In myeloid leukemia, inhibition of 
ERK signaling causes an expression in anti-apoptotic proteins resulting in an elongated neutrophil 
survival (Simard et al., 2015). The ERK pathway modulates the expression of Mcl-1, so the 
expression Mcl-1 anti-apoptotic protein via immunofluorescence was investigated. Indeed there was 
in expression of the Mcl-1 protein after 120 minutes of PMA activation. As NETosis progresses, Mcl-
1 is suppressed (Figure 15C). We tested the Mcl-1 expression levels in the presence of the PKC-
Raf-MEK-ERK inhibitors and the expression levels of Mcl-1 were partially blocked. This data 
suggests that apoptosis is stopped by the expression of anti-apoptotic proteins allowing NET 
formation to continue. All of this regulatory signaling proves that NET formation is a controlled cell 
death mechanism, and not an uncontrolled cell explosion.    
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Figure 15. Raf-MEK-ERK pathway is upstream of NADPH oxidase. Influence of MAPK kinase inhibitors on 
the generation of reactive oxygen species (A). Neutrophils were treated with 100 µM of the compounds for 20 
min prior to stimulation with 20 nM PMA to induce an oxidative burst. ROS were detected in situ using the 
luminol/HRP reagent. Data shown correspond to percent of generated ROS after 15 min stimulation with 
PMA. US: unstimulated cells. Validation of ERK protein by immunobloting analysis in NET Formation. (B) 
Phospo-ERK (pERK) is present in activated cells and not in unstimulated neutrophils. Anti-apoptotic protein 
Mcl-1 is expressed allowing NETosis to occur (C and D) (C). (D). Immunofluorescence using anti-Mcl-1 and 
DNA was stained with Hoechst 33342 and SYTOX. These representative experiments were performed in 
triplicate and presented as mean ± s.d. Significance *P < 0.05; n paired, two-tailed Student’s t-test. The 
relationship between ROS formation and Mcl-1 expression was tested for significance with a two-way 
ANOVA, with Bonferroni correction (Hakkim et al., 2011).  
 
A common theme in NET-related diseases is the uncontrolled overproduction of NETs. Many 
physicians are hesitant to stop immune processes for fear of a full body immunosuppression. An 
immunosuppressed patient is less than ideal since the patient will suffer constant severe infections. 
Besides NETosis, phagocytosis and degranulation, other neutrophil functions are essential in 
maintaining homeostasis and to keep infections under control. Ideally, a small molecule therapeutic 
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would stop NET formation without affecting the other neutrophil functions. To investigate this we 
subjected neutrophils again to MAPK inhibitors and studied their effect on degranulation and 
phagocytosis. As mentioned in the introduction, lactoferrin is a neutrophil granular protein and it is 
produced during degranulation. Interestingly, the Raf-MEK-ERK signaling inhibitors did not halt 
lactoferrin production in comparison to cells treated with DMSO (Figure 16A). To study 
phagocytosis, neutrophils were encouraged to phagocytose fluorescent latex beads and the 
phagocytic activity was measure via flow cytometer. Raf-MEK-ERK signaling inhibitors did not affect 
the phagocytic activity of neutrophils. There was only a slight change in activity when the cells were 
exposed to U0126 or DPI (Figure 16B). We were able to place the Raf-MEK-ERK pathway 
upstream of NADPH oxidase and determined that this oncogenic pathway also plays a role that is 
directly linked with cell death mechanisms. In the case of NET formation neutrophils must bypass 
other cell mechanism to allow NET formation to occur, e.g. via apoptosis. Finally, we showed that 
anti-apoptotic proteins are indeed expressed to allow NETosis to occur. The kinase inhibitors used 
in these experiments in fact open the gate to many future pharmaceutical opportunities as they 
seem not to affect regular neutrophil cell function.  
 
6.4 Project Conclusion 
The first protocol to identify NET inhibitors was described. Using this protocol a library of 1266 
commercially available small molecules (LOPAC library from Sigma) was screened. The Raf-MEK-
ERK kinase inhibitors were identified as group 1 phenotype inhibitors. These inhibitors were active 
regardless of the NET formation activator. We were able to prove that group 1 compounds arrest 
NET formation at an early stage. Also, we show the involvement of the ERK pathway upstream of 
NADPH oxidase which occurs in the first 20 minutes of NET formation. We showed that anti-
apoptotic proteins are expressed to allow NETosis to occur and are regulated by MAPK signaling 
pathway. Neutrophil phagocytic and degranulation function is maintained in presence of inhibitors 
(Hakkim et al., 2011).  
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Figure 16. Raf-MEK-ERK inhibitors do not affect phagocytosis or degranulation.  MAPK kinase 
inhibitors do not halt degranulation when neutrophils are activated with Helicobacter pylori (A). Neutrophils 
were pre-incubated with compounds then stimulated MOI of 100 of Helicobacter pylori  for 90 min. 
Supernantant was tested for lactoferrin production using an anti-lactoferrin enzyme-linked immunosorbent 
assay (ELISA). Phagocytosis of fluorescent carboxylated beads is not effected by the MAPK inhibitors. (B) 
Neutrophils were pre-treated with compound for 30 min in siliconized tubes. Cells were exposed to the green 
fluorescence latex beads and incubated for 60min for binding and internalization. Cell suspensions were 
analyzed by flow cytometry and normalized to percent total cell count.  
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Initial experiments described in this section were performed alongside with Abdul Hakkim.  
7.1 Hypothesis 
As part of the hits, there were inhibitors of the eicosanoid pathway among some of the potent 
inhibitors. It hypothesized that there is a direct involvement of the eicosanoid pathway in NET 
formation. NET formation is induced with signaling lipids such as DAG and PAF. This lipid signalling 
pathway can be incorporated in the traditional view of cell-to-cell communication to NETosis. To 
further investigate this pathway several inhibitors of the cyclooxygenase (COX) / lipoxygenase 
(LOX) pathways were screened and identified as NET generation inhibitors. Our results elucidate a 
new function in leukocytes, contributing to a novel field of study for neutrophil biology.  
7.2 Introduction to the eicosanoid pathway 
Immune cell trafficking pathways are regulated by signaling lipids (Wymann and Schneiter, 
2008). These lipids are synthesized via autocrine or paracrine depending on the regulatory signal 
(Nathan, 2006). They regulate cell proliferation, apoptosis, metabolism and migration (Wymann and 
Schneiter, 2008). In the introduction neutrophil migration was discussed and specific 
phosphoinositides were highlighted for their involvement in this neutrophil migration and invasion. 
Phosphoinositides can be hydrolyzed by phospholipase C (PLC) to diaglycerol (DAG) where DAG 
activates protein kinase C (PKC) releasing calcium ions (Ca2+) (Mackay and Twelves, 2007; 
Wymann et al., 2003). This signaling activates the synthesis and release of several lipids, including 
lysophosphatidic acid (LPA) and activation of several proteins, for instance G protein-coupled 
receptors (GPCRs). Together LPA and GPCRs are responsible for release of specific eicosanoids 
(Futerman and Hannun, 2004). Eicosanoids are a very active type of lipids derived from arachidonic 
acid (AA). The most predominant lipid categories are lipoxins (LX), leukotrienes (LT), 
hydroxyeicosatetraenoic acids (HETE), prostaglandins (PG), thromboxanes (TX), resolvins (Rv), 
and eoxins (EX) (Sala et al., 2010). Eicosanoids have a very short half-life, typically of the order of 
seconds or minutes, and they bind mainly to GPCRs and nuclear receptors. Besides eicosanoid 
synthesis, PLA2 produces lysolipids, for example lysophosphatidlcholine (lyso-PC), which is 
converted to platelet-activation factor (PAF), and is a powerful inflammation activator (Cyster, 
2005).      
For years it has been known that the imbalance in these lipid signaling pathways contributes to 
chronic inflammation, autoimmunity, allergy, cancer, atherosclerosis, hypertension, and metabolic 
and degenerative diseases. Specifically, the main source of inflammation is the release of granular 
content and the formation of PG, TX, and LT by leukocytes (neutrophils, lymphocytes, 
macrophages, mast cells and granulocytes) as a result of high levels of Ca2+, cytokines or 
chemokines. For decades, the treatment for inflammation diseases has been some form of 
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regulation of the production of these lipids. Aspirin, which was synthesized by Felix Hoffmann at 
Bayer in 1897, was based on the studies of willow tree leaves used in the treatment of fever and 
pain relief (Wymann and Schneiter, 2008). This gave birth to modern non-steroidal anti-
inflammatory drugs (NSAIDs) which are selective cyclooxygenase (COX) inhibitors. 
Cyclooxygenase (COX) is an enzyme that converts arachidonic acid into prostaglandin (PG), a 
principal member of the eicosanoid cascade.  
In chronic inflammation, ceramide kinase (CerK) and cystolic phospholipase (cPLA2) release 
arachidonic acid to activate the GPCRs that, together with chemokines, cytokines and histamine-
caused bronchial restriction, is detrimental in late allergies and inflammation (Yedgar et al., 2007).  
The role of signaling lipids such as AA, DAG and PAF on neutrophils is well-established. Due to 
the short-lived nature of both the lipids and neutrophils, all the details of their mechanisms of actions 
are unknown. Obviously, new techniques such as lipidomics, where LC/MS/MS techniques are 
applied to the identification and quantification of lipids, and microscopy techniques, are likely to 
shed more light on lipid function. In the literature the concept of NETs and lipids is limited. In a few 
findings, including our research, NETs are shown to be generated by PAF and DAG (Clark et al., 
2011; Hakkim et al., 2011; Yost et al., 2010). 
 
7.3 Eicosanoid pathway and NET formation 
We reported that NET formation can be induced by messenger lipids (Hakkim et al., 2011). The 
initial reasoning was that platelet activation factor (PAF) and diaglycerol (DAG) are signaling 
molecules that activate PKC protein. PAF and DAG were used in the assay as physiological 
alternative to PMA. PAF and DAG are traditionally involved in cell-to-cell communication signaling 
pathways and they are well known to be involved actively in immune responses. Typically, to 
activate the generation of PAF or DAG in the cell, neutrophils are stimulated with calcium ions or 
combinations of granulocyte macrophage colony-stimulating factor (GM-CSF) and N-
formulmethionyl-leucyl-phenylanine (fMLP) or calcium with fMLP (Cronstein and Weissmann, 1995). 
In the case of NETs these combinations did not prove to be good NET formation activators. 
Nevertheless, we were able to activate the neutrophils with PAF and DAG at concentrations of 3 µM 
using fatty acid-free BSA as vehicle. In the case of DAG, 1–2-dioctanoyl-sn-glycerol was used 
which is a membrane-permeable DAG analog (Figure 17 A-B and C-D). Besides activating PKC, 
DAG also activates protein kinase D (PKD). Activating the signaling pathways of PKC or PKD as a 
result of increased ROS activation leads to an induction in survival pathways protecting the cell from 
apoptosis (Toker, 2005). In the context of NET formation, this signaling keeps the neutrophil alive 
long enough for NETosis to take place. Phosphatidic acid (PA) is produced by phosphorylation of 
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DAG-activated kinases. It is known that these enzymes affect signaling to ERK pathway via 
GTPase (Toker, 2005). This supports our findings that the Raf-MEK-ERK pathway is involved in 
NET formation.  
As mentioned before, the lipid 1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) activates 
PKC and this activity negatively regulates the PAF receptor, but this is one of many PAF functions 
(Ali et al., 1994). Notably PAF is the most established lipid in cell-to-cell communication. It was first 
established as a messenger protein by specifically binding to its own GPCR, platelet activation 
factor receptor (PAFR) (Prescott et al., 2000). PAF has both autocrine and intracrine effects. PAF-
induced activity is highly regulated upon availability, specific expression of the receptor, which can 
be sensitized and desensitized, and finally rapid degradation of PAF by acetyl hydrolysis inside and 
outside the cell. PAF, like many other lipids, has a very short half-life of a few minutes in the blood 
stream. This tight regulation is attributed to its autocoid nature and efficiency affecting neighboring 
cells and cells where it is synthesized (Prescott et al., 2000). PAF is known to be synthesized in 
immune cells, mainly neutrophils, and endothelial cells and the synthesis occurs in periods of acute 
inflammation response. In neutrophils, it is known to affect the adhesion response by β2 integrin 
(Harris et al., 2000). In addition to neutrophils, PAF has been linked to neuronal migration and 
neurotransmitter release (Kato et al., 1994). In the plasma, where PAF acetyl hydrolase has been 
connected to low density lipoproteins (LDL) and high-density lipoproteins (HDL), it has a role in 
vascular disease (Tellis and Tselepis, 2014). Similar to DAG signaling mechanisms, PAF has been 
associated to the ERK signaling pathway upon direct activation of PKC with PAF. As PAF is known 
to activate the PAF receptor, it was shown to maintain phosphatidylinositol levels. Interestingly, 
similar to our findings for the NET formation, no activation of Ras was observed (Honda et al., 
1994).    
Both lipids, DAG and PAF, trigger the eicosanoid pathway and we decided to investigate 
whether arachidonic acid (AA), the main precursor for this pathway, was able to activate NET 
formation. Arachidonic acid was used to stimulate neutrophils at 3 µM using fatty acid-free BSA as 
vehicle to activate NETs. NETs were obtained in 15 to 45 min which is faster than observed for 
PMA (which takes 2 to 4 hours for NET formation) (Figure 17 A-B and E). Overall, AA was shown 
to be less effective compared to PMA since fewer cells were triggered to produce NETs after 4 
hours of incubation. This could be due to the fact that AA is quickly metabolized, as it was 
mentioned in previous chapters. This would explain why all lipids were most active at 3 µM 
compared to PMA which is already very active at 40 nM. From studies known in literature it is not 
clear at what concentrations these lipids should be active. The mechanism in which neutrophils are 
known to synthesize eicosanoid lipids physiologically after an infection or inflammatory response is 
depicted in Figure 17 F.   
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Figure 17. PAF, DAG and AA activate NET formation. Neutrophils were stimulated with 3 µM PAF (A, B 
and C), 3 µM DAG (A, B and D) or 3 µM AA for 240 min (A, B and E). Cells were stained with SYTOX Green 
to detect dead cells (A) followed by fixation and permeabilization. The detailed nuclear morphology was 
quantified (B). Representative images of cells treated with PAF (C), DAG (D) and AA (E). Data are mean 
values ± s.d. (N=3, n=3). (F) Scheme of transcellular biosynthesis of eicosanoids. US: unstimulated cells. 
DAG: Diaglycerol analog: 1–2-dioctanoyl-sn-glycerol, PAF: Platelet Activating Factor, AA: Arachidonic acid.  
 
In PMA-activated NET formation there are important regulatory roles for NE and MPO. Next, 
it was of interest to see if the granular proteins NE and MPO were present in lipid generated NETs. 
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Since, MPO and NE have been used as NET markers in recent reports (Papayannopoulos et al., 
2010) it has become of general practice to demonstrate the expression of the proteins via 
immunoflouresnce. AA and PAF-induced NETs contained NE and MPO proteins. These results 
confirm that NETs can be generated upon activation with lipids (Figure 18).  
 
Figure 18. NE and MPO localize in AA and PAF-induced NETs. Neutrophils were stimulated with 3 µM AA 
or 3 µM PAF for 240 min followed by fixation and permeabilization. Cells were stained with DAPI, anti-NE and 
or anti-MPO antibodies. PAF: Platelet Activating Factor, AA: Arachidonic acid.  
 
In vivo PMA will not be able to activate NETosis, therefore, it was relevant to show that 
NETs are generated by physiologically relevant compounds like PKC activators DAG and PAF. In 
addition, to activating PKC, it is known that PAF and DAG are important signaling lipids for 
neutrophils and they are involved in cell-to-cell communication. Eicosanoid lipid synthesis is initiated 
by arachidonic acid and we showed that NETs can be activated with AA.  
 
7.4 LOX inhibitors stop NET formation, but COX inhibitors do not  
In addition to the identification of arachidonic acid as a NET activator, the NET screen was 
expanded to the MicroSource US Drug compound library. The US drug library is a collection of 1360 
compounds of FDA-approved pharmaceutical compounds. In both screening campaigns, we 
identified COX/LOX inhibitors such as resveratrol and curcurmin. In order to identify the signaling 
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mechanism, in which the eicosanoid pathway is involved in NET formation, additional inhibitors 
were screened in the NET inhibition screen. The COX/LOX inhibitors suggest a very promising 
therapeutic component for NET inhibitors. These inhibitors, specifically COX1/2 inhibitors, are 
common therapeutics for inflammation diseases. These compounds are commonly known as 
nonsteroidal anti-inflammatory drugs (NSAIDs) and are widely used for pain and inflammatory 
treatments. 
Resveratrol and curcumin are both natural products that are known to have antioxidant 
properties and have been identified as COX inhibitors. Additional studies showed that they were not 
specific to COX but showed inhibitory activity for LOX as well. Their promiscuity as ROS 
scavengers and inhibitors of many other enzymes that are involved in the redox mechanisms has 
been reported (Fremont, 2000; Jankun et al., 2016). We tested the compounds as positive controls 
in addition to other dual inhibitors of COX/LOX like nordihydroguaiaretic acid (NGDA) and 
eicosatetraynoic acid (ETYA) (Kleniewska et al., 2012). These dual inhibitors were most active upon 
the activation with PMA since 40 to 60 % cell death and large nuclei was observed. This would 
classify them as group 2-type NET inhibitors (Figure 19 A-B). They showed an efficient inhibition at 
the last stage where NET formation stopped right before the cell ruptures to expel the nuclear 
content.  
Zileuton, MK-866 and PD146196 are specific LOX inhibitors. Zileuton is a 5-LO inhibitor, MK-
866 is a 5-LO activating protein (FLAP) inhibitor and PD146196 is 15-LO inhibitor. Both 5-LO 
inhibitors caused 70% cell death and large nuclei morphology. They are classified as a group 2-type 
of NET inhibitor. The most efficient NET inhibitor was PD146196 with a cell death of 68% and group 
1-type morphology (Figure 19 C-D).  
Celecoxib and indomethacin were used as selective COX inhibitors. Celecoxib is a COX2 
inhibitor used in the treatment of arthritis while indomethacin is a COX inhibitor used for fever and 
inflammation suppression. Both compounds failed to inhibit NET formation with an observed cell 
death of 90% or higher and a large nuclei morphology (Figure 19 F-E). All COX inhibitors were not 
found to be inhibitors of NET formation. In addition to these two compounds, other NSAIDs such as 
diclofenac, meclofenamic and sulindac sulfone were tested and showed no inhibition of NET 
formation (data not shown).  
From the COX/LOX inhibition data it can be concluded that the eicosanoid pathway is indeed 
involved in NET formation. Dual LOX/COX inhibition confirmed this finding although the lack of 
selectivity of these compounds needs to be taken into consideration. The selective inhibitors that 
were used provide new insights into the mechanisms involved in NET formation. Whereas COX 
enzymes do not influence NET formation, LOX enzymes regulate NETosis. Notably, LOX inhibitors 
are not the most effective NET formation inhibitors.  
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Figure 19. LOX and COX/LOX dual inhibitors stop NET formation. Dual COX/LOX and LOX inhibitors halt 
NETosis (A-D). COX inihibitors fail to stop NET formation (E-F). Neutrophils were pre-incubated with the 
compounds for 20 min (30 µM), except for MK-866 (1 µM), by stimulation with 40 nM PMA and further 
incubation for 240 min to allow NET formation. Cells were stained with SYTOX Green to detect death cells (A, 
C, and E). Nuclear morphology was analyzed upon fixation and permeabilization using automated microscopy 
(B, D and F). Data are mean values ± s.d. (N = 3, n = 3). US: unstimulated cells. 
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  Next, the possibility that inhibitors of the arachidonic acid pathway exert their action through 
ROS generation was explored. Therefore, an oxidative burst assay after the exposure to the 
compounds was performed. Surprisingly, resveratrol and ETYA failed to inhibitor ROS generation 
after 30min although it was expected that all dual inhibitors halt ROS formation. The COX inhibitors 
failed to inhibit ROS generation as well. However, all LOX inhibitors reduced ROS generation 
placing the involvement of this 5-LO and 15-LO upstream of ROS generation (Figure 20). This is in 
line with previous findings where DAG and PAF were found to activate the ERK pathway (Prescott 
et al., 2000; Toker, 2005). We show that the ERK pathway is upstream of ROS generation in NET 
formation. It was hypothesized that this COX/LOX pathway would be involved upstream of ROS. 
Nevertheless, further experiments would be necessary to confirm this finding. 
 
 
Figure 20. Influence of COX and LOX inhibitors on ROS generation. Neutrophils were treated with 15 µM 
of the compounds for 20 min prior to stimulation with 20 nM PMA to induce an oxidative burst. ROS were 
monitored in situ using the luminol/HRP reagent every minute for 120 minutes. Data shown correspond to 
percent of generated ROS after 30 min stimulation with PMA for dual COX/LOX (A), LOX (B), and COX (C) 
inhibitors.  Data are shown as mean values ± s.d. (N=3, n=3). US: unstimulated cells. RLU: relative light units.  
 
 The failure of COX-specific inhibitors to halt NETosis supports with earlier reports where 
neutrophils activated with AA or ERK signaling were completely independent of COX activity 
(Capodici et al., 1998).  In their findings the activity was due to 5-LO. They tested ERK activity, with 
both indomethacin (COX inhibitor) and zileuton (5-LO inhibitor) upon activation with AA, zileuton 
affected the ERK activity and indomethacin showed no effect. The results presented here for the 
different COX and LOX inhibitors follow a similar pattern. 
 The involvement of lipoxygenases in NETs suggests another interesting role and that is cell-
to-cell communication. Lipoxins are produced by the metabolism of arachidonic acid by 12/15-
lipoxygenase and 5-lipoxygensae (5-LO). Lipoxin production is a typical response to transcellular 
metabolism. Traditionally, in neutrophils calcium ions stimulate the production of lipoxin A4 (LXA4) 
which is later used to activate and communicate with platelets (Edenius et al., 1988). If this is the 
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case in NET formation, hypothetically, lipoxin synthesis can be triggered to either activate or 
deactivate NET formation in adjacent cells and signaling to other adjacent cells.  
 
7.5 Novel finding of lipid bodies in NETs 
In an attempt to prove the presence of lipids on NETs, oil red O staining was performed. The 
neutrophils were activated with PMA to generate NETs and fixed on glass slides. The unstimulated 
neutrophils (used as control) and NETs were stained with SYTOX green, a DNA dye, and oil red O, 
a classical lipid stain. Oil red O is a soluble diazole dye with an absorption of 518 nm that stains 
neutral lipids and cholesteryl esters, but not biological membranes (Mehlem et al., 2013). This 
surprisingly revealed a presence of lipid bodies on the NETs and on the neutrophils as illustrated in 
Figure 21. Lipid bodies are also known as lipid droplets or adiposomes, organelles that are known 
to be involved in metabolism and lipid storage. In the context of immune cells, specifically 
inflammation, lipid droplets get triggered by oxidative stress and inflammatory factors, i.e. LPS, 
pathogens, PAF, eicosanoids, and cytokines (Melo et al., 2011a). Lipid droplets can be used as 
inflammation markers in disease (Melo et al., 2011b).  In the case of NETs, this is the first account 
in which lipid bodies are seen in NETs. Therefore, their role and composition is unknown.  
On the unstimulated cells lipid bodies were surrounding the nucleus and were present in the 
cytoplasm (Figure 21 A-B). Detailed inspection revealed that the lipid bodies on the NETs were 
located on the strings of the NETs and on the outside rim of cell membrane remnants (Figure 21 E-
G). After, micrococcal nuclease (MNase)–mediated digestion of the DNA and centrifugation, the 
lipid bodies were isolated (Figure 21 C). After imagining, it was not possible to investigate the lipid 
bodies further. There was much optimization needed for proper storage and identification 
techniques.  
It can be speculated that the lipid bodies are composed of AA, PAF, leukotrienes or lipoxins 
which are synthesized during NET formation and are encapsulated in a lipid body. It is known that 
lipid bodies are composed of a neutral core containing triacylglycerols (TG) and cholesterol esters 
(CE) surrounded by phospholipids (Deevska and Nikolova-Karakashian, 2017). These fatty acids 
can be converted to AA or into any other fatty acid intermediate. These lipid bodies decorate the 
NETs, like the granular proteins, and may serve to send pro-inflammatory signals to adjacent cells. 
A basis for this hypothesis comes from the image where a NET string connects an adjacent cell and 
the DNA string is decorated with lipid bodies (Figure 21 D). The role of these lipid bodies would be 
dependent on the type lipid the lipid body is composed.  
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Figure 21. Lipid bodies found in NETs. Unstimulated neutrophils stained with Oil O Red and counterstained 
with SYTOX green (A-C). Red colored lipid bodies surround the nucleus (B). Lipid bodies (C) Neutrophils 
activated with PMA have lipid bodies on the periphery of the diffused NETs (D-E). (F-G) Lipid bodies are also 
found along the NETs. (D, F-G) Lipid bodies are present on the strings of DNA from the NETs that are 
connecting two different neutrophils. 
  
7.6 Project Conclusion 
The involvement of the eicosanoid pathway in NET formation was confirmed. NETs were 
generated with signaling lipids that are precursors of the eicosanoid synthesis pathway. The LOX 
inhibitors had an effect on NET formation and COX inhibitors did not. This excludes COX signaling 
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pathway from the NETosis mechanism. It can be postulated that once the eicosanoid pathway is 
activated it chooses the lipoxygenase route to synthesize leukotrienes or lipoxins followed by 
activation of adjacent cells which eventually triggers NET formation. The eicosanoid pathway is a 
signaling pathway whose primary role is communication and this was confirmed by the finding of 
lipid bodies on the NETs. We hypothesize that the lipid bodies are composed of a signaling lipid. 
Our first attempts to identify the composition of the lipid bodies, was via HPLC identification using a 
9-antryl diazomethane (ADAM) for identification of eicosanoids. However, this was not successful 
due to lack of experience and appropriate setup (Moraes et al., 2004). Therefore the content of the 
detected lipid bodies remains to be determined and their role on NETosis remains to be confirmed. 
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8.1 Hypothesis 
The NET phenotypic screening of annotated libraries led to the identification of Raf-MEK-ERK 
signalling and eicosanoid pathways involved in NET formation. The screen was expanded to the in-
house library of natural product-(NP)-inspired compound to identify novel NET inhibitors or new 
biological targets that will elucidate NETosis. Additionally, these compounds may represent a 
starting point for development of future therapeutics.  
8.2 Identification of novel inhibitors: Aminothiazoles 
The screen was expanded to the in-house developed library of 8407 compounds to identify 
inhibitors of NET formation based on natural product inspired chemical scaffolds. For this compound 
library, the compounds are based on NP-derived scaffolds and the targets are mostly unknown. The 
same readouts for the assay as before were used, i.e. nuclear morphology and cell death of 
neutrophils (Figure 22). The compounds were screened at an initial concentration of 100 µM. The 
screen produced 134 hits a less than 2 % hit rate.     
 
Figure 22. NET screen workflow and inhibitor classification 
2-substituted aminothiazoles were identified as novel potent NET inhibitors. At a 
concentration of 100 µM the compounds blocked NET formation and maintained cell viability. 
Aminothiazole derivatives were causing two different nuclear morphologies, i.e. group 1 and group 
2. The aminothiazole scaffold represents an attractive compound series due to their structure and 
well established biological activity. Thiazoles are potent compounds found in drugs such as 
sulfathiazole, an antibacterial agent; ritonavir, an antiviral compound; and abafungin, an antifungal 
agent (Siddiqui, N. Thiazoles 2009). The most active compounds were AT4-AT6 from Table 6. 
These three compounds induce the same group 1 phenotype. Compounds AT15, AT2, and AT9 
(Table 6) exhibited a group 2 morphology. The hypothesis is that compounds with a group 2 nuclear 
morphology would be involved in the later stages of NET formation, where the mechanistic steps 
remain unknown. This NETosis step must be of important since it lasts from 30 to 120 minutes and 
results in cell death.   
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Twelve out of the fifteen aminothiazoles have a dihydroxyphenyl group at the R1 position. If 
the R1 position is substituted with a methoxy phenyl or dimethoxy phenyl (compound AT11 and 
AT12, Table 6) the inhibition is partially lost. This is also observed when substituted with pyridine 
(compounds AT13 and AT14, Table NS1). From this, we deduce that the dihydroxylphenyl is 
essential for activity. With a larger set of 3,4-dihydroxyphenyl R1 substituted compounds available, 
significant SAR can be derived regarding the R3 position (compare entries AT1-AT0, Table 6). No 
differences in cell toxicity were observed for the ortho-, meta-, para-phenyl-, compounds AT3, AT4, 
AT5, (Table 6) respectively, they all maintain cells viable. However, there is a slight increase 
towards the small nuclei phenotype observed for compound AT3. Here, a more decondensed 
phenotype is found. When the hydroxyl is substituted to a methoxy or a phenyl (compounds AT9 
and AT10), an increase in cell toxicity of more than 40 % is observed compared to compound AT3. 
All these observations are however overshadowed by the fact that these compounds have a 
catechol moiety. These dihydroxyphenol moieties, 1, 2- or 1,4- oriented, are known to scavenge 
ROS, which can account for the activity measured. As stated before, ROS are important initiators of 
NET formation.  However, compound AT15 does not contain the catechol moiety and does retain 
NET inhibitory activity. This keeps open the possibility that the aminothiazoles do have a unique 
mode of action.  
In order to measure the ROS scavenging properties of aminothiazoles, an oxidative burst 
assay with in situ using luminol/HRP reagent was performed to test for ROS generation. Most of the 
compounds stop ROS generation, except for compound AT8 which maintains a ROS generation of 
62%. In addition to the ROS generation experiments, an oxygen consumption assay using a Clark 
electrode was used. The results clearly showed that most aminothiazoles do consume oxygen for 
the exception of AT6 and AT9, where the levels of oxygen are lowered to 20%. Combining the 
results from both assays it is clear that the NET formation inhibition activity of this class of 
compounds is likely due to ROS scavenging rather than targeting a distinct protein target. This 
discredits the aminothiazoles as an interesting class of compounds to study in regard to NET 
formation. 
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Table 6. Aminothiazoles inhibit NET formation. Neutrophils were pre-incubated with 100 µM of the 
compounds for 20 min at 37
o
C followed by stimulation with 40 nM PMA and further incubation for 240 min to 
allow NET formation. Cells were stained with SYTOX Green to detect death cells. Nuclear morphology was 
analyzed upon fixation and permeabilization using automated microscopy. For ROS detection, neutrophils 
were treated with compounds (100 µM) for 20 min prior to stimulation with 20 nM PMA to induce oxidative 
burst. ROS were detected in situ using luminol/HRP reagent. Oxygen consumption was measured with a 
Clark electrode after pre-treating the neutrophils with compounds (100 µM) for 20 min. Data shown 
correspond to percent of generated ROS after 12 min stimulation with PMA (PMA-induced ROS were set to 
100%). Data are mean values ± s.d. (N =2, n = 2). AT = Aminothiazole. 
 
8.3 Catechol: an undesired moiety in studying NET formation 
Catechol is a moiety that is easily oxidized to highly reactive chemicals within a cellular 
environment. These reactive species can cause oxidative stress in an uncontrolled manner. 
Neutrophils rely on ROS generation for several functions such as, activation of pathways, granule 
maturity, signaling within cells and cell-to-cell communication. Generation of ROS is a highly 
controlled process. If it takes place in excess it causes tissue and DNA damage, and actives several 
pathways uncontrollably, such as lipid peroxidation, ROS generation, which results in undesired 
inflammation (Nathan and Cunningham-Bussel, 2013).  
Therefore, there was a decision to investigate the catechol moiety in further detail. As a test-
substrate we used pyrotcatechol, which is the smallest example of a catechol. Additionally, 
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apocynin, a NADPH oxidase inhibitor with a substituted catechol was chosen as a tool to investigate 
the catechol moiety in neutrophil NET formation (Figure 23 A-B). Apocynin is derived from the plant 
Apocynum cannabinum and prevents p47phox from associating to the membrane. Also, apocynin 
lacks selectivity as it is also known to inhibit MPO and to scavenge hydrogen peroxide (Stefanska 
and Pawliczak, 2008; t Hart et al., 1990). In the NET assay neutrophils are activated with PMA. 
PMA in addition to activating PKC, it is involved in the regulation of p47phox (Bey et al., 2004; 
Fontayne et al., 2002). This protein is a component of NADPH oxidase (Nox) and during screening 
for NET inhibitors it can be expected to obtain NADPH oxidase inhibitors as hits as well as specific 
inhibitors of the several Nox proteins, i.e. p47phox,  (Kleniewska et al., 2012).  
The NET assay and ROS generation experiments were performed using DPI as a positive 
control. Both compounds, pyrocatechol and apocynin, inhibited NET formation and exhibited a 
group 1 phenotype. Apocynin, which caused a 80% small nuclei inhibitor was more comparable to 
DPI than pyrocatechol (Figure 23 C-D). Both compounds, pyrocatechol and apocynin, showed no 
significant toxicity towards neutrophils. It is expected that these compounds have antioxidant 
properties. In addition, compounds were subjected to ROS production and oxygen consumption 
assays. Both apocynin and pyrocatechol inhibited ROS productions as effective as DPI (Figure 23 
E). Both showed excellent levels of oxygen consumption superior to DPI (Figure 23 F). This 
supports the hypothesis that NET formation inhibition activity of molecules with catechol moieties 
can be directly correlated to their ROS scavenging abilities. Such compounds can be considered 
undesired moieties in the search of a NET formation inhibitor. Undesired compounds would be 
avoided in further exploration.   
Small molecules with the properties of ROS scavenging or inhibition of ROS production can 
have serious consequences. A clear example of when it would be advantageous to avoid such 
undesirable effects is, in patients suffering from chronic granulomatosus disease (CGD). These 
patients have a genetic mutation in their NADPH oxidase subunits and are unable to effectively 
produce ROS. Their immune system is compromised because it can neither effectively kill 
pathogens nor control infections (Winkelstein et al., 2000). The objective of the development of this 
high-content screen is to learn about NET formation as well as to find an efficient NET formation 
inhibitor. This requires early exclusion of undesired compounds and a critical view on identifying 
structural elements that can cause non-specific interaction with cellular processes. 
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Figure 23. ROS scavengers inhibit NET formation. (A-B) Structure of pyrocatechol and apocynin. (C-D) 
Pyrocatechol and apocynin inhibit NET formation. Neutrophils were pre-incubated with 100 µM of the 
compounds for 20 min at 37
o
C followed by stimulation with 40 nM PMA and further incubation for 240 min to 
allow NET formation. Cells were stained with SYTOX Green to detect death cells (C). Nuclear morphology 
was analyzed upon fixation and permeabilization using automated microscopy (D). (E-F) Pyrocatechol and 
apocynin scavenge ROS. For ROS detection, neutrophils were treated with compounds (30 µM) for 20 min 
prior to stimulation with 20 nM PMA to induce oxidative burst. ROS were detected in situ using luminol/HRP 
reagent. Data shown corresponds to percentage (related to cells that were treated only with PMA) of 
generated ROS after 12 min stimulation with PMA (E). Oxygen consumption was measured with a Clark 
electrode after pre-treating the neutrophils with compounds (30 µM) for 20min (F). Data are mean values ± 
s.d. (N =2, n = 2).  
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9.1 Hypothesis 
During the screening of the in-house compound library we identified an additional compound 
series as novel small-molecule inhibitors of NET formation. These tetrahydroisoquinolines (THIQs) 
induced, in addition to a group 1 phenotype, a group 2 morphology, which has not previously been 
investigated further. These compounds can enable the study of NET formation at different stages 
that is so far not possible with the known NET inhibitors.  
 
9.2 Identification of tetrahydroisoquinolines as NET Inhibitors 
Besides aminothiazoles a second compound class, tetrahydroisoquinolines (THIQs), were 
identified as low micromolar NET formation inhibitors. These compounds induced a group 1 and 2 
phenotype (Figure 24 A-C). Group 2 phenotype inhibitors, rendering the neutrophils viable and 
displaying large nuclei, have not been reported in literature. THIQs were found to suppress the 
PMA-induced NET formation up to 80% at a concentration of 30 µM. They were as effective, to a 
certain extent, as the well-established NADPH oxidase inhibitor diphenyl iodonium (DPI). 
Compound T1 was found to be the most potent compound with an EC50 for inhibition of NET 
formation of 1.9 ± 0.6 μM (Figure 24 A). Cells treated with compounds T1, T2, and T3 (Table) 
displayed decondensed nuclei assigned to group 2 indicating that NET formation was arrested at a 
later stage (Figure 26). Compounds T4, T5 and T6 resulted predominantly in small nuclei, i.e. both 
lobulated and delobulated. This phenotype indicates inhibition of NET formation at an early stage of 
NETosis.   
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Figure 24. Tetrahydroisoquinolines inhibit NET formation. Structures of tetrahydroisoquinolines that 
inhibit NET formation and their EC50 values for inhibition of NET formation, respectively (A). Neutrophils were 
pre-incubated with serial dilutions of the compounds for 20 min followed by stimulation with 40 nM PMA and 
further incubated for 240 min to allow NET formation. Cells were stained with SYTOX Green to detect dead 
cells and permeabilized for microcopy analysis. EC50 were determined using nonlinear regression. (B-C) 
Neutrophils were pre-incubated with 30 µM of the compounds for 20 min at 37
o
C followed by stimulation with 
40 nM PMA and further incubation for 240 min to allow NET formation. Cells were stained with SYTOX Green 
to detect death cells (B). Data are mean values ± s.d.  (N = 3, n =5). Nuclear morphology was analyzed upon 
fixation and permeabilization using automated microscopy (C). Data are mean values ± s.d. (N = 3, n = 5). 
US: unstimulated cells. 
A library of 100 THIQ derivatives was synthesized as described previously in collaboration 
with Tobias Zimmermann (Zimmermann et al., 2013). The library was screened for NET formation 
inhibition to assess the structure activity relationship (SAR) (Figure 25). Major structural changes 
around the tetrahydroisoquinoline scaffold led to complete loss of activity. Introduction of different 
substituents around the core scaffold resulted in complete loss of activity (Figure 25 A). No 
substitution was allowed on the nitrogen of the tetrahydroisoquinoline and only methoxy groups 
were tolerated on the R2 and R3 positions. The position that allowed more structural diversity was 
the R1 position regarding the substitution pattern on the phenyl ring (Figure 25 A). It is noteworthy, 
that the different functional groups led to different morphology of the nuclei. Small nuclei 
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phenotypes were induced if a thiophene substituent was present in T5 and T6 (Figure 26), whereas 
the m-methoxy-phenyl substituent in T2 and T3 (Figure 26), led to group 2 phenotypes. The non-
substituted phenyl group changed the phenotype dependent on the activators as was the case for 
compounds T1 and T4 (Figure 26). Next, we investigated the importance of the stereogenic center. 
For THIQs T1, T3, T4 and T6, both R and S enantiomers were separated by HPLC chromatography 
on a chiral stationary phase and tested separately. Both isomers displayed similar inhibitory activity 
showing that stereochemistry was not essential for activity (Figure 25 B). 
 
Figure 25. Structure activity relationship of the THIQs for inhibition of NET formation. (A) Structure 
activity relationship based on NET inhibition and cell death. (B) Separate enantiomers (E1 and E2) of THIQs 
were assayed at a concentration of 30 µM. Neutrophils were pre-incubated with 30 µM of the compounds for 
20 min at 37
o
C followed by stimulation with 40 nM PMA and further incubation for 240 min to allow NET 
formation. Cells were stained with SYTOX Green to detect dead cells. Data are mean values ± s.d. (N = 5, n = 
3). US: unstimulated cells. 
The THIQ compound class is a tool to study NET formation, since one structural change 
leads to different NET formation inhibition phenotypes. Figure 26 illustrates how compounds T1-3 
give neutrophils with a large nuclei and T4-6 give small nuclei when cells were stimulated with PMA. 
Focusing on these active THIQs, a pattern emerges concerning morphology based on variation 
applied to the R1 position. Compounds T3 and T2 have a m-methoxyphenyl substituent and display 
a large nuclei phenotype (illustrated in pink Figure 26). Compounds T5 and T6 have a thiazole in 
the R1 position and both show a small nuclei phenotype (illustrated in blue in the Figure 26).  
Compounds T1 and T4 have a non-substituted phenyl group and their phenotype is dependent on 
the NET formation activator that was used (this will be discussed in more detail below). This 
possibility of arresting the neutrophil NET formation process at different stages with different THIQs 
offers a new opportunity for studying this poorly understood type of cell death in a more precise 
manner.  
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Figure 26. Structure activity relationship of the active THIQs based on their nuclear morphology. 
Graphic representation of the different phenotypic NET formation inhibitors based on the substitution on R
1
 
(A). Neutrophils were pre-incubated with 30 µM of the compounds for 20min at 37
o
C followed by stimulation 
with 40 nM PMA and further incubation for 240 min to allow NET formation. Cells were stained with SYTOX 
Green. Nuclear morphology was analyzed upon fixation and permeabilization using automated microscopy 
(B). US: unstimulated cells 
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Since PMA is an artificial PKC activator, we investigated the ability of the THIQs to inhibit 
NET formation using more physiologically relevant PKC activators such as diacylglycerol (DAG) or 
platelet activation factor (PAF) (Etulain et al., 2015; Hakkim et al., 2011). Upon NET activation with 
the DAG analog, THIQs successfully suppressed NET formation as detected by a decrease in cell 
death (Figure 27) and by an increase in cells with lobulated nuclei (Figure 27 B-C).  
 
 
Figure 27. Influence of THIQs on NET formation using DAG as an activator. Neutrophils were pre-treated 
with the compounds prior to stimulation with 3 µM DAG (A-C). Cells were stained with SYTOX Green to detect 
dead cells (A) followed by fixation and permeabilization. The detailed nuclear morphology was quantified (B). 
Representative images of DAG induced NETs with or without treatment with 30 µM T1, displaying neutrophil 
nuclei that were stained with SYTOX Green (C). Data are mean values ± s.d. (N=3, n=3). DAG: Diaglycerol 
analog: 1–2-dioctanoyl-sn-glycerol, US: unstimulated cells. 
 
Equally, stimulation with PAF halted NET formation by most THIQs as decline in cell death 
and a decondensed nuclei was observed (Figure 28). In both cases, compounds T3, T5, T6 
maintained their phenotype. These results establish that the THIQs are efficient NET inhibitors 
when induced by both physiological occurring and non-physiological PKC activators. Compounds 
retained the same phenotypes with the exception of THIQs T1 and T4. 
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Figure 28. Influence of THIQs on NET formation using PAF as activators. Neutrophils were pre-treated 
with the compounds prior to stimulation with 3 µM PAF for 240 min (A-C). Cells were stained with SYTOX 
Green to detect dead cells (A) followed by fixation and permeabilization. The detailed nuclear morphology was 
quantified (B). Representative images PAF induced NETs with or without treatment with 30 µM T1, displaying 
neutrophil nuclei that were stained with SYTOX Green (C). Data are mean values ± s.d. (N=3, n=3). PAF: 
Platelet Activating Factor, US: unstimulated cells. 
NET formation occurs in vivo as a response to pathogenic stimuli, for instance during 
bacterial infections. Pseudomonas aeruginosa was used to investigate inhibition by THIQs in a 
more complex physiological scenario (Yoo et al., 2014). Upon treatment with the compounds, 
neutrophils were infected with 100 MOI of P. aeruginosa to stimulate NET formation. In the 
presence of THIQs, cell death was reduced and nuclei displayed a predominant lobulated 
morphology failing to generate NETs (Figure 29).  
 
Figure 29. Influence of THIQs on NET formation activated by P. aeruginosa. Neutrophils were treated 
with the compounds prior to stimulation with MOI 100 P. aeruginosa (A-C). Cells were stained with SYTOX 
Green to detect dead cells (A). After fixation and permeabilization, the detailed nuclear morphology was 
- 93 - 
 
determined (B). Representative images of P. aeruginosa induced NETs with or without treatment with 30 µM 
T1, displaying neutrophil nuclei that were stained with SYTOX Green. In the case of P. aeruginosa cells were 
only fixed (C). Data are mean values ± s.d. (N=3, n=3). P. a.: Pseudomonas aeruginosa, US: unstimulated 
cells.  
 
Moreover, the influence of THIQs on NET formation was explored in the presence of glucose 
oxidase (GO). This enzyme bypasses NADPH oxidase by exogenously generating ROS from 
glucose, oxygen and water to produce gluconic acid and hydrogen peroxide, thereby inducing NET 
formation (Fuchs et al., 2007). When GO was added to THIQ-pretreated neutrophils, the extent of 
cell death induced by GO was reduced by 60% and the nuclear morphology was predominantly 
decondensed (Figure 30). GO-activated NET formation simulates an uncontrolled and escalated 
NETosis, which is present in several diseases. The fact that the NADPH oxidase inhibitor DPI, does 
not inhibit the formation of GO-induced NETs (Figure 30 A) suggests that the THIQs act 
downstream of NADPH oxidase. This demonstrates the effectiveness of the THIQs as NET 
inhibitors. They can inhibit the formation of NETs in the presence of various activators and under 
physiological conditions.  
 
 
Figure 30. Influence of THIQs on GO activated NET formation. Neutrophils were treated with the 
compounds prior to stimulation with 100 mU/mL GO (A-C). Cells were stained with SYTOX Green to detect 
dead cells (A). After fixation and permeabilization, the detailed nuclear morphology was determined (B). 
Representative images of GO induced NETs with or without treatment with 30 µM T1, displaying neutrophil 
nuclei that were stained with SYTOX Green (C). Data are mean values ± s.d. (N=3, n=3). GO: Glucose 
Oxidase, US: unstimulated cells.  
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9.3 Do THIQs interfere with known NET formation mechanisms? 
NET formation is a complex process controlled by various essential enzymes, e.g. NADPH 
oxidase which is responsible for the production of reactive oxygen species (ROS) in the first twenty 
minutes of the NET formation process (Patel et al., 2010; Urban et al., 2009). ROS are involved in 
the signaling and the mobilization of granular proteins. Neutrophil granules are very important to 
NET formation, specifically myeloperoxidase (MPO) (Campos et al., 2007) and nuclear elastase 
(NE) (Papayannopoulos et al., 2010). MPO, a protein downstream of NADPH oxidase, uses 
hydrogen peroxide to generate hydrogen hypochlorite (HOCl) to activate NETosis. After the ROS 
generation during NETosis, NE migrates to the nucleus and degrades histones leading to DNA 
decondensation. MPO is also known to migrate to the nucleus (Metzler et al., 2011; 
Papayannopoulos et al., 2010). To investigate where the THIQ compound class interferes with the 
NET formation machinery, it was crucial to identify the molecular target. 
Thus, the influence of THIQs on the oxidative burst was investigated. Interestingly, the 
compounds did not interfere with ROS formation (Figure 31) and the THIQs T1, T2, T4, and T5 do 
not scavenge ROS. This suggests that these compounds act downstream of ROS formation. 
However, compound T6 weakly inhibited the PMA-induced generation of ROS, while compound T3 
was found to significantly inhibit ROS formation (Figure 31 A). All inhibitors of NET formation 
reported to date inhibit ROS generation upon stimulation with PMA (Fuchs et al., 2007; Metzler et 
al., 2011; Nishinaka et al., 2011; Palmer et al., 2012; Patel et al., 2010) or using other PKC activator 
(Hakkim et al., 2011). However, except for compound T3, THIQs do not inhibit ROS production 
within 30 min of NET activation. The THIQ-based NET formation inhibitors allow ROS generation 
upon initiation of NET formation and therefore, inhibit the process downstream of ROS production. It 
is crucial to maintain physiological ROS levels and, thus, maintain functional neutrophils when 
targeting NETs to ensure a sustained immune response in humans.  
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Figure 31. THIQs do not inhibit reactive oxygen species generation. (A-C) Neutrophils were treated with 
15 µM of the compounds for 20 min prior to stimulation with 20 nM PMA to induce an oxidative burst. ROS 
were detected in situ using the luminol/HRP reagent every minute for 120 minutes. Data shown correspond to 
percentage of generated ROS after 30 min stimulation with PMA (A). (B and C) Effect of individual THIQ 
compounds, T1 (B) and T5 (C) over time on ROS generation. Data are shown as mean values ± s.d. (N=3, 
n=3). US: unstimulated cells. RLU: relative light units.  
 
Next, we investigated whether THIQs inhibit the enzymes MPO and NE. No inhibition of 
MPO activity by any of the THIQs could be detected at 15 µM (Figure 32 A-C). Additionally, most 
THIQs did not influence the enzymatic activity of NE (Figure 32 A and D-E). Only THIQ T2 and T6 
reduced the initial activity of NE to 57% and 35% respectively indicating partial inhibition of NE. Until 
now few proteins have been identified as involved in NETosis, such as the granular proteins 
myeloperoxidase and neutrophil elastase. Interestingly, most THIQs do not inhibit these granular 
proteases, suggesting a different mode of action.  
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Figure 32. Influence of THIQs on myeloperoxidase (MPO) and neutrophil elastase (NE) activity. (A-C) 
Influence of THIQs on myeloperoxidase (MPO). (A, D, E) neutrophil elastase (NE) activity. Enzymes were pre-
incubated with 15 µM of the compounds for 10 min followed by detection of enzymatic activity with a 
chromogenic substrate for 2 hours. (B-C) Effect of individual THIQ compounds overtime on MPO activity: T1 
(B) and T5 (C). (D-E) Effect of individual THIQ compounds overtime on NE activity: T1 (D) and T5 (E).  Data 
are shown as mean values ± s.d. (N=3, n=3) *: partial inhibition.  
To test the cytotoxicity of the compounds, we monitored the release of lactate 
dehydrogenase (LDH) into the cell culture medium. No cytotoxicity was observed upon incubation of 
neutrophils with the compounds for 6 h, even at concentrations as high as 200 μM (Figure 33 A).  
Previously, the involvement of the Raf-MEK-ERK pathway in the process of NET formation 
was identified (Hakkim et al., 2011). To establish if the THIQs compounds affect MAPK signaling 
pathway, the phosphorylation of ERK was tested in the presence of the inhibitors. The initial 
immunoblotting for p-ERK1/2 showed no inhibition of ERK phosphorylation by the compounds 
(Figure 33 B). This result confirmed our hypothesis that the THIQs compounds are not involved in 
the early stages before NADPH oxidase. 
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Figure 33. THIQs are not toxic and do not inhibit ERK phosphoralation. (A) Influence of THIQs on the 
release of LDH . Extracellular LDH activity was determined upon treatment with the compounds or DMSO and 
DPI as controls for 6 h followed by detection of LDH enzymatic activity using a chromogenic substrate. Data 
are shown as mean values ± s.d. (N=3, n=3). (B) Detection of ERK phosphorylation via immunoblotting in 
NET formation. Neutrophils were activated with 40 nM PMA with or without the inhibitors for 90 min prior to 
cell lysis and immunoblotting for phosphorylated ERK 1 and 2 using anti-p-ERK-1 and 2 antibodies and 
peroxidase-conjugated goat anti-mouse, or goat anti-rabbit 2nd antibody. (n = 2) 
 
This concluded the series of experiments that link the THIQs to one of the known pathways 
involved in NET formation. Interestingly, THIQs do not significantly interfere with any of these 
signaling pathways or proteins. T2 and T6 inhibit NE activity slightly, although when these 
compounds are compared in detail to the well-established NE inhibitors used as control they are not 
as effective. The next step was to perform a series of target identification experiments that include 
proteomic experiments and compound labelling and which will be discussed in further detail in the 
following chapters.   
9.4 THIQs and NET Related Disease 
Besides elucidation of the mechanism of NET formation for scientific research purposes, 
NET formation inhibitors can be used to investigate the involvement of NETs in diseases. As 
mentioned before, NETs have been related to autoimmune diseases such as systemic lupus 
erythematosus (SLE) (Garcia-Romo et al., 2011; Hakkim et al., 2010; Lood et al., 2016), rheumatoid 
arthritis (Dwivedi et al., 2012; Khandpur et al., 2013), chronic granuloma disease (CGD) (Bianchi, 
Blood 2009 114), and in the pathogenesis of sepsis (Clark et al., 2007). Recently, cancer (Park et 
al., 2016), preeclampsia (Hahn et al., 2012), thrombosis (Fuchs et al., 2010) and diseases that 
involve necrotic inflammation (e.g., vasculitis (Kessenbrock et al., 2009) and colitis (Bennike et al., 
2015)) where added to the list. A hallmark of many of these disorders is the overproduction and lack 
of degradation of NETs.  
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Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder. The etiology of 
SLE is the overproduction of anti-neutrophil cytoplasmic antibodies (ANCA). The main antibody 
markers are anti-double-stranded (ds) DNA and anti-histones found in patient sera. Recently, 
another characteristic for SLE was established and that is the over-production of NETs which 
occurs without stimulus and which is referred to as spontaneous NETs (Figure 34). In SLE this is 
combined with the inability to disintegrate the NET components properly (Podolska et al., 2015; Yu 
and Su, 2013). This hallmarks SLE as the ultimate NET disease and ideal candidate for NET 
formation inhibitors as possible treatment. Therefore, SLE patient-derived neutrophils were 
employed to evaluate the ability of THIQs to inhibit NET formation. These cells where obtained from 
SLE patients being treated in the Charité under the care of Dr. med. Tobias Alexander.  
 
Figure 34. Representative images for spontaneous NET formation in SLE patient cells and the 
inhibition effect of THIQ T1. Neutrophils were purified from blood of SLE patients. Neutrophils were pre-
incubated with 30 µM of the compound T1 for 20 min prior to activation with 40 nM PMA for 240 min to allow 
NET formation. Cells were stained with SYTOX Green to detect dead cells prior to fixation and 
permeabilization and image acquisition. PMA-induced NET formation in SLE patient cells as well as inhibition 
of NET formation by T1 upon PMA-induced NET formation SLE patient cells.  
 
Interestingly, in SLE patient cells the compounds were effective in inhibiting formation of 
spontaneous NETs by more than 45 % and NETs activated by PMA by more than 68% (Figure 35). 
This change becomes stagering when the THIQ NET inhibition is compared between healthy and 
SLE patients neutrophils. Specifically, the THIQs reduced neutrophil cell death (Figure 35 A and 
C), together with an increase in cells with lobulated or delobulated nuclei (Figure 35 B and D). 
These results clearly indicate that THIQs are able to inhibit NET formation in neutrophils from 
patients, most likely at an early stage of the process. Remarkably, THIQs inhibited formation of 
spontaneous NETs which occur naturally in a patient experiencing a flare. Also, the THIQs inhibit 
the PMA-NETs, which can be speculated to represent NETosis that occurs in a SLE patient 
suffering an infection. NET formation inhibitors can offer a novel opportunity for the treatment of 
SLE without impairing normal functions of neutrophils (i.e. ROS production or granular protein 
functions). 
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Figure 35. THIQs inhibit NET formation in cells derived from SLE patients. Neutrophils were purified from 
blood of healthy individuals or SLE patients. The influence of the compounds on spontaneous NET formation 
was assessed upon incubation with 30 µM of THIQs for 240 min (A). Alternatively, neutrophils were pre-
incubated with 30 µM of the compounds for 20 min prior to activation with 40 nM PMA for 240 min to allow 
NET formation (C). Cells were stained with SYTOX Green to detect dead cells prior to fixation and 
permeabilization and image acquisition (A and C). Quantification of the nuclear morphology induced by the 
compounds in SLE patient neutrophils (B and D). Data are mean values ± s.d. (N=3, n=3).  
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10.1 Hypothesis 
In the previous chapters, the discovery of a new compound class of NET formation inhibitors 
was described. Tetrahydroisoquinolines (THIQs) were shown to stop NETosis at different stages of 
the process depending on the chemical structure. The molecular target could not be identified 
among the known proteins that are involved in NETosis. The next step is to resort to known 
chemical biological techniques in order to identify the target. We decided to use affinity-based 
proteomics, i.e. pulldown experiment, as technique to identify the biological target. For this purpose, 
it is necessary to functionalize THIQs.   Besides this proteomics approach, additional techniques 
were also used in an attempt to identify the THIQ target protein including in silico prediction 
approaches.  
 
10.2 The art of target identification  
The field of chemical biology generates large data sets and expanded the “Omics Era” (”Omics” 
meaning ‘the large study of’) (Di Girolamo et al., 2013).  The Omics era started with genomics and 
the human genome project, which was a large collaboration to sequence the entire human genome 
(Franzosa et al., 2015). More recently, proteomics and metabolomics were introduced. 
Metabolomics is the study of metabolites from chemical processes and it is applied in toxicology 
and environmental sciences. The basic definition of proteomics would be the study of structure and 
proteins on a large scale, in reality it entails much more (Weinstein, 2001).  
Proteomics is an essential tool for chemical biologists aiming to identify the molecular target for 
a compound of interest. Target identification is a complex science and there is no one correct way 
to identify a previously unknown small molecule protein target. Often small changes in experimental 
procedures can make the difference between success and failure. Many parameters have to be 
taken into consideration in setting up the successful experiment. In the past decade, chemical 
biologists have developed and improved upon many techniques to troubleshoot issues that arise in 
the identification of the target for bioactive molecules. Several approaches can be taken, however, 
the affinity-based proteomics experiment a.k.a. “the pulldown” has rapidly become the go-to-
technique for identifying an unknown molecular target (Schenone et al., 2013; Ziegler et al., 2013).  
The pulldown is an experiment where the protein of interest is trapped on a solid support 
and isolated from a complex protein mixture (e.g. cell extract) followed by mass spectroscopy 
identification (Figure 36). The main steps in performing a pulldown are first the chemical 
preparation of a synthetic tool compound that is equipped with a functional group to allow for 
attachment to a solid support. Second, the isolation of the desired protein with functionalized active 
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compound and, finally, the proteomic analysis of the isolated proteins. To correctly identify the 
target protein several background experiments have to be performed to avoid the identification of 
false positives or failure to bind the target protein. The established structure activity relationship 
(SAR) around the chemical compound that is used as tool compound must be studied. This allows 
for attachment of a linker to the molecule without negatively affecting binding to the target protein. 
The chemically modified compound, or probe, consists of three main components: the biologically 
active molecule, a linker, and a functional group. The functional group allows the probe to attach to 
the solid support, usually polymer beads, which will further permit extensive washings in order to 
wash away the unbound proteins. The functional group is chosen based on the nature of the 
investigation. The most common affinity tag is biotin which binds with high affinity to avidin, 
streptavidin or neutravidin. There are a wide variety of linkers, the most commonly used is an 
ethyleneglycol of a length of at least three units. The length of the linker needs to be chosen 
carefully and depends on the size of the molecule of interest. There should be no steric hindrance of 
the compound-target protein interaction by the solid support (Schenone et al., 2013; Thompson et 
al., 2012; Ziegler et al., 2013).  
Regarding the biochemistry of the pulldown several aspects must be optimized. For 
example, the biological nature of the sample, i.e. cell lysates; use of stringent washings; control 
experiments; and possible incorporation of isobaric labels all enable the quantification to be 
considered and optimized.  
For choosing the correct proteomic analysis, understanding the design of the experiment is 
crucial. Assuming that there is access to an appropriate instrument such as a LC-MS/MS or a GC-
MS/MS, instrumental measuring time is the rate determining step. Ideally, qualitative and 
quantitative data achieved in the shortest time possible is desirable. Over the years analytical 
protocols have become more sensitive and improved instruments have greatly improved the quality 
of these experiments. Laboratory techniques and reagents such as isotopic labeling have been 
developed allowing for the data to be analyzed both qualitatively and quantitatively (Di Girolamo et 
al., 2013; Rabinowitz et al., 2011; Reaves and Rabinowitz, 2011). Stable isotopes, such as arginine 
and lysine, can be incorporated in which biomolecules in cells before cell lysis (Figure 36). They do 
not interfere with the physico-chemical properties of the proteins. Isotopes are incorporated into 
cellular proteins metabolically using labeled essential amino acids in a method called stable isotope 
labeling by amino acids in cell culture (SILAC). Usually two different types of cell lysates are 
generated, one with regular growth media called “light” and the other media containing isotope-
containing amino acids called “heavy amino acids.” The cells are cultured for usually two or three 
passing rounds to secure that the amino acids have been incorporated to all the cells. These cells 
are eventually lysed and the obtained lysates are used in pulldown experiments (Ong et al., 2002). 
For those cell lines for which cell culture is not possible, in vitro labeling such as isotope-coded 
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affinity tags (ICAT) or isobaric tags for relative and absolute quantification (ITRAQ) is possible 
(Figure 36). For ICAT, the amino acid labeling occurs on the proteins before the trypsin digestion, 
i.e. during the pulldown in the lysate. In ICAT the label is a deuterium and carbon thirteen (13C) 
(Gygi et al., 1999). In the case of iTRAQ, the labeling occurs after the trypsin digestion i.e. during 
the isolation of the peptides. In ITRAQ the labeling occurs on the N-terminus and side chains of 
peptides with several tags of different masses (Zieske, 2006). For some experiments described in 
this chapter, the ITRAQ technique was used since neutrophils cannot be maintained in culture 
longer than twelve hours and there was previous experience with the ITRAQ technique.  
10.2.1 Nonspecific Binding  
In pulldown experiments, the cell lysate is exposed to the ligand immobilized to solid support. 
This creates high local concentration of immobilized ligand and will enable binding to high affinity 
targets but also low affinity proteins present in high concentrations in the cell lysate. Identification of 
this high-affinity target protein becomes overwhelmed by low-affinity proteins binding non-
specifically. This issue becomes a problem when the protein of interest is a low-expressing protein 
(Ziegler et al., 2013).  
Most of the target identification pulldown experiments reported in literature made use of high 
affinity probes with abundant target proteins. In such a case low affinity proteins are removed during 
the washing steps or marginalized during analysis by the presence of the high-affinity target protein. 
The proper use of statistics becomes essential when dealing with both non-specific protein binding 
and the true target attached to the probe. Several techniques have been developed to discriminate 
the “false positives” from the true target proteins. For instance, “black lists” have been established 
where frequent binders are listed that bind to probe. The specifics of the proteome of the used cells 
can be considered to exclude vastly abundant proteins that can give rise to false positives. 
Nonetheless, it should always be re-examined if the abundant protein is indeed the target, for 
example, tubulexin A’s target was tubulin which is an abundant protein (Voigt et al., 2013).   
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Figure 36.  Overview of an affinity-based proteomics. A solid-supported immobilized compound that has 
affinity for the target protein of interest is synthesized (pulldown probe). During the experiment, a cell lysate is 
exposed to the pulldown probe allowing for protein binding. The formed complex is washed to remove non-
(specific) binding proteins. The protein(s) that did bind to the probe is removed and the elution is subjected to 
digestion and identification using mass spectroscopy (MS/MS). Isotopic labeling can be incormporated into 
the cells or on the protein/peptides. The ratios between the isotopic labeled and non-labeled peptides are 
used to determine the interaction (direct or indirect).  Image modified from Schenone, et.al. (Schenone et al., 
2013). 
 
10.3 Affinity-based proteomics for NET formation  
The known biological pathways for NET formation were examined in the context of the THIQs 
but none were connected to this compound series. To identify the target(s) of the 
tetrahydroisoquinoline, pulldown experiments were performed. For this purpose it was necessary to 
prepare a set of pulldown probes based on the THIQ structure and established SAR as described in 
chapter 10. The structures of the prepared probes are described in Figure 36.  
10.3.1 THIQs pulldown probes  
From the SAR established around the THIQ scaffold, it can be derived that the R1 position 
substitution has little impact on compound activity. This makes this part of the molecule ideal for 
linker attachment. A triethylene glycol moiety was chosen as a linker unit. The most common affinity 
tag used for pulldown experiments is biotin which binds with high affinity to avidin. The active probe 
P1 (Figure 37) is based on compound T3, T4 and T5, featuring the most active compounds with a 
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methoxy group on the R2 and R3 position (Figure 24). For the design of the inactive control, it is 
common to use an enantiomer specifically if one is active and the other is inactive. The SAR studies 
indicated that there was no difference in activity between R and S enantiomers. However, 
substitution of the basic nitrogen on the THIQ core resulted in complete loss of activity. Therefore, 
an intermediate in probe synthesis, a Boc protected version of T3, was used as a negative control 
P2 (Figure 37). Both biotinylated probes were synthesized by Tobias Zimmermann (Figure 37 A-
B).  
The first pulldown results showed no protein to bind specifically to the active probe. Indeed, 
there were proteins binding to the active probe. However, these proteins also showed affinity for the 
inactive probe. Therefore, it was hypothesized that the Boc group might fall off during the pulldown 
experiment. After a series of unsuccessful pulldown experiments with the biotinylated probes 
(Figure 37 A-B), the probe design was reconsidered. It was decided to change the biotin affinity tag 
for a pulldown construct containing a free amine functional group (P3, Figure 37 C). This amine 
probe can bind covalently to N-hydroxysuccinamide (NHS)-coated polymer beads. The new probe 
is based on the more active THIQ T1. This compound has only one methoxy at the R2 position. For 
the inactive probe (P4), a compound with a methyl group on the nitrogen was prepared. A methyl 
group is chemically more stable than a Boc group. The synthesis of these compounds is described 
in the experimental section. In addition to synthesizing the probes required for pulldown 
experiments, a fluorescently labelled compound (P5) was prepared to allow localization and target 
validation studies. Bodipy was selected as a fluorophore since it has been shown to be less prone 
to photo-bleaching compared to other known fluorophores (Figure 37 E-F). 
In addition to the traditional compound-linker-solid support probes, a collaboration with Max 
Planck-RIKEN Joint center for Systems Chemical Biology provided access to a photo-linked beads. 
The beads are functionalized with oligo-ethylene glycol linkers with aryldiazirine groups that upon 
UV irradiation form highly reactive carbenes that react with the added compound in a non-specific 
manner. This alternative method attaches the small molecule to the solid support via photo-
activation. In doing so, the compound is bound to the resin in various conformations of which at 
least one should still be able to bind the target protein in a high affinity. The principle of this method 
is illustrated in Figure 37 E (Kanoh et al., 2003). This technology has been successfully applied to 
the target identification for natural products with complicated structures that require long and difficult 
total synthesis for their preparation or for which no synthesis route is available. The method was 
developed by the Osada group and colleagues in the RIKEN Global Research Cluster in Wako, 
Japan. THIQs T1 and T3 immobilized on beads by means of this technique by Zimmermann in 
RIKEN Japan (Figure 37 D).  
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Figure 37. Overview of the THIQs probes. (A) Structures of P1 and P2 biotinylated probes.  (B) Structures 
of P3 and P4 probes for covalent coupling via free amine groups. (C) Structure of P5 the fluorescently labelled 
THIQ T1 and bodipy fluorophore structure. (D) THIQs T1, T3, and T8 used for photocrosslinkingg-mediated 
immobilization to functionalized beads. (E) Scheme to obtained photolinked polymer beads.  
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10.3.2 Optimization of the affinity-based proteomics 
As mentioned above many characteristics of an affinity-based proteomic experiment need 
optimization.  
Features of a pulldown experiment that need to be considered are the nature of the cells, the 
stringent washings, control experiments and possible incorporation of isobaric labels to aid the 
analysis. First, the generation of a stable neutrophil lysate is necessary to perform the pulldown. 
Neutrophils are charged with granules filled with proteases. Once the cells are lysed all the granules 
are lysed and all proteases are released causing protein degradation. Therefore, Figure 38 A 
shows protein degradation upon cell lysis in the cytoplasmic layer, (low spin supernantant (LSS)) as 
quickly as within 60 minutes after lysis kept on ice. It was observed that the granular component 
(high spin supernatant (HSS)) and nuclear component (high spin pellet (HSP)) were affected by 
degradation by the proteases. After 24 hours on ice, the degradation is more pronounced and it was 
obvious that the added protease inhibitors were not capable of preventing protein degradation. 
Eventually, it was found that the serine protease inhibitors phenylmethylsulfonyl fluoride (PMSF) 
and diisopropylfluorophosphate (DFP) were capable of preventing the significant protein 
degradation in addition to the known protease inhibitors. However, DFP is extremely toxic and 
should be used with extreme caution and with an adrenaline shot and medical support in close 
proximity. No protein degradation was observed upon 24, 48 and 72 hours and even after long 
storage of up to 5 days on ice (Figure 38 B). The stable PMN cell lysate was obtained.  
After observation of the initial pulldowns’ lack of specificity for the active probe, it was 
thought that isotopic labeling enabled quantitative proteomics would increase the chances of the 
identification of the target protein. Alternatively, it was opted for isobaric tagging for relative and 
absolute quantification (iTRAQ) labeling. This was further optimized by Monica Schmidt at the 
proteomic facility of the Max Planck Institute for Infection Biology (MPIIB).  During iTRAQ, the amine 
groups of the peptide are labeled with tags that have an added mass of 114-117 Da and appear as 
one peak in the MS (Ross et al., 2004).  
 
10.4 Affinity-based proteomics results 
 
Mass spectroscopy analysis performed by Dr. Petra Janning from the MPI of Molecular 
Physiology and Monica Schmidt of the MPI of Infection Biology 
Pulldown experiments were performed using lysates of PMA-activated and non-activated 
neutrophils. As controls, the beads alone or immobilized inactive probe were used. These 
experiments were processed simultaneously under the same conditions. The beads-only control is 
expected to enrich proteins that bind to the polymer matrix. Enriched proteins were subjected to 
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tryptic digest followed by protein identification by means of mass spectrometry. The first round of 
three experiments were performed with the biotinylated probes. In the second round two 
independent experiments were performed with the free amine probes. In addition, four experiments 
were performed with the photo-linked beads. A total of nine pulldown experiments were evaluated. 
Proteins that were found are summarized in the table in Figure 38 D. Unfortunately, no proteins 
were selectively enriched with the active probe in comparison to the controls. From the proteins list, 
neutrophil elastase and RAS-related C3 (RAC2) were of interest. Neutrophil elastase was 
disregarded an elastase activity assay was performed and compound T1 and T3 failed to inhibit 
elastase (data shown in Figure 32 A and D). RAC2 was examined by a pulldown experiment 
followed by immunoblotting and failed to show specificity since the protein was enriched with both, 
active and inactive probe (Figure 38 E).  
Consequently, it was hypothesized that the target might not be a cytoplasmic protein.  At the 
time, during the pulldown experiments, the lysates were not prepared to incorporate membrane 
proteins in the lysates. Another explanation for the unsuccessful target identification using affinity 
based chromatography. Is that probes were tested in NET assay and activity was lost upon 
functionalization (Figure 38 C). That the pulldown probe fails to pass the cell membrane and 
maintain the activity is not a requirement to precede with the pulldown experiments. The reason is 
that during the pulldown procedure the probes will be exposed to the cell lysate and have direct 
interaction with the proteins found in the cell.  
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Figure 38. THIQs pulldown optimization and results. (A-B) Neutrophil lysate optimization. cytoplasmic 
proteins, Low Spin Supernatant (LSS), granular proteins, high spin supernantant (HSS), and nuclear proteins, 
high spin pellet (HSP) (A). Protein degradation inhibited by PMSF and DFP upon addition to neutrophil cell 
lysate, LSS after 24, 48, 72 h up to 5 days and incubated on ice (B). (C) Pulldown probes did not retain NET 
inhibitory activity. Neutrophils were pre-incubated with 30 µM of the compounds for 20min at 37
o
C followed by 
stimulation with 40 nM PMA and further incubation for 240 min to allow NET formation. Cells were stained 
with SYTOX Green. US: unstimulated cells. (D) Proteins that were identified the performed enriched by the 
active (+) or control probe (-). The number indicate how often the protein was identified in total out of 9 
independent experiments. (E)  RAC2 binds unspecifically to the probes. Detection of RAC2 via 
immunoblotting. Neutrophils, HL60 lysates and pur RAC2 were subjected to pulldown experiment with a 
immublotting readout with fluorescence conjugated goat anti-mouse, or goat anti-rabbit 2nd antibody (n = 3). 
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10.5 Localization studies 
In attempt to study the THIQ behavior in cells, localization studies were performed with the 
fluorescently labeled P5 (Figure 37 C). Neutrophils were subjected to a NET formation time course 
after activation with PMA. After fixation and permeabilization the slides were with the P5 compound 
and nuclear stain DAPI (Figure 39). Compound P5 was found to localized to the neutrophils 
undergoing NETosis. This is illustrated in the images in Figure 39 at min 45, highlighted with a red 
circle, which shows neutrophils which are losing their lobules and becoming rounded, and showing 
an increased fluorescence. In contrast to the neutrophils that have a lobulated nucleus, which 
usually indicates that NETosis is yet to start, there is no fluorescence present. After 240min, when 
NET formation has finished, the fluorescent probe is localized in a ring-like structure around the 
expanded DNA and not on the actual NETs. If the THIQ target would be a granular protein, such as 
NE, P5 would be found on the NETs. This result strongly suggests that THIQs target a protein that 
is involved in NETosis and not a protein that is a component of NETs. 
This result presents a possible explanation for why the protein targeted by THIQs was not 
identified in the affinity based proteomic experiments. The pulldown probes were performed on 
unactivated PMNs. During the optimization of the lysate, the focal point was to restrain the 
proteases. As mentioned before, pulldown experiments are not ideal for identifying proteins that are 
of low abundancy. From this experiment, it can be speculated that if the target of THIQs is a protein 
that is only overexpressed when NETosis is undergoing and maintained in low concentration in an 
unactivated neutrophil the protein concentration would be low.  
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Figure 39. Bodipy-labeled THIQ P5 is enriched in cells that undergo NETosis. Neutrophils were 
stimulated 40 nM PMA for 45min or 240min allowing NETosis to occur. Followed by fixation and 
permeabilization, then the slides were blocked with 3% BSA and stained with DAPI (blue) and 1µM P5 (green) 
1µM compounds. 
 
10.6 G-protein coupled receptors (GPCR) and NETs 
 
The target identification of the THIQs has proven to be a complicated task, since the 
conventional affinity-based proteomics approach failed to identify any protein targeted by the 
compounds. An alternative and relatively simple method is to apply computational inference 
methods (Schenone et al., 2013). These in silico methods make use of known protein-small 
molecule combinations and the structural features of a compound of interest are related to them. 
This gives an indication if the compound is likely to have binding affinity for one or several known 
target proteins. We used the statistic-based similarity ensemble approach (SEA) to investigate THIQ 
T1 (Keiser et al., 2007).  SEA compares the compound of interest to known ligands for over 1400 
different proteins. The program scored the compound a low E-value and the smaller this value is the 
closer the resemblance to the ligand. For the best NET formation inhibitor THIQ T1 identified, the 
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results are given in Figure 40 A. The list gives 10 proteins for which T1 is most likely to be an 
interaction partner. This list includes eight different GPCRs including the dopamine D5 receptor. 
The E-value for this receptor is 8.90e-6 and for the α-adrenergic receptor 9.84e-4. These GPCRs are 
both targeted by compounds that were hits in the initial NET screen (Figure 40 C). However, the 
top-of-the-list protein suggested as the target was not a GPCR but an enzyme, quinone reductase 
with an E-value is 9.58e-15. The second on the list is a GPCR, the melatonin receptor with an E-
value of 2.95e-10. Additionally to the SEA, flexible alignment studies using computer software MOE 
(Molecular Operating Environment) program were performed. Here the chemical structure of THIQ 
T1 was compared to seratindole (Figure 40 B). Seratindole is an antipsychotic drug that targets 
dopamine, 5-HT2 and adrenogenic receptors. The model shows how the structural features of both 
molecules aligned in 3-dimentional space. The software places the basic amine of both compounds 
on top of each other and the flat aromatic rings are easily aligned.  
These results strongly suggest that the THIQs may target a GPCR. This would also explain 
why no target was convincingly identified through pulldown. To identify a membrane protein via a 
conventional pulldown technique would not be possible unless the appropriate modifications have 
been taken into experimental consideration. For instance non-denaturing detergents such as NP-40 
should be used together with specific centrifugation speeds. During the evaluation of the mass 
spectroscopy analysis, the membrane proteins are deliberately sought.  
From our initial NET formation screen, several GPCR interacting compounds were identified 
as effective NET formation inhibitors (Figure 10).  The compounds aminoclodine hydrochloride; 
apomorphine; and benzazepine hydrobromide were identified as effective inhibitors of NETosis. 
These compounds target the α2-adrenergic receptor and also the dopamine receptors. Due to the 
lack of knowledge considering the relationship between GPCR functions and the process of NET 
formation these hits were not further investigated. Clearly, there is an undeniable structural similarity 
between apomorphine and the THIQs. The original hit data was reinvestigated and it was observed 
that aminoclodine hydrochloride, apomorphine, and benzazepine hydrobromide and THIQs induce 
the same nuclear morphology of group 2 (i.e. large nuclei) although this data has to be taken with 
caution since both apomorphine, and benzazepine hydrobromide have a catechol moiety in their 
chemical structures (Figure 40 C). This again supports the hypothesis that GPCRs may be involved 
to NET formation.  
The link between GPCRs (e.g. dopamine, adrenergic, melatonin receptors) and neutrophil 
functions is a unexplored field. The first report of the involvement of GPCRs, being chemokine 
receptor (CXCR4), in NET formation was published only recently. It showed that stimulating the 
cells with integrin and chemokines (CXCL4 or CCL5) simultaneously can induce NET formation in a 
mice model for acute lung injury (ALI) (Rossaint et al., 2014). Another plausible relation between a 
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GPCR and NETs can be inferred for the dopamine receptors. These GPCRs, traditionally affecting 
the brain, were related to high levels of infection of the central nervous system (CNS). Dopamine 
receptors regulate acute immune responses, investigated in a new field called neuroimmunology 
(Beck et al., 2004; Mifsud et al., 2011) . As reported previously in the literature, dopamine-receptors 
are implicated in the assembly of NADPH oxidase. The production of catecholamines by this 
enzyme bridge the regulation of NFκB and other cytokines in the intensification of the acute 
inflammation (Kleniewska et al., 2012). Furthermore, a role for catecholamines has been described 
in phagocytosis by neutrophils and other immune cells during acute inflammation and indicates a 
cross talk between the nervous system and the immune system (Flierl et al., 2008; Flierl et al., 
2007; Flierl et al., 2009). A proposed mechanism for the role of the GPCRs in the context of 
NETosis in depicted in Figure 40 D. Several GPCRs activate through cAMP production the protein 
kinase A (PKA) and initiate the Raf-MEK-ERK kinase pathway. If the Raf-MEK-ERK pathway is not 
involved after activating PKA via cAMP production, then a new signaling mechanism is triggered 
when the PKA is activated. From the compound morphology of the NET inhibitors, it is hypothesized 
that this novel cAMP mechanism could be involved in a later stage NETosis or as a feedback 
mechanism to NET formation. This is supported by the data published by Rossaint, et. al., who used 
chemokines in combination with integrins to activate NETosis in mice neutrophils increasing 
inflammation, and ultimately causing complications in acute lung injury (Rossaint et al., 2014).  
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Figure 40. Computational target predictions for THIQ T1 implicate GPCR as targets. (A) SEA results for 
THIQ compound T1. (B) Results of flexible alignment of T1 (left) and seratindole (right) and their structures. 
(C) GPCR-targeting hits in the initial NET screen. (D) Illustration of the proposed GPCRs involved mechanism 
in NET formation.  
 
Next, THIQ T1 was profiled against a panel of 28 GPCRs for both agonist and antagonist 
activity. Interestingly, THIQ T1 was found to be a dopamine receptor D5 antagonist with 59% 
inhibition at 30 µM. Also, for the melatonin receptor MT2 an antagonist activity was measured with 
77% inhibition at 30 µM. The BLT1 receptor was inhibited to 74% at the same concentration. To a 
lesser extent B2 adrenergic (B2) receptor and calcium (CaS) were antagonized by this compound 
with 50% and 50%, respectively (Figure 41 A). An agonist effect of THIQ T1 was not significant in 
any of the receptors tested.  
To further investigate these antagonist findings, well-known agonist and antagonist for these 
particular receptors in the NET formation assay were tested. First, the receptor agonists were tested 
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for NET formation activation. Melatonin, dopamine, and adenosine failed to significantly activate 
NET formation at concentrations of 100 µM, 10 µM, 1 µM, and 100 nM (Figure 41 C-E). Melatonin, 
dopamine and adenosine agonists obtained a maximum of 10% NET formation compared to the 
unstimulated control. The lipid leukotriene B4 (LTB4) was the best activator from all the agonists 
tested activating NET formation by 50% (Figure 41 C- E). This result correlates with the findings of 
other lipids of the eicosanoid pathway such as arachidonic acid and PAF activate NET formation as 
well.  
In the case of melatonin and adenosine there was a very mild activation of 10% of NET 
formation. Interestingly, dopamine appears to have an inhibitory effect at higher concentrations. 
Using this neurotransmitter even more neutrophils were alive and in a lobulated state than the 
unstimulated neutrophils. Both the quantitative microscopy and the images (Figure 41 E) revealed 
that the melatonin, adenosine and LTB4 compounds induce more variety of morphologies 
compared to dopamine where the lobulated cells dominate (Figure 41 C-E). This inhibitory effect 
was confirmed when the GPCR agonists were tested for NET formation inhibition. All agonists were 
tested at 30 µM in the assay and, all compounds showed an inhibitory effect with the exception of 
LTB4. LTB4 maintains the activity of NET activator rather than NET inhibitor. Dopamine is an 
effective NET inhibitor causing a group 1 (small nuclei) morphology (Figure 43 A-B and E-F). 
Adenosine, melatonin and dihydrophenylglycine (3,5-DHPG), a glutamate receptor agonist, led to a 
40-60% inhibition and a group 2 morphology (decondensated nuclei) (Figure 41 F-G). The GPCR 
agonists were tested for both NET formation activation and inhibition, because this will set the basis 
for activity of these particular receptors tested in the context of NETosis. The only GPCR that is 
known to have an effect on neutrophils is the LTB4 receptor which is involved in cell to cell 
communication in the innate immune system (Sala et al., 2010). 
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Figure 41. Effect of THIQ T1 on GPCR receptors and effect canonical GPCRs agonists on NET 
formation. (A-B) THIQ T1 was profiled against 26 GPCR. (C-G) Influence of the GPCR agonists melatonin, 
dopamine, and adenosine on NET formation (C and F) cell death (D and G) quantification of the nuclear 
morphologies. Neutrophils were stimulated with various concentrations of the agonists. (E) Representative 
images of neutrophils upon treatments with the different agonists and staining with the nuclear dye SYTOX 
Green. Neutrophils were pre-incubated with 30 µM of the compounds for 20 min at 37
o
C followed by 
stimulation with 40 nM PMA and further incubation for 240 min to allow NET formation. Cells were stained 
with SYTOX Green to detect dead cells. Nuclear morphology was analyzed upon fixation and permeabilization 
using automated microscopy (D and G). Data are mean values ± s.d. (N = 3, n = 3). Images were acquired 
using a 20X objective. US: unstimulated cells, LTB4: Leukotriene B4, 3,5-DHPG: dihydroxyphenylglycine. 
    
 Also, GPCR antagonists for the melatonin, dopamine, LTB4 and calcium receptors were 
tested for their effect on NET formation.  All antagonists showed a slight inhibitory effect at 30 µM 
on the PMA-induced NET formation and, more interesting, provoked group 2 nuclear morphology, 
indicating inhibition of NET formation during the last stage (Figure 42). The melatonin antagonists 
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were the most effective NET formation inhibitors from all the antagonists tested. Luzindole inhibited 
NET formation with a cell death less than 35% and 70% decondensed nuclei morphology.  The 
other melatonin antagonist tested, K185, also inhibited NETosis with a cell death of 60% and a 70% 
decondensed nuclei (Figure 42 A-C). To find the scientific evidence in the literature to explain why 
the melatonin antagonists were better NET inhibitors compared to the other GPCR antagonists 
tested will have to be postponed. Not much is known in the literature of role of melatonin and 
neutrophils even less when it comes to melatonin and NETs. Both, LY23111 and leukotriene B4 
ethanolamide (LTB4-EA) triggered similar nuclear morphology of large nuclei above 50 %. The 
LTB4 antagonist were the only compounds to show a 10 % of lobulated nuclei the other GPCR 
antagonists tested had 0 % lobulated nuclei. Nevertheless, the compounds show a high level of cell 
death (Figure 42 H-I). The calcium receptor antagonist, SK96365, and the dopamine receptor 
antagonist, SCH23330, showed a very similar pattern of cell death of 50% and 50% ratio between 
small nuclei vs. large nuclei (Figure 42 D-F and J-L). Interestingly, the antagonists of the LTB4 
receptor showed a clear inhibitory effect. 
In the previous paragraphs, GPCR receptor agonists and antagonists were investigated in 
an attempt to find a correlation between GPCRs and NETosis. In particular, dopamine, melatonin, 
glutamate have yet to be investigated in more detail regarding their regulatory role on neutrophil 
function. 
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Figure 42. Effects of known GPCRs antagonists on NET formation. Neutrophils were pre-incubated with 
30 µM of the antagonists of the melatonin, dopamine, LTB4 and calcium receptors for 20min at 37
o
C followed 
by stimulation with 40 nM PMA and further incubation for 240 min to allow NET formation. Cells were stained 
with SYTOX Green to detect dead cells (A, D, G, and J). Nuclear morphology was analyzed upon fixation and 
permeabilization using automated microscopy (B, E, H, and K). Data are mean values ± s.d. (N = 3, n = 3). 
Representative images of neutrophils at different conditions stained with nuclear dye SYTOX Green (C, F, I, 
and L). Images were acquired using a 20X objective. US: unstimulated cells, LTB4: Leukotriene B4.  
 
Noteworthy is that, the association of dopaminergic receptors with immune cells during 
acute immune responses is established (Beck et al., 2004). Dopamine receptors are known to be 
involved in the assembly of the NADPH oxidase. However, the dopamine and apomorphine-
mediated inhibition of NET formation most likely results from the suppression of ROS generation. 
Catecholamines bridge the regulation of NFκB and other cytokines in the intensification of the acute 
inflammation. Apomorphine and dopamine are known to be involved in radical scavenging due to 
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the catechol moiety in their structure (Kancheva, Biochimie 2012). The investigation of the 
dopamine receptor was extended to apormophine and a small library of apormorphine analogs.  
It was found that apomorphine inhibited NET formation as effectively as dopamine and both 
were as potent as the control DPI. There was a difference in the nuclear morphology caused by 
these compounds. Dopamine led to a group 1 (small nuclei) morphology and apormorphine caused 
a group 2 (large nuclei) morphology (Figure 43 B-F). Since both compound have a catechol moiety 
it was vital to investigate if the NET formation inhibition was due to the scavenging activity of the 
catechol moiety rather than a receptor interaction. Both compounds suppressed ROS formation. 
Determination of oxygen consumption dopamine and apormorphine revealed lack of scavenging of 
oxygen (as demonstrated for pyrocatechol and apocynin) (Figure 23 F). Interestingly, apormorphine 
showed the same profile as DPI which does not consume oxygen. This result strongly suggests that 
the oxygen scavenging is not the mechanism of action for these compounds.  
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Figure 43. Influence of dopamine and apormorphine on NET formation. (A and B) Structure of dopamine 
and apormorphine. (B-F) Neutrophils were pre-incubated with 30µM of inhibitor for 20min at 37
o
C. Followed 
by PMA (40nM) stimulation and incubated for 240 min to allow NET formation prior to SYTOX Green to detect 
dead cells. (G) Influence on ROS generation. Neutrophils were stimulated with 40nM PMA to induce oxidative 
burst upon pre-treatment with compounds for 20 min at a concentration of 15µM for 120min. ROS were 
detected in situ using luminol/HRP reagent. (H) Effect on oxygen consumption. Cells were pre-treated with 
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30µM of compound and incubated for 20min followed by activation with 40nM PMA. Oxygen consumption was 
detected using a “Clark-type” electrode for 30min. (N = 3, n = 3).  
 
Considering the structural similarity of the THIQs to apomorphine we decided to study 
apomorphine and analogues in more detail. Several apomorphine analogs stopped NET formation 
(Table 7). Compounds A1, A2, A3, and A4 have group 1 morphology. Noteworthy, apomorphine 
analogue A5 showed group 2 morphology, same as apormorphine and the THIQs. As for 
apomorphine, A1 and A2, both inhibit ROS generation. Compounds A3, A4, A5 do not inhibit ROS 
formation.  Apomorphine and analogues were never further investigated due to the fact that they 
contain a catechol moiety. THIQs do have a different mode of action and lack the catechol moiety 
making them a better compound class to progress compared to the apomorphine-type compounds. 
 
 
Table 7. Apomorphine analogs inhibit NET formation. Neutrophils were pre-incubated with 30 µM of the 
compounds for 20min at 37
o
C followed by stimulation with 40 nM PMA and further incubation for 240 min to 
allow NET formation. Cells were stained with SYTOX Green to detect dead cells. Nuclear morphology was 
analyzed upon fixation and permeabilization using automated microscopy. For ROS detection, neutrophils 
were incubated with compounds for 20 min prior to stimulation with 20 nM PMA to induce oxidative burst. 
ROS were detected in situ using luminol/HRP reagent. Oxygen consumption was measured with a Clark 
electrode after pre-treating the neutrophils with compound for 20min. Data shown correspond to percent of 
generated ROS after 12 min stimulation with PMA. Data are mean values ± s.d. (N =2, n = 2) 
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Neutrophils are the most abundant cells of the innate immune system. Once activated, they 
communicate with other cells via cytokine excretion and eradicate sites of infection by means of 
degranulation, phagocytosis and NETosis. The release of NETs, which are composed of chromatin 
decorated with anti-bacterial granular proteins, leads to a unique form of cell death called NETosis.  
The onset and progression of NETosis are poorly understood. Instead, perturbation with bioactive 
small molecules that act rapidly and conditionally offers a chemical-biological alternative to unravel 
the mechanisms of neutrophil-related processes.  
We developed a semi-automated high content phenotypic screen using human neutrophils 
that is set up for NET formation inhibitor identification. For this purpose, human neutrophils were 
treated with small molecule compound libraries prior to activation with PMA. The identified small 
molecule hit compounds were grouped into four categories based on their influence on nuclear 
morphology and cell viability. Compounds assigned to groups 1 and 2 are of highest interest since 
the induced phenotypes correspond to inhibition of NET formation. Inspection of morphological 
changes allowed to postulate the stage of NET formation in which the cells were arrested.  
 
11.1 RAF/MEK/ERK Pathway regulates NETs 
Commercially available compound libraries (Sigma) were screened. GW5074, a c-Raf kinase 
inhibitor was identified as a NET formation inhibitor with group 1 characteristics. The c-Raf protein is 
part of the MEK/ERK signal transduction pathway. The involvement of the Raf-MEK-ERK pathway 
in NET formation was confirmed by screening U0126, a MEK inhibitor, and ERK peptide inhibitor. 
Additionally, the role of the Ras protein was ruled out using indirect Ras-signaling disrupting 
compounds. All of the indirect inhibitors failed to block NET formation. Therefore, Ras is excluded 
from the signaling mechanism. The involvement of this pathway in NET formation was confirmed by 
immunoblotting of the phosphorylated ERK. Consistently, all kinase inhibitors, staurosporine, 
GW5074, and U0126 blocked ROS formation, implying that they act upstream of NADPH oxidase. 
We were the first to show the involvement of the Raf-MEK-ERK pathway in the NET formation and 
its function upstream of NADPH oxidase.  
In addition to investigating the location of the Raf-MEK-ERK pathway, there is a link between 
this signaling pathway and cell survival. Mcl-1, an anti-apoptotic protein, is expressed during early 
NETosis. This proves that the cell suppresses apoptosis keeping the cell alive and allowing the cell 
to undergo NET formation. A follow-up on this finding would see if other anti-apoptotic signals are 
triggered. It is known that anti-apoptotic signals are not only affected by ERK but by other kinases, 
for instance JNK.  
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The continuation of this work it would be of interest to investigate the involvement of kinases 
downstream from ERK and specifically, if there is any role other than regulation of the NADPH 
oxidase activation. If in NET formation any other regulatory pathways are affected (e.g. cytoskeleton 
organization and motility), the detail signaling that leads to such large structural changes would be 
of major interest. Also, what links this signaling mechanism to the eicosanoid pathway and GPCRs 
signaling cascades needs to be validated. Also the ERK signaling pathway needs to be challenged 
with better and more specific kinase inhibitors that would better elucidate further into the details of 
the NET formation mechanism.    
 
11.2 NET Communicate with Eicosanoid Lipids  
The eicosanoid pathway was shown to be involved in NET formation. Eicosanoid pathway 
activator arachidonic acid was identified as triggering NETs, in the similar to diaglycerol and platelet 
activation factor. Furthermore, it was shown that lipoxygenase (LOX) is required for NETosis by 
using a selective LOX inhibitor that stopped NETosis and the exclusion of the cyclooxygenase 
(COX) protein. In addition to the direct involvement of this pathway lipid bodies localize to NETs. 
Traditionally in innate immunity, lipid signalling is involved in cell-to-cell communication. Our results 
elucidate a new function in leukocytes, contributing to a novel field of study for neutrophil biology. 
As a continuation of this research much is yet to be discovered. In order to complete the 
mechanism, it needs to be proven that this lipid signalling occurs either upstream or downstream of 
the known NET formation mechanisms. LOX inhibitors should be challenged with bacterial stimuli 
and lipid stimuli. In the eicosanoid signalling cascade the downstream product of the LOX protein 
are lipoxins. Lipoxins are of detrimental importance to neutrophils in cell-to-cell communication and 
inflammatory response. The information regarding the role of lipoxins in NET formation mechanism 
is missing. In addition to the LOX signalling it is important to verify the values of lipids in the 
neutrophils upon activation of NET formation and determine the physiological relevance in an 
arthritic mouse model.  
Additionally, the composition of the lipid bodies is an essential part of the mechanism which is 
still lacking. I propose that there should be an establishment of a lipidomics investigation upon the 
establishment of a proper protocol for isolation of lipid bodies. Lipid bodies would be tested to see if 
they trigger NET generation on unstimulated neutrophils. It would be of value to know the the 
response of other immune cells and endothelial cells once they are exposed to the lipid bodies.   
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11.3 Tetraisoquinolines as a New Class of NET formation Inhibitors  
After screening the MPI Dortmund in-house-compound library, tetrahydroisoquinolines (THIQs) 
were identified as a novel class of NET formation inhibitors. Unlike known inhibitors of NET 
formation (e.g., NADPH oxidase inhibitor DPI, neutrophil elastase inhibitor GW311616A, 
myeloperoxidase inhibitor ABAH, RAF inhibitor GW5074) these compounds arrest NETosis at an 
early stage and have a small nuclei with lobulated and delobulated morphology.  
THIQs inhibit NETosis at low micromolar concentration independent of the stimulus and at 
different stages of NET formation. Compound T1 was found to be most potent with an EC50 for 
inhibition of NET formation of 1.9 ± 0.6 μM with a phenotype of group 2. Treatment with compound 
T6 resulted predominantly in cells with small, lobulated and delobulated nuclei. Compounds T1 and 
T6 did not influence ROS formation suggesting that they act downstream of ROS generation. No 
MPO nor NE inhibitory activity could be detected by these NET inhibitors.  
Unraveling the underlying mechanism of action for these THIQs will contribute to a better 
understanding of NETosis and may provide novel targets and opportunities for therapeutic 
intervention to treat NET-related diseases. A library of approximately 100 THIQs was synthesized 
and a SAR was established. Based on the structure activity relationship (SAR) target identification 
probes were synthesized. Compound T1 was functionalized with a linker with biotin, free amine or a 
fluorophore. Pulldown experiments were performed with human neutrophil lysates. Enriched 
proteins were subjected to tryptic digest followed by protein identification by means of mass 
spectrometry. Unfortunately, no proteins were identified that were selectively enriched with the 
active probe in comparison to the control. Computational profiling of THIQ T1 suggested that the 
target might be a GPCR. Testing compound T1 against 28 GPCRs for agonist and antagonist 
activity resulted in the first positive results regarding the target identification of THIQ T1. Also, this 
established the basis for the novel involvement of GPCRs in NET formation.  Interestingly, 
compound T1 was identified as an antagonist for dopamine receptor D5, melatonin receptor, and 
BLT1 receptor. Known GPCR antagonists for these receptors showed an inhibitory effect on NET 
formation and, more interestingly, they all shared the same group 2 nuclear morphology, although 
they were not as potent as the THIQs compounds.  
Clearly, GPCRs are likely to mediate the THIQs-provoked inhibition of NET formation. However, 
results are inconclusive with the limited research performed so far. The establishment of a 
mechanistic role for GPCRs in NETs is missing. The cellular target, or targets, of the THIQs remains 
to be properly identified. The next target identification experiments should focus on membrane 
proteins as these were not covered in the pulldown experiments performed. More GPCRs should be 
validated against more THIQs and EC50s determined, and eventually correlated to the morphology 
data. Simultaneously, the role of GPCRs should be validated through other means. Neutrophils 
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should be examined for the expression of the receptors for melatonin, dopamine and any other 
receptor that is identified as an interacting partner for the THIQs. Additionally, calcium ions and 
cAMP levels released during NET formation remains to be investigated. These measurements will 
prove the direct biological link to the identified GPCR on human neutrophils favoring NETs. The link 
between GPCR activation and Raf-MEK-ERK signaling should be established.  Finally, a study on 
how the feedback and cell communication plays a role in the NET formation signaling pathways is to 
be pursued.  
A hallmark of many immune disorders is the overproduction and lack of degradation of NETs. 
NET formation inhibitors are considered promising candidates for the treatment of the autoimmune 
disease systemic lupus erymatosus (SLE). THIQs inhibit NET formation efficiently in non-activated 
and PMA-activated SLE patient isolated neutrophils. These results clearly indicate that THIQs have 
great potential as tool compounds and as a starting point for the development of novel small 
molecule therapeutics. The optimization and efficacy of THIQs should be further pursued and 
potency ought to be improved. Validation in an appropriate animal model should be pursued. For 
this, ADME parameters ought to be taken into consideration and optimized to determine if this 
compound class would be considered for therapeutic use.  
The study of the neutrophil NET formation enigma is a perfect example wherein a chemical 
biology approach can be very successful. An assay protocol was established allowing NET 
formation to be studied quickly and could be scaled up to a high throughput technique. Novel 
signalling mechanisms were identified and added to the overall mechanism of NETosis. A novel 
NET inhibitor compound class was identified and added to the toolbox to study NETs, together with 
additional biochemical techniques.  
 
 
 
 
 
 
 
 
 
 
- 131 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 132 - 
 
1 
2 
3 
4 
5 
6 
7 
Experimental Section 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 133 - 
 
1. General materials and methods 
 
1.1 Laboratory devices  
 
Instrument Name Manufacturer 
Autoklav (Varioklav®400) Thermo scientific, USA 
Axiovert 200M with a Plan-Neofluar 100×/1.3 NA Carl Zeiss MicroImaging, Inc 
Balance (BP301S) Sartorius, D 
CASY Model TT (Cell counter) Roche, D 
Cell –Surelock TM Novex Mini-cell (Device to run 
precast gel) 
Invitrogen 
Centrifuge (Centrifuge 5415R) Eppendorf, D 
CO2- incubator (NUAIRE IR Autoflow and NUAIRE 
DHD Autoflow) 
Integra Biosciences, D 
 
Confocal microscopy TCS-SP Leica and a Fluotar 100× 
objective lens 
Leica 
Countess® Automated Cell Counter Invitrogen Life Technologies 
Electrophoresis system (Mini-PROTEAN 
Elektrophorese System 165-8025) 
BioRad, USA 
Fluorescence scanner (Typhoon TRIO + TM variable 
Mode Imager) 
GE Healthcare 
 
Fluorometer (Ascent Fluoroskan MTP reader) Thermo Scientific 
Infinite M200 TECAN (Plate reader) TECAN 
Leica DM R upright epifluorescence microscope with 
Leica 10×/0.3, 20×/0.5, and 40×/0.75 objective 
Leica 
LI-COR scanner (Odyssey Infrared Imaging System LI-
COR) 
Biosciences, D 
 
Microscope Leitz (Labovert type 090-122.012)  ERNST LEITZ WETZLAR, D 
Monolight 3096 reader (ROS assays) BD Biosciences 
Monolith NT.115 Series Nanotemper 
Neubauer Cell counting chamber  Carl Roth, D 
Nikon DXM1200F camera and Nikon ACT-1 software Nikon 
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pH - meter (Mettler Toledo FiveEasy) Mettler Toledo 
Power supply device (Power PAC 1000) BioRad, USA 
Semi-dry transfer device (Trans-Blot ®) SD BioRad, USA 
Sonoplus HD2070 (Sonicator for cell lysis) BANDELIN 
Sterile bench (Microflow, Hera Safe type HS12  
NUAIRE, class II) 
Kendro laboratory, D 
Integra Biosciences, D 
Thermomixer comfort  Eppendorf, D 
Ultrasonic bath (EMMI® 30HC) AMAG, D 
UV spectrometer (Biophotometer) Eppendorf, D 
Vacuum concentrator (Concentrator 5301) Eppendorf, D 
VIBRAX VXR (Shaker ) Basic IKA 
Vortex devices (Vortex Genie 2) Carl Roth, D 
 
 
1.2 General Materials and Reagents 
Name Details Company 
1,4-Dithio-D,L-threitol hight purity 
(DTT)  
CAS = 3483-12-3, MW = 154.25 Gerbu Biotechnik, D 
12% Pierce TM protein gels  
 
10 wells,#25202 Thermoscientific, USA 
 
2-chloroacetamide CAS = 79-07-2, MW = 93.51,  
802412 
Merk Millipore 
4-20 % Pierce TM protein gels  10 wells, #25204 
 
Thermoscientific, USA 
 
Acetic acid  CAS = 64-19-7 J.T. Baker, Holland 
Acetone reagent ACS  CAS = 67-56-1 Sigma Aldrich, D 
Acetonitrile HPLC grade  CAS= 75-05-8 Fisher Scientific 
Acrylamid 4K- solution 30%   AppliChem , D 
AgNO3  CAS = 7761-88-8, MW = 169.87 Sigma Aldrich, D 
alpha-cyano-4-hydroxycinnamic 
acid 
CAS = 28166-41-8, MW = 189.17,  
C2020 
Sigma 
- 135 - 
 
Name Details Company 
Amonium persultate analytical 
grade  
CAS= 7727-54-0, MW = 228.2, 
#13375 
Serva, D 
BIOCHEMISTRY    
Bio-Rad-protein assay  #500-0006 Bio-Rad laboratories, D 
Bromophenol blue-Na salt   Serva, D 
Chocolate powder Slim fast   
CL-Xposure TM  Film for WB development, #34091 Thermo scientific, USA 
Criterion Precast Gel 12.5 %, 45 µL 5671045 Bio-Rad laboratories, D 
Criterion Precast Gel 4-15 %, 15 µL 5671095 Bio-Rad laboratories, D 
Criterion Precast Gel 4-15 %, 45 µL 5671083 Bio-Rad laboratories, D 
Criterion Precast Gel 4-20 %, 45 µL 5671093 Bio-Rad laboratories, D 
CuSO4  CAS= 7758-99-8, MW =249.68  Sigma Aldrich, D 
Developing solution for Western 
blot  
#100296 TETENAL-Eukobrom , D 
Dimethylsulfoxyde (DMSO) cell 
culture grade anhydrous 
Research Grade D260 
276855 
Serva, D 
Sigma Aldrich, D 
Sigma Aldrich, D 
Dodecylsulfate sodium  SDS-b, CAS= 151-21-3, MW = 
288.38 
Gerbu Biotechnik, D 
EDTA- disodium  CAS = 6381-92-6, MW= 372.34 
 
Gerbu Biotechnik, D 
Ethanol absolute  CAS = 64-17-5 Sigma Aldrich, D 
Ethylenglycol-bis(2-
Aminoethylether)-N,N,N’,N’-
tetraacetic acid (EGTA) 
CAS = 67-42-5, MW = 380.35 
E3889 
Sigma Aldrich, D 
Fixing solution for Western blot #102762 TETENAL-Eukobrom , D 
Formaldehyde 37%, for molecular 
biology 
CAS= 7732-18-5, #BP531-500 
 
Fischer Scientific 
Glycerol 9%  CAS = 56-81-5 Sigma Aldrich, D 
Glycine 99%  CAS= 56-40-6, MW = 75.07 Carl Roth, D 
Guanidine hydrochloride CAS= 50-01-1, MW= 95.53, 
#369079 
CalBiochem, USA 
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Name Details Company 
HCl Concentrated 37%  CAS = 7647-01-0 Sigma Aldrich, D 
High perfomance extractions disks, 
C18 Octadecyl 
2215 3M Empore 
Hydrophilic Streptavidin magnetic 
beads 
S1421S New england Biolabs 
Iodoacetamide  CAS = 144-48-9, MW = 184.96 Sigma Aldrich, USA 
KH2PO4  CAS= 7778-77-0, MW = 136.09 J.T. Baker Holland 
Methanol  CAS = 67-64-1 Sigma Aldrich, D 
MgCl2, Magnessium Chloride, 
(hexahydrant) 
CAS = 7791-18-6, MW = 303.3, 
HNO3.1 
Roth 
N,N,N’, N’-
tetramethylethylendiamine, 
electrophoresis reagent (TEMED) 
CAS = 110 – 18-9, MW= 116.21  Sigma Aldrich, D 
 
Na2CO3  CAS = 497-19-8, MW = 105.99 Sigma Aldrich, D 
Na2HPO4 ; 2H2O  CAS= 10028-24-7, MW = 177.99 Merck, D 
Na2S2O3 anhydrous  CAS = 7772-98-7, MW = 158.11 Alfa Aesar  
Na3VO4  CAS= 13721-39-6, MW= 183.91 Sigma Aldrich, D 
NaCl, Sodium Chloride  CAS = 7647-14-5, MW = 58.44 Sigma Aldrich, D 
NaF  CAS= 7681-49-4, MW = 41.99 Sigma Aldrich, D 
NHS Mag Sepharose  28-9513-80 GE Healthcare  
NP-40 Alternative CAS = 9016-45-9, #492016  CalBiochem , D 
PageRuler TM prestained protein 
ladder plus  
#SM1811 Fermentas 
 
PIPES buffer CAS = 227-057-6, MW = 302.37, 
9156.1  
Roth 
Potassium chloride, KCl  CAS = 7447-40-7, MW = 74.55 J.T. Baker , Holland 
PVDF -transfer membrane  Immobilon®-FL Millipore, USA 
RC DC Protein Assay kit  
 
Catalog # 500-0119, -120,-121, -
122 
Bio-Rad laboratories, D 
Sodium HEPES salts  
 
CAS = 75277-39-3, MW = 260.3, 
#25249 
Serva, D 
Streptavidin magnetic beads (4 #S1420S New england Biolabs 
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Name Details Company 
mg/ml) 
 
Super Signal ® West femto 
Chemiluminescence substrate  
34095 Thermo Scientific, USA 
Super Signal ® West Pico 
Chemiluminescence substrate  
34087 Thermo Scientific, USA 
TBTA 97%, TRIS[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl] amine 
CAS= 510758-28-8 , MW= 530.63 
 
Sigma Aldrich, D 
 
t-Butanol  CAS = 75-65-0 Sigma Aldrich, D 
TCEP.HCl  
 
CAS = 51805-45-9, MW= 286.65, 
#20490 
Thermo Scientific, USA 
TFA for peptide synthesis  CAS= 76-05-1 Carl Roth, D 
TRIS-HCl  CAS= 1185-53-1, MW = 121.14 Carl Roth, D 
Triton X-100  CAS= 9002-93-1 Serva, D 
Trypsin Recombinant  Proteomic analysis, #03 708 969 
001 
Roche,D 
Tween 20  CAS= 9005-64-5 Serva, D 
Urea 99%, ACS Reagent CAS= 57-13-6, MW=60.06 Sigma Aldrich, D 
β-Mercaptoethanol CAS = 60-24-2, MW = 78.13,  
39563.01 
Serva 
CELL CULTURE    
 Lipopolysaccharide 
(LPS) from  
 Salmonella typhimurium S-form 
 
581-011 Alexxis/ENZO 
Bovine Serum Albumin (BSA) – 
fatty acid free 
CAS = 9048-46-8 Sigma Aldrich, D 
Complete Mini EDTA-free protease 
inhibitor  
2683400 Sigma/Roche Diagnostics, D 
Costar®Assay plate, sterile, flat 
bottom,black  
#3616 Sigma Aldrich, D 
Cytotoxicity Detection Kit (LDH) 11644793001 Roche_Sigma 
DMEM  high glucose (4.5g/l) with L-
glutamine 
PAA, Pasching, A 
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Name Details Company 
 
Endotoxin-free human albumin HSA   Grifols 
epidermal Growth Factor (EGF), 
recombinant human 
#PHGO315 Invitrogen, USA 
Fetal bovine serum (FBS)  #10270 GIBCO-Invitrogen, D 
Hank’s Balanced Salt Solution 
(HBSS) 
14170112 GIBCO-Invitrogen, D 
Heparin   Ratiopharm, D 
HEPES 15630080 GIBCO-Invitrogen, D 
Histopaque-1119 gradient 11191 Sigma Aldrich, D 
Monolinth NT Protein Labeling kit 
Green NHS 
L002 Nanotemper 
Monovette with EDTA  Sarstedt, D 
Nunc plates 96-well plates with white walls and 
clear bottom 
Thermo scientific, D 
PBS  10010023 GIBCO-Invitrogen, D 
Penicillin (10. 000U/ml) –
Streptomycin (10 mg/ml) in 0.9% 
NaCl  
10378016 GIBCO-Invitrogen, D  
Percoll 17-0891-01 GE Healthcare Life Sciences 
RPMI  11875093 GIBCO-Invitrogen, D 
RPMI Phenol-free medium 11835030 GIBCO-Invitrogen, D  
Sodium pyruvate solution 
11360070 
GIBCO-Invitrogen, D 
Trypan blue solution  
 
CAS = 72-57-1, #93595 Fluka, D 
 
Trypsin-EDTA (1%)  cell culture laboratory grade 
15400054 
PAA, Pasching, A 
GIBCO-Invitrogen, D 
PROTEINS   
15-lipoxygenase inhibitor I CAS: 928853-86-5, MW = 313.4 
Sc-220625 
Santa Cruz 
15-lipoxygenase-2 blocking peptide 10004457 Cayman 
Arachidonic acid CAS: 506-32-1, MW = 304.47,  Sigma 
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Name Details Company 
A3555 
Chloro-amidine (TFA salt) CAS: 1043444-18-3, MW = 424.11, 
10599 
Caymann 
COMPOUNDS    
Cytochalasin B CAS: 14930-96-2, MW = 479.61 
C6762 
Sigma 
Cytochalasin D  CAS: 22144-77-0, MW = 507.62 
C8273 
Sigma 
Diisopropyl flourophosphate (DFP) CAS: 55-91-4, MW = 184.15,  
D0879 
Sigma 
Formylated methionyl-leucyl-
phenylalanine (fmlp) 
CAS: 59880-97-6, F3506 Sigma 
Glucose oxidase (GO) 
 
 Worthington biochemical 
corporation 
Miltenyi 
Horse Radish Peroxidase (HRP)  1200U/ml Serval 
Luminol Cat. 11050, 50 mM DMSO AAT Bioquest, 
Myeloperoxidase human 475911  Calbiochem 
NE inhibitor, GW311616A  
 
CAS: 197090-44-1, MW = 433.99, 
G8419 
Sigma 
NE substrate I 324696 Calbiochem 
Neutrophil Elastase, human 
 
324681 Calbiochem 
Oil Red O CAS: 1320-06-5, MW = 408.49, 
O0625 
Sigma 
Phenylmethanesulfonyl fluoride 
(PMSF) 
CAS: 329-98-6, MW = 174.11 
P7626  
Sigma 
Phorbol myristate acetate (PMA) CAS: 16561-29-8, MW = 616.83, 
P8139 
Sigma 
Platelet activation factor (PAF) CAS: 74389-68-7 PAFC-16, 
#60900 
PAFC-16, #511075 
Caymann 
Calbiochem 
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Name Details Company 
SYTOX Green 5 mM DMSO, Excitation⁄Emission: 
504⁄523 nm, S7020 
Invitrogen, D 
U0126  
 
CAS: 109511-58-2, MW= 380.50, 
#662005 
CalBiochem, USA 
U75302 CAS: 119477-85-9, MW = 361.50, 
sc-201331 
Santa Cruz 
 
1.3 Antibodies 
IB = Immunoblotting 
Antigen Type Organism Company Concentration 
used for IB* 
Blocking 
buffer for IB* 
CD66b, GPI 
FITC 
Monoclonal Mouse, 
MsIgM  
BD 
Pharmigen 
(555724) 
  
Anti-α-Tubulin 
50 kDa 
Monoclonal Mouse Sigma Aldrich 
(T9026) 
1:1000 
1 : 10000 
2%BSA in 
TBST 
CD62L, L-selectin 
PE 
Monoclonal Mouse Ms 
IgG1 
BD 
Pharmigen 
(555544) 
  
HRP rabbit 
ImmunoPure® antibody 
Secondary goat anti-
rabbit IgG 
(H+L) 
Thermo 
Scientific (# 
31460) 
1:10000 TBST 
HRP mouse 
ImmunoPure® antibody 
Secondary goat anti-
mouse IgG 
(H+L) 
Pierce (# 
31430) 
1:10000 TBST 
Phospho- p44/42 
ERK1/2  
 
Monoclonal Mouse Sigma Aldrich 
(#M8159) 
1:1000 5% Skim 
milk/TBST or 
2%Choco/TBST 
Phospho- p44/4, 
ERK1/2  
 
Monoclonal Rabbit Cell Signalling 
(#9101S) 
1: 1000 5% Skim 
milk/TBST 
2%BSA in 
TBST 
p44/42 MAPK (ERK 1/2) 
(Thr202/Tyr204) 
Total ERK1/2  
Monoclonal Rabbit Cell signalling 
(#M4695) 
1:1000 5% Skim 
milk/TBST 
2%BSA in 
TBST 
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1.4 Buffers and solutions 
Buffer Composition 
10X PBS (phosphate buffered saline) 
 
1.37 M NaCl 
27 mM KCl 
0.1 M Na2HPO4 
20 mM KH2PO4 
pH = 7.4 
10x Running buffer 
 
250 mM TRIS 
2 M Glycine 
 1 % (w/v) SDS 
10X TBS (TRIS-buffered saline) 
 
0.2 M TRIS-HCl 
1.5 M NaCl 
pH = 7.4 
5X SDS-PAGE loading buffer 
 
0.225 M TRIS-HCl pH = 6.8 
50% glycerol 
5% SDS-b 
0.05% Bromophenol Blue 
700 mM β-Mercaptoethanol 
Alkylating solution for protein digestion 55 mM iodacetamide 
in 25 mM NH4HCO3 
Ammonium bicarbonate buffer 50 mM ammonium bicarbonate 
Filter 0.2 µm  
APS solution  10 % Ammonium persulfate (w/v) 
Binding buffer (TBS) for pulldown using NHS beads 50 m M Tris 
150 mM NaCl 
pH 7.5 
Block A buffer for pulldown using NHS beads 0.5 M Ethanolamine 
0.5 M NaCl 
pH 8.3 
Block B buffer for pulldown using NHS beads 0.1 M Sodium acetate 
0.5 M NaCl 
- 142 - 
 
pH 4.0 
C18 Disks Empore 2215-C18 
store in small petri dish 
seal with parafilm 
Cell freezing buffer  90% (v/v) FBS 
 
10% (v/v) DMSO 
Chloracetamide Stock* 0.5 M choracetamide in H2O 
* newly made 
Coomassie staining solution for proteomics 
 
Solution A:      2 % (v/v) ortho-Phosphoric acid 
                      10 % (w/v) Ammonium sulphate 
Solution B: 5 % (w/v) Coomassie Brillant Blue G-250 
Solution C: Mix A+B add 20% MeOH (v/v) before use  
Coupling buffer A for pulldown using NHS beads 0.15 M Triethanolamine 
0.5 M NaCl 
pH 8.3 
Differentiation medium for PLB, NB4, HL60 cells  RPMI with phenol red 
5 % (v/v) FBS 
1 % (v/v) L-Glutamate 
1 % (v/v) penicilium/streptomycin 
Differentiating agent: 
5 µM KN-62 or  
1.25% DMSO or 
 30 ng/mL GCSF or   
2 µM ATRA 
DTT Stock* 1 M DTT  
in 50 mM ammonium bicarbonate buffer 
* newly made 
E1 buffer for protein digestion using STAGE Tips 1.1 µL DTT stock 
13.75 µL trypsin stock (5 µg/mL) 
1085.15 µL urea stock 
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Always fresh 
E2 buffer for protein digestion using STAGE Tips 11 µL chloroacetamide stock 
1089 µL urea stock 
Elastase storage buffer 20 mM sodium acetate 
100 mM NaCl 
pH 5.0-6.0 
store at -80
o
C 
Equilibration buffer for pulldown using NHS beads 1 mM HCl (ice cold) 
Gel casting reagents 
 
3.3 ml H2O 
4.0 ml 30% acrylamide mix 
2.5 ml 1.5M TRIS.HCl, pH= 8.8 
0.1 ml 10% SDS 
0.1 ml 10% ammonium persulfate 
0.01 ml TEMED 
Granule preparation buffer 20 mM Hepes pH 7.4 
100 mM KCl 
3 mM NaCl 
3 mM MgCl2 
1 mM EGTA 
100 mM Sucrose 
Granule preparative lysis buffer for pulldown 20 mM HEPES pH7.4 
100 mM KCl 
3 mM NaCl 
3 mM MgCl2 
1 mM EGTA 
100 mM Sucrose 
0.1% NP40 
0.1% Triton X-100  
0.1% Tween 20 
Complete EDTA free Protease Inhibitor(add freshly) 
phosphoSTOP (add freshly) 
0.1 mM PMSF (add freshly) 
Lysis buffer for pulldown 50 mM PIPES (pH 7.4) 
50 mM NaCl 
5 mM MgCl2 
5 mM EGTA 
0.1% NP40 
0.1% Triton X-100  
0.1% Tween 20 
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Complete EDTA free Protease Inhibitor(add freshly) 
phosphoSTOP (add freshly) 
DTT orβ-Mercaptoethanol (add freshly) 
Membrane stripping buffer 6M guanidine Hydrochloride 
 
MPO storage buffer 
 
20 mM Hepes 
100 mM KCl 
50% Glycerol 
MPO substrate solution  1 mg O-phenylenediamine 
10 ml PBS 
PBST PBS + 0.1% Tween 20 
 
Phosphate buffer  10 mM Na3PO4 
300 mM NaCl 
pH = 7.4 
PMN lysis buffer for pulldown * 50 mM HEPES pH7.4 
150 mM NaCl 
5 mM MgCl2 
2 mM CaCl2 
2 mM EGTA 
100 mM Sucrose 
0.1% NP40 
0.1% CHAPS 
0.1% Tween 20 
Complete EDTA free Protease Inhibitor(add freshly) 
phosphoSTOP (add freshly) 
0.1 mM PMSF (add freshly) 
* for neutrophil add 1 µL of DFP 
PMN washing buffer for pulldown PMN lysis buffer for pulldown  
75 mM of MgCl2 
No protease inhibitors, nor fresh additives 
Pseudomonas storage buffer 1 mL of LB  
20% glycerol  
Store at -80
o
C 
Reducing solution for protein digestion 50 mM DTT  
In 25 mM NH4HCO3 
RIPA buffer 
 
50 mM TRIS pH 7.4   
150 mM NaCl  
0.25% Sodiumdeoxycholate                
1% NP40 Alternative        
1 mM EDTA 
PhosphoStop (add freshly) 
Complete mini (add freshly) 
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Separating gel buffer  
 
1,5 M TRIS 
0,4 % (w/v) SDS 
pH = 8.8 (HCl) 
Stacking gel buffer  
 
 
0,5 M TRIS  
0,4 % (w/v) SDS 
 pH = 6.8 (HCl) 
Starving medium for adherent cancerous cell lines 
MDCK, HeLa 
500 ml DMEM 
5 ml L-Glutamate 
5 ml non-essential amino acid 
5 ml sodium pyruvate 
5 ml penicilium/streptomycin 
TBST  TBS + 0.1% Tween 20 
Thawing medium for NB4, PLB, HL60   RPMI with phenol red 
20% (v/v) FBS 
1% (v/v) L-Glutamate,  
1% (v/v) penicilium/streptomycin 
Transfer or blotting buffer 
 
25 mM TRIS.HCl 
0.2 M Glycine 
50 mM TRIS-HCl pH = 7.4 
25% MeOH (add before use) 
TRIS Buffer (TBS) 50 mM TRIS 
pH 7.5 
autoclave 
Trypsin digestion solution for protein digestion using 
STAGE Tips 
(Stock solution, 0,1 µg/µL) 
 
25 µg Trypsin in 250 µL 10 mM HCL. 
Store at -80 °C for 4 weeks max.  
Trypsin stock for protein digestion 0.4 µg/ µL Trypsin in 10 mM HCl 
store at -20°C 
Trysinating solution   
Urea Stock* 1.2 g urea 
9 mL 50 mM TRIS-Buffer (pH 7.5) 
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*newly made 
Wash solution 1 for pulldown  25 mM NH4HCO3  
Acetonitrile   
ratio 3:1 
Wash solution 2 for pulldown 25 mM NH4HCO3  
Acetonitrile   
ratio 1:1 
Washing buffer for pulldown Lysis buffer for pulldown 
75 mM of MgCl2 
No protease inhibitors, nor fresh additives 
 
2. Mammalian cell culture  
During the course of this work, several cell lines and cells isolated from donors were used. All cell 
culture were approved by safety class S1 and S2. The waste generated was discarded according to 
required S2 protocol.  
2.1 Cell lines 
CELL 
LINE 
NAME ORGANISM ORIGIN 
TISSUE 
MORPHOLOGY CELL  MEDIUM 
HeLa “Henrietta 
Lacks” 
Human Cervical 
Cancer 
Epithelium; 
Adherent  
DMEM 
10% (v/v) FBS 
  1% (v/v) L-Glutamate 
  1% (v/v) non-essential 
amino acids 
   1% (v/v) sodium 
pyruvate 
   1% (v/v) 
penicilium/streptomycin 
HL60 Human 
Leukemia 
Human Myeoloblast Blood cells; 
Suspension  
RPMI with phenol red 
10% (v/v) FBS 
  1% (v/v) L-Glutamate 
  1% (v/v) 
penicilium/streptomycin 
NB4 Human 
promeolocytic 
Human Myeoloblast Blood cells; 
Suspension 
RPMI with phenol red 
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leukemia 10% (v/v) FBS 
  1% (v/v) L-Glutamate 
  1% (v/v) 
penicilium/streptomycin 
PLB-985 Human diploid 
myeloid 
leukemia  
Human  Myeoloblast Blood cells; 
Suspension 
RPMI with phenol red 
10% (v/v) FBS 
  1% (v/v) L-Glutamate 
  1% (v/v) 
penicilium/streptomycin 
PLB-MD Human diploid 
myeloid 
leukemia 
Human Myeoloblast Blood cells; 
Suspension 
RPMI with phenol red 
10% (v/v) FBS 
  1% (v/v) L-Glutamate 
  1% (v/v) 
penicilium/streptomycin 
 
 
2.1.1 Cell Counting 
To count the cells three main methods were used: the hemocytometer, Countess TM, and CASY. 
2.1.1.1 Hemocytometer method 
10 µL of a mixture (100 µL) containing cells (10 µL) and trypan blue (90 µL) was placed in the 
hemocytometer and covered with a coverslip. The cells were counted with a 10X objective using a 
light microscope. The dilution factor was determined and the total cell amount was calculated.   
2.1.1.2 Countess TM method  
10 µL of a mixture (100 µL) containing cells (10 µL) and trypan blue (90 µL) was placed in the 
hemocytometer and covered with a coverslip. The chamber was placed in the Countess slot and the 
microscope had to be manually focused. The cell number was determined automatically.   
2.1.1.3 CASY counting method  
CASY cell counting method is similar to the flow cytometer. 10µL of the cells were dissolved in of 
CASY Buffer (10 mL) in a siliconized CASY tube. The tube was placed into the instrument to count 
the cells. Using a program incorporated in the instrument, cells were counted automatically and a 
viability graph was given.   
2.1.2 Cell maintenance 
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Cells were incubated at 37°C at 5% CO2 until confluence or in the case of suspension cells until 
concentration of 1x106/mL was reached. The medium monitored via the phenol red used as a pH 
indicator for nutrients are depleted.  For adherent cells, the old medium was discarded. Cells were 
washed twice with PBS buffer (10 mL) and detached from the surface with trypsin/EDTA solution 
(5mL).Cells were incubated for 2-5 min at 37°C, 5% CO2 and immediately re-suspended in 5-10 mL 
of fresh medium. Cells were pelleted (1250 rpm, 5 min) and resuspended with medium (10 mL) and 
transferred to a cell culture flask (sterile, 75cm2) in a 1:13 dilution. For the differentiable cell lines 
(HL60, NB4, PLB) avoid pH changes since it can start of cell differentiation. Cells were counted and 
seeded at the appropriate concentration, usually 1.0x105/mL in a 25 cm2. Cells should not be kept in 
high passage numbers, such as 24 or for longer than 3 months, after they are thawed.  
2.1.1 Long term storage of cells 
The lowest passage number is preferred when storing cells or when they have only been a week in 
culture to make sure that the frozen cells are healthy and non-apoptotic. A minimum of 1.0x106 per 
mL as final concentration is advised. Once the cells were collected and the supernatant was 
discarded, cells were washed with PBS twice. The cell pellet was resuspended in freezing buffer 
(9:1 (v/v) FBS:DMSO). The cell suspension is aliquoted (1-1.5 mL of 1.0x106 cells/ mL) in properly 
labeled cryotubes. Cells were gradually frozen until and then stored in liquid nitrogen for long term 
storage.  
2.1.2 Defrosting cells 
Cells were thawed at room temperature and were rapidly diluted into a 15mL of thawing medium. 
Certain cell lines require a thawing medium which contains higher concentration FBS (15 or 20 % 
instead of 10% (v/v)). The FBS concentration varies depending on the cell line. The cells were 
pelleted (10 min, 800 rpm). The supernatant was removed and cells were placed in growth medium 
(8 mL, 50 cm2 flask).  For PLB, NB4 and HL60 cells, after thawing the cells were washed three 
times with thawing medium (RPMI with phenol red 20% (v/v) FBS, 1% (v/v) L-Glutamate, 1% (v/v) 
penicilium/streptomycin, section 2.2). The cells were incubated in the thawing medium for 3 days.  
On the third day, cells were passaged into normal growth medium.  
2.2  Isolation of human blood cells 
2.2.1 Culture conditions 
Human neutrophils were used extensively in the work on this thesis. Consequently, it was important 
to avoid unnecessary centrifugation/vortexing/mechanical steps and to work with them promptly 
since they have a short life and they are easily pre-activated.  Conditions were established to store 
purified neutrophils for sufficient time to screen the library with a single batch of cells. Neutrophils 
isolated from donors were viable for 6 hours, when kept at room temperature (approximately 25oC). 
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For longer storage, blood could be kept at 4oC before isolation. Notably, storing neutrophils at 4oC 
should be avoided.  
2.2.2 Isolation of human peripheral blood neutrophils 
Human neutrophils were isolated from peripheral blood using a density gradient method (Aga et al., 
2002). The study was approved by the ethics committee of the Charité Medical Centre, Berlin. 
Peripheral venous blood from a healthy donor was drawn using heparin (10 U/ml) or heparin 
containing commercial tubes. Carefully, blood (5-6 mL) was layered tube (15 mL) onto Histopaque-
1119 (5 mL, 1:1) using a sterile plastic pipettes. It is important to use sterile plastic pipettes to avoid 
cell degradation. The blood was centrifuged (20 min, 800g) at room temperature. It is important that 
no “break” is on during the centrifugation and that the acceleration and deceleration is kept to a 
minimum. Histopaque separates blood into plasma (top phase), peripheral blood mononuclear cells 
(PBMC) (interphase), neutrophils contaminated with red blood cells (RBC; bottom phase) and RBCs 
(pellet). The top phase was discarded using a vacuum pump with a sterile glass Pasteur pipette. 
The red diffused layer (neutrophil-rich phase) was collected and transferred to a sterile falcon tube 
(15 mL). The red (RBC phase) pellet was discarded. Cells were washed with washing buffer (PBS 
with 0.5% HSA). Cells were mixed gently and centrifuged (10 min, 300g) at room temperature. The 
supernatants were discarded carefully using a vacuum pump with a sterile glass Pasteur pipette.  
The pellets were resuspended in the falcon tubes with PBS (2-3 mL). During the spinning cycles, 
the Percoll-gradients are freshly prepared and can be stored for maximum 2 days at 4oC (important: 
storage is possible as Percoll dilution or gradient stock, not as a gradient). This is a discontinuous 
gradient consisting of Percoll-layers with densities of 1.105 g/ml, 1.100 g/ml, 1.093 g/ml, 1.087 g/ml, 
and 1.081 g/ml.   
2.2.2.1 Gradient Preparation 
The Percoll gradient stock was prepared with sterile Percoll (36 mL) and sterile 10X PBS (4 mL). 
The preparation of gradients of 85, 80, 75, 70 and 65% was as follows. 
Conc. of Gradient Gradient Stock 1 x PBS 
85% 8.5 ml 1.5 ml 
80% 8.0 ml 2.0 ml 
75% 7.5 ml 2.5 ml 
70% 7.0 ml 3 ml 
65% 6.5 ml 3.5 ml 
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Using sterile pipette in a falcon tube (15 mL), the 85% gradient (2 mL) was added tube, followed by 
80% gradient (2 mL) layering very slowly and carefully and continued in this manner in sequential 
order until gradient 65%. The final tube contained a gradient ranging from 85% to 65% Percoll with 
the final volume of 10ml. The resuspended cells (2-3 mL max.) are carefully layered onto the 
gradient.  The tubes were centrifuged (20 min, 800 g) at room temperature. The interphase between 
70-75% Percoll layers are collected and transferred to a fresh tube. This layer looks like a white 
cloud. The cells were washed with washing buffer in the same manner as indicated before. The 
tubes are centrifuged (10 min, 200g) at room temperature. The pellet is re-suspended with RPMI-
HEPES medium (5 mL) and cells are counted.  
2.3  Cell differentiation  
Cells (PLB, NB4, HL60) were seeded at 1x106/mL in differentiation medium containing 5% FCS 
RPMI medium supplemented with several different stimulators or combinations of the differentiating 
agent (Papayannopoulos et al., 2010; Tsuchiya et al., 2010). The cells were allowed to differentiate 
for different time periods. Every two days the medium was changed. Cells were microscopically 
inspected for viability. After the differentiation time, cells were centrifuged (5min, 1250 rpm) and 
washed with PBS (10 mL).  Cells were fixed with 4 %PFA and assessed by GIEMSA staining and 
for neutrophil makers CD15/CD66b using FACS.  
2.4 Cytotoxicity Assay 
2.4.1 Lactate dehydrogenase (LDH) cytotoxicity assay in immune cells 
To detect cytotoxic compounds, a colorimetric assay was employed based on the detection of 
lactate dehydrogenase (LDH) activity in the extracellular space. Neutrophils (5x104 cells/mL) were 
seeded per well in a 96-well plate and incubated with serial dilutions of the compounds (100µL). The 
controls were the following: background control (assay medium, no cells), spontaneous LDH 
release (cells alone), substance control (cells with vehicle DMSO) and maximum LDH release (cells 
treated with Triton X 2%). Cells were incubated (6h, 37°C at 5% CO2). After incubation, LDH activity 
was detected according to the manufacturer’s instructions. Absorbance was determined at 490 nm 
using the Monolight 3096 reader.  
3 NET Induction and Inhibition  
 
3.1  General Protocol for NET Activation  
Neutrophils (2.5x105 cells) were seeded in a 24-well plate flat bottom. In the case of experiments 
performed in 96-well plate, 5x104-5x105 cells were seeded depending on the experiment. 
Alternatively, 1 x106 cells were seeded in 6-well flat bottomed plates.  Cells were allowed to settle 
(10-20 min) at room temperature or in some cases at 37°C at 5% CO2. Neutrophils were activated 
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with phorbol myristate acetate (PMA). Cells were incubated at 37°C at 5% CO2 and microscopically 
monitored until NET formation was complete (process takes 2.5-4h). For SYTOX Green viability and 
staining, SYTOX Green (2 µM, 10 µL, 10min) was added and samples were incubated (10min). 
Fluorescence intensity (ex/em 485/518 nm, room temperature) was recorded. For further 
investigation cells were fixed with PFA (4%, 10 µL) and permeabilized with Triton X-100 (0.01 %, 10 
µL). Later, images were acquired on an epifluorescence microscope or using the automated 
microscope. Image analysis (determination of different nuclear morphologies) was performed using 
Scan^R software or Cell Profiler (www.cellprofiler.org) (Kamentsky et al., 2011) and Cell Analyzer 
(www.cellprofiler.org) (Jones et al., 2008) software.  For time course experiments, cells were fixed 
with PFA (4%, 10 µL) at different time points. For microscopy experiments, glass slides were placed 
on plates and washed with PBS (3mL, 2 times) before the cells were seeded. Cells were seeded (1 
x106 cells), as described above. After NET formation, cells were fixed with PFA (4%, 10 µL) and 
analyzed according to specific protocols.  
3.1.1 NET activation with eicosanoic lipids  
The lipids were dissolved in fatty acid-free BSA as a vehicle in medium. Neutrophils (see section 
3.1) were activated with 1-3 μM of platelet activating factor (PAF-(C16)), 1-3 μM of 1–2-dioctanoyl-
sn-glycerol a potent analog of diacylglycerol (DAG) or 1-3 μM of arachidonic acid. Each lipid was 
added individually and promptly to avoid decomposition of the lipid. DMSO and unstimulated cells 
were used as controls. NET formation was shorter using this stimulus.  
3.1.2 NET activation with glucose oxidase 
Cells (section 3.1) were activated with 100mU/mL of glucose oxidase (GO). NET formation occurred 
after 1-2 hours after activation.  
3.1.3 NET activation with Bacteria  
3.1.3.1 Pseudomonas aeruginosa PA14 
A fresh culture Pseudomonas aeruginosa PA14 was made by shaking overnight at 37oC in LB 
medium (5 mL). The bacterial culture was washed PBS (10 mL) and centrifuged (10 min, 4000 
rpm). The bacterial pellet was resuspended in medium (2 mL). The MOI was determined by 
measuring optical density (OD) (OD = 1 = 1x109 cells/mL). Medium was removed by centrifugation 
(10 min, 4000 rpm). Bacteria were opsonized (30 min, 37oC) in FBS (10%). Neutrophils (5x104 
cells/well) were seeded in a 24-well plate and the inhibitors were added at concentration pre 
incubated (30min,  37oC). Neutrophils were activated with MOI of 100 followed by the general 
protocol described in (3.1) using PMA as control. The general 3.1 protocol, was slightly modified 
cells were not fixed nor permeabilized. Images were collected immediately and plates are discarded 
(cannot be preserved for later use due to bacterial overgrowth and safety). 
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3.1.3.2 Helicobacter pylori (experiment performed by 
Abdul Hakkim) 
Helicobacter pylori type 1 strain P12 was grown on brain heart infusion agar plates supplemented 
with 10 μg/liter of vancomycin, 1 μg/liter of nystatin, and 5 μg/liter of trimethroprim. Plates were 
incubated at 37 °C in a microaerophilic atmosphere and were sub-cultured every 2 days. 
Neutrophils were activated with MOI of 100 followed by the general protocol described in (3.1) using 
PMA as control. The general 3.1 protocol, was slightly modified cells were not fixed nor 
permeabilized. Images were collected immediately and plates are discarded (cannot be preserved 
for later use due to bacterial overgrowth and safety). 
 
3.2  General Protocol for NET Inhibition 
For the initial screen, compounds were diluted (30 µM, final concentration) in phenol red–free RPMI 
medium supplemented with 10 mM HEPES. 5x104 neutrophils were seeded per well in a clear 
bottom 96-well plate in presence of the compounds and pre-incubated (30 min, 37°C at 5% CO2). 
Followed by  neutrophils activation with PMA (40 nM, 10 µL) to induce NET formation. Unstimulated 
cells and cells treated with DMSO, 30 µM Diphenylidonium chloride (DPI), or PMA only were used 
as controls. Cells were incubated (4 h, 37°C at 5% CO2). For SYTOX Green viability and staining, 
SYTOX Green (2 µM, 10 µL, 10min) was added and samples were incubated (10min). 
Fluorescence intensity (ex/em 485/518 nm, room temperature) was recorded. For further 
investigation cells were fixed with PFA (4%, 10 µL) and permeabilized with Triton X-100 (0.01 %, 10 
µL). Later, images were acquired on epifluorescence microscope or using the automated 
microscope. Image analysis (determination of different nuclear morphologies) was performed using 
Scan^R software or Cell Profiler (www.cellprofiler.org) (Kamentsky et al., 2011) and Cell Analyzer 
(www.cellprofiler.org) (Jones et al., 2008) software.  A quality control was performed manually. 
 
3.2.1 Automated Protocol for NET Inhibition (experiments performed 
by Abdul Hakkim) 
Library compounds were arrayed by a pipetting robot Zymark SciClone ALH 500 in conjunction with 
a Tecan EvoWare robot in sterile 384, clear bottom, microtiter plates (MTPs). The final reaction 
volume 20 μL, neutrophil suspension (10 μL of a 10,000) were seeded in the plates. The cells were 
allowed to settle (10 min, room temperature) and the compound library was added (100 μM final 
concentration, 0.2 μL). Followed by PMA (40 nM, 10 μL) addition, DMSO was added as control. For 
SYTOX Green viability and staining, a mixture (10 µL, 10min, room temperature) containing SYTOX 
Green (2 µM) and PFA (2%) was added and samples were incubated. Fluorescence intensity 
(ex/em 485/518 nm, room temperature) was recorded by a Genios Pro MTP reader. To analyze the 
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nuclear area, cells were permeabilized with Triton X-100 (0.01%). The images (10x objective, 2 
images/well, 30 ms exposure, 10 μm offset from the plate bottom) were acquired using GFP 
channel in a Scan^R automated microscope.  The images of DNA staining were analyzed using the 
Scan^R automated microscopy system. 
 
4 Microscopy 
4.1  Immunocytochemistry 
Glass slides were placed on 24 well plates and washed with PBS (3mL, 2 times). Neutrophils 
(2.0x105 cells) were seeded and allowed to settle (10min, room temperature). The inhibitors were 
added at the concentration needed and the cells were activated depending on the experiment 
(section 3.1 and 3.1.1-3.1.3) and incubated (2.5-4 h, 37oC in 5% CO2). After NET formation, cells 
were fixed with PFA (4%, 10 µL, 10 min).  Cells were washed twice with washing buffer composed 
of BSA (3%, 30 µL) in PBS. Cells were permeabilized with a solution of Triton-X (0.5%), BSA (3%) 
in PBS. Cells were washed three times with washing buffer and blocked with blocking buffer (3% 
normal donkey serum, 3% cold water fish gelatin, 1% bovine serum albumin, and 0.05% Tween 20 
in PBS) (30 µL, 30min, room temperature). After two washes with washing buffer, the cells were 
incubated with primary antibodies (dilution for the primary antibodies is in the materials table 1.3, 
1hr,  37oC) followed by three washes with washing buffer and incubation with secondary antibodies, 
which were coupled to fluorophores (45min, 37oC) in the dark.  For DNA detection, Hoechst 33342 
(1:1000), DAPI (1:1000), or SYTOX Green were used. Specimens were mounted in Mowiol or 
AquaPoly/Mount and analyzed with epi-fluorescence microscope. Slides were stored at 4oC.  
4.2 Quantitative Analysis of Images Using Scan^R (performed by A. Hakkim and 
protocol modified from his original protocol) 
Following image acquisition (section 3.2.1), quantitative measurements from each image were 
performed based on the size of the nuclei and detailed morphology of nucleus during NET 
formation. For the detection of nuclei with the Scan^R image analysis software an algorithm was 
applied based on an intensity threshold for the SYTOX signal. The algorithm in the image analysis 
software detects objects based on an intensity threshold for the fluorescent signal. The sensitivity of 
the fluorescence was set (200) very low to allow the software to compute multi-lobulated nucleus of 
naïve neutrophils as single particles. At this threshold (200), the lowest intensities 
measured/background of zero and a maximum of 4095. After the image acquisition a background 
correction was performed. The low threshold also increases the object size. The object size and 
threshold had to be optimized to detect the appropriate morphologies of lobulated nuclei and 
decondensed nuclei simultaneously. After optimization the sizes were described as follow: lobulated 
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nuclei are 1000 pixels, delobulated nuclei are 800 pixels, decondensed are 2000 pixels and NETs 
are <2000 pixels. All detected objects were plotted with Heywood Circularity Factor (HCF) against 
perimeter and gates were applied separating the different nucleus types. The HCFs were 
established as follow: lobulated nuclei are 1 to 2, delobulated nuclei are 1, decondensed are 1 and 
NETs are > 2. To verify that the algorithm was running appropriately it was verified manually to 
confirm that the quantification represented the images. 
4.3 Quantitative analysis using CellProfiler and CellProfiler Analyst 
After initial training by Marc Bickle from the screening facility Max Planck Institute of Molecular Cell 
Biology and Genetics in Dresden, I established the new pipeline using CellProfiler and CellProfiler 
Analyst (Jones et al., 2008; Kamentsky et al., 2011). CellProfiler is a free image-analysis software 
provided by the BROAD institute available on http://cellprofiler.org/  The pipeline was trained to 
recognize the SYTOX green stained nuclei based on the size of the nuclei and detailed morphology 
of nucleus during NET formation.  Images containing predominantly each morphology (lobulated, 
delobuted, decondensed, NETs) were used to establish the parameters. Based on our previous 
experience, I used of chemical NET inhibitors to obtain images with the specified nuclear 
morphologies. The lobulated nuclei were unstimulated cells, the delobulated images were obtained 
by incubating them with DPI and activating them with PMA following the general NET protocol 3.1. 
The decondensated nuclei were obtained by incubating the cells with apomorphine and following 
protocol 3.1. The NET nuclei were obtained by stimulating the cells with PMA. Images were 
selected to initialize the basic pipeline. This basic pipeline was optimized for each individual 
microscope that was employed as a constant was the image format which was the .tiff format. To 
further train each pipeline several images were collected from each particular microscope and the 
program was trained to detect and the parameters were modified to obtain accurate results. After 
each experiment, quality control was performed manually to make sure that the pipeline was 
running smoothly.  
 
5 Enzymatic activity methods 
 
5.1  Determination of ROS Production 
ROS production, using an in situ horseradish peroxidase-luminol complex, was measured by means 
of chemiluminescence. Oxidation of luminol-HRP amplified by ROS causes emission of light that 
allows the detection ROS formation (Liu et al., 1996). Neutrophils (1 x106 cells, 50 µL) were seeded 
per well in a 96-well plate. Compounds were added (30 or 15 µM final concentration, 30 µL) and 
cells were incubated (30 min, 37oC in 5% CO2). Followed by the addition a mixture (20 µL) 
containing luminol (500 µM) and horseradish peroxidase (HRP) (120 U/mL). Finally, neutrophils 
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were activated PMA (40 nM, 10 µL) and chemiluminescence was continuously recorded (every 2 
min, 2 h total) at 37°C.   
5.2  Determination of activity neutrophil elastase using chromogenic substrate 
Neutrophil elastase (NE) was reconstituted in elastase buffer. Compound (15 µM, 50 µL) and NE 
(25 ng/mL, 50 µL) dissolved in sodium phosphate buffer were added to the wells of a clear 96-well 
plate in and incubated (10 min, room temperature). The NE inhibitor G8419 (15 µM, 100 µL) and 
DMSO were used as controls. The reaction was initiated with NE substrate I in same buffer (12.5 
µM, 100 µL). The absorbance was immediately recorded (410 nm, every 1 min, 2 h total, 37°C) 
using a Monolight 3096 reader. 
5.3  Determination of activity of myeloperoxidase using a chromogenic substrate 
Myeloperoxidase (MPO) was reconstituted in MPO buffer. Compound (15 µM, 50 µL) and MPO 
(100 nM, 40 µL) in HBSS buffer were added to the wells of a clear 96-well plate followed by 
incubation (10 min, room temperature). The MPO substrate (100 µL) was added. DMSO and the 
MPO inhibitor, 4-aminobenzoic acid hydrazide (ABAH) (15 µM, 50 µL) were used as controls. The 
reaction was initiated with H2O2 (0.5 mM, 10 µL). The absorbance was immediately recorded (450 
nm, every 1 min, 2 h total, 37°C) using a Monolight 3096 reader.  
 
6 Biochemical methods 
 
6.1 Preparation of cell lysates 
Several methods required the lysis of cells for affinity chromatography experiments, i.e.pulldown.  
Consequently, several methods were developed and optimization of buffers was needed.  
6.1.1 Preparation of human neutrophil cell lysate 
Cell lysis of neutrophils is complicated due to large amounts of proteases that are released. To 
solve this problem it was required to use potent protease inhibitors such as phenylmethanesulfonyl 
fluoride (PMSF) and diisopropyl flourophosphate (DFP) in different combinations. Before handling 
DFP is necessary to have the antidote and full knowledge for handling DFP. Details can be found in 
the book “Prudent practices for handling hazardous chemicals in laboratories, 1980.” DFP is 
extremely toxic. Atropine antidote together with 2-PAM (pyridine-2-aldoxime) should be present for 
rapid administration if necessary. DFP is rapidly decomposed in a 2 M NaOH solution. There should 
be a large container with basic solution available in a HEPA ventilated hood. DFP was the only 
protease inhibitor capable of stopping protease degradation. During the course of this work, several 
different lysis buffers were optimized and used for the experiments presented. In the case of 
western blotting techniques depending on the detection of the protein of interest different lysis 
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buffers were utilized. For proteomic purposes, optimization of the neutrophil lysate generation was 
crucial decrease contamination and increase reproducibility. The methods used for PMN cell lysing 
are described. Every neutrophil lysate was prepared with freshly isolated neutrophils.  
6.1.2 Preparation of human neutrophil cell lysate using nitrogen bomb 
PMN were isolated from human fresh blood as (section 2.2.2). Cells (5x107-1x108 cells) were 
placed in a falcon tube (15mL) and centrifuged (10 min, 800 rpm, room temperature) and washed 
with PBS (10 mL, ice cold) and centrifuged (10 min, 800 rpm, room temperature). Cells were 
resuspended in ice chilled granule preparation buffer (2-4 mL). The nitrogen bomb was chilled on 
ice. An aliquot of cells (2-3μl) were set aside in a glass slide for later microscopic verification of the 
lysis. Cells were placed in the nitrogen bomb, nitrogen pressure (400 psi, 2-5 min) was applied. 
Pressure was released and the cell lysate was collected from the nitrogen bomb.  The collected 
lysate was compared via microscopy to the collected aliquot of intact cells to verify proper lysis. The 
lysate was placed in a siliconized Eppendorf tube, and centrifuged (15 min, 300 x g, -4˚C). This low 
speed supernatant (LSS, i.e. cytosol fraction) was collected and stored at 4oC for 4-5days on ice.  
The LSS from ~5.3x107/mL produces ~1.9 mg/mL of protein. 
6.1.3 Preparation of human neutrophil cell lysate using DFP 
PMN were isolated from human fresh blood as (section 2.2.2). Cells (5x107-1x108 cells) were 
placed in a falcon tube (15mL) and centrifuged (10 min, 800 rpm, room temperature) and washed 
with PBS (10 mL, ice cold) and centrifuged (10 min, 800 rpm, room temperature). Protease 
inhibitors were added freshly to 10mL of neutrophil lysis buffer: 1 tablet of complete EDTA free 
protease inhibitor, 1 tablet of phosphoSTOP, and 0.1mM PMSF and chilled on ice.  Cells were 
resuspended with lysis buffer (2-4mL, 0-4oC) in low binding tubes (each tube holds a maximum of 2 
mL) and placed on ice. Inside a chemical hood with HEPA filter, DFP (100 µM) was added to each 
tube by syringe and tubes were incubated (5-10min, 0-4oC on ice).  After the addition of the DFP, 
the tubes were incubated (30min to 1h, 0-4oC on ice). Cells were lysed mechanically with a syringe 
and centrifuged (15min, 13 000 rpm, 4oC).  The supernatant was transferred to a new low binding 
tube. Protein concentration was determined directly using Lowry method (section 6.3.2). Lysates 
were stored at -80oC.  
6.1.4 Preparation of human neutrophil cell lysates using SDS loading 
buffer 
Neutrophils (1 x106 cells) were seeded in 6-well plates (flat bottom). Compounds (30 µM, 500 µL) 
and controls were added and incubated (30 min, 37°C at 5% CO2). Cells were activated with EGF 
(200ng/ml) or PMA (40 nM) and incubated (90 min, 37°C at 5% CO2).  The supernatant was 
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removed, 4x SDS loading buffer was added to the samples directly to lyse the cells avoiding 
degradation.  
6.1.4.1 Neutrophil lysis using DFP  
Neutrophils were seeded as explained above (section 6.1.4). After incubation with the NET 
activator and the compounds the medium was removed carefully. Inside a chemical hood with 
HEPA filter, DFP (100 µM, 5 µL) was added to each well (5-10min, 0-4oC on ice).  Chilled RIPA 
buffer (100 µL) was added to each well. The cells were mechanically removed from the well using a 
cell scraper and collected in low binding tubes. To remove precipitates, lysates were centrifuged (15 
min, 13000 rpm, 4 °C) and transferred to new low binding tubes. Protein concentration was 
determined using the Lowry method.  
6.1.5 Preparation of HL60 cell lysate for pulldown experiments 
HL60 cells were allowed to grow to 1x106/mL in normal grow medium in flask depending on amount 
of protein needed. Cells were collected by centrifugation (5min, 1250 rpm, room temperature) and 
resuspended in differentiation medium (RPMI medium supplemented with 1.25% DMSO). Cells 
were allowed to differentiate for 5 days and the medium was refreshed (every 2 days). After 
differentiation, cells were centrifuged (5 min, 1250 rpm, room temperature) and washed with PBS 
(10mL). After removal of the PBS, cells were resuspended in lysis buffer (2mL) that was freshly 
supplemented with protease inhibitors and transferred to low binding tubes. Cells were incubated 
(30min to 1h, 0-4oC on ice). Cells were lysed mechanically with a syringe and centrifuged (15min, 
13 000 rpm, 4oC). Supernatants were transferred to new low binding tubes and the protein 
concentration was determined using Lowry method (section 6.3.2). 
6.2 Cell Fractionation Method 
6.2.1 Neutrophil Low Speed Supernatant preparation 
Neutrophils were purified as previously described in section 2.2.2. Cells (5 x 107 cells/ml to 1x108 
cells/mL) were collected centrifuged (10 min, 800 rpm, room temperature) and washed with PBS 
(10 mL, ice cold) and centrifuged (10 min, 800 rpm, room temperature). Cells were resuspended in 
ice chilled granule preparation buffer (2-4 mL). The nitrogen bomb was chilled on ice. An aliquot of 
cells (2-3μl) were set aside in a glass slide for later microscopic verification of the lysis. Cells were 
placed in the nitrogen bomb, nitrogen pressure (400 psi, 2-5 min) was applied. Pressure is released 
and the cell lysate is collected from the nitrogen bomb.  The collected lysate was compared via 
microscopy to the collected aliquot of intact cells to verify proper lysis. The lysate was placed in a 
siliconized Eppendorf tube, and centrifuged (15 min, 300 x g, -4˚C). This low speed supernatant 
(LSS, i.e. cytosol fraction) was collected and stored at 4oC for 4-5days on ice.  
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6.2.2 Neutrophil High Speed Supernatant and High Speed Pellet 
preparation  
The high speed supernatant (HSS, cytosol without granules) high speed pellet (HSP, mitochondria 
membrane and granules) were prepared by collecting the LSS (section 6.2.1), followed by 
ultracentrifugation (1 h, 100,000 x g, 4oC). The HSS section was stored in granule prep buffer. The 
HSP pellet is resuspended in granule prep buffer (1 mL). HSS/HSP is stable on ice at 4oC for 4-5 
days. 
6.3 Determination of protein concentration 
To determine the protein concentrations of cell lysates two main methods were utilized: the Bradford 
assay and the Lowry method (sections 6.3.1-6.3.2).  
6.3.1 Bradford Assay 
The Bradford assay measures the protein concentration by means of colorimetry at 595 nm. 
Bradford stock solution was made and titrated with known concentrations of BSA (0 to 5 μg) using 
linear regression curve. In a disposable cuvette, Bradford solution (1 mL) and the BSA solution (1 
μL) was mixed and incubated (5min) and the absorbance is recorded. Standard curve is determined 
and the equation was obtained to calculate future protein concentration using this Bradford stock 
solution.  To determine the protein concentration of unknown protein solutions, the stock Bradford 
solution (1mL) was mixed with protein solution (1 μL) and incubated (5min) and the absorbance is 
recorded. Using the equation the protein concentration is determined.  
6.3.2 RC DC Protein Lowry Assay  
The RC DC Protein Assay kit from Biorad was employed. A stock BSA solution (10 mg/mL) was 
used to obtain a standard curve (BSA concentrations were 0.5 μg/mL to 1.5 μg/mL). The assay was 
performed according to the manufacturer’s instructions. Using linear regression a standard curve 
was obtained to determine the concentration of the samples. In a 96-well plate, a mixture containing 
sample and the solutions from the kit (5 µL, 20 µL of solution A, 200 µL of solution B) were mixed  
and incubated (15 min). The absorbance was recorded within an hour (750 nm, room temperature) 
using a Monolight 3096 reader. 
6.4  SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
6.4.1 SDS- PAGE gel casting 
A casting chamber from Biorad was used to cast the gels. The percentage of the gel was chosen 
according to the sizes of proteins to be separated. The resolving gel solution was prepared and 
added first and covered with ethanol to get a straight gel. The gel was polymerized (1 h). In a 
prompt manner the ethanol layer was removed from the chamber. The gel stacking solution was 
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added and the loading comb was placed in the gel. Upon polymerization (30-60 min), the gels were 
used immediately or stored at 4oC in a damp paper to keep moisturized for about 4-5days.  
Composition for resolving gel/ stacking gel solution 
 12% resolving gel 
(total = 10mL) 
11% resolving gel 
(total = 10mL) 
Stacking gel 
(total = 1mL) 
Water 3.3mL 3.45 mL 0.68mL 
Acrylamide 4.0mL 3.45mL 0.17mL 
1.5 M TRIS-HCl,  
pH = 8.8 
0.5M TRIS-HCl,  
pH = 6.8 
2.5mL 
- 
2.5 mL 
- 
- 
0.13 mL 
10% SDS 0.1mL 0.1mL 0.01 mL 
10%  
Ammonium Persulfate 
0.1mL 0.1mL 0.01 mL 
TEMED 0.01mL 0.01mL 0.001mL 
 
6.4.2 SDS- PAGE electrophoresis  
The samples were loaded onto the apparatus, usually MiniProtean 3 Gel Electrophoresis (Biorad) 
filled with SDS-running buffer. To avoid contamination with neighboring samples one empty pocket 
was left empty in-between if possible. The proteins wre separated (100V or 15mA, 15min) followed 
by an increase in voltage (200V, 35min or 30mA, 45min).  
7 Immunoblotting 
 
7.1 Protein transfer 
7.1.1 Semi Dry transfer 
After SDS-PAGE (section 6.4) the gel and filter papers, were pre-wet in cold transfer buffer for 5-
10min.  If a PVDF membrane was used, it was activated in methanol for 5 min prior to incubation in 
cold transfer buffer. A “sandwich” is made with two filter papers, PVDF membrane, gel, and two filter 
papers all wet in transfer buffer. The transfer was performed at 25V for 45min. The successful 
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transfer was assessed by visual inspection of the pre-stained protein ladder on the membrane and 
using staining with Ponceau S.  
7.1.2 Wet Blotting transfer 
The wet blotting technique is preferred when proteins are large. In advance two liters of transfer 
buffer was prepared and cooled to 4oC.  It also follows the same principle of section 7.1.1. The 
sandwich was placed vertically and additionally to the filter paper also sponges were used. 
Everything was be kept under buffer at all times to avoid air bubbles. The transfer was performed 
under stirring (4oC, 100V for 1.5-2 h or 20V overnight).  
 
7.2 Blocking of the membrane  
After the protein transfer (section 7.1.1-2), the membranes need to be blocked to retain the proteins 
on the membrane. Membranes were placed in blocking buffer and shaken (1 h, room temperature).  
The blocking solution is highly dependent on the antibody and detection method. A common 
blocking buffer was 5% skim milk in TBST was used for HRP-based detection; for antibody 
detection by means of fluorescence LICOR blocking buffer was used.    
 
7.3 Immunodetection of proteins immobilized on membranes 
7.3.1 General protocol for detection using HRP-conjugated antibodies 
After blocking (section 7.2) membranes were incubated with the primary antibody which was 
diluted at a concentration specified by manufacturer, typically in BSA (2%, in TBST), and incubated 
(1 at room temperature, or overnight at 4°C). The membrane was washed TBST (5 times, for 5 
min/time) while shaking. The membrane was incubated with the secondary HRP-labelled antibody 
(1 h, room temperature) while shaking. Prior to development the membrane was washed again with 
TBST (3 time, 5 min/time) and TBS (1 time, 10 min/time). For detection, SuperSignal ® West Pico 
or Femto was used according to the manufacturer’s instruction. Membranes were later detected by 
exposing them to an X-ray film or scanned using Odyssey Infrared Imaging System LI-COR, 
(Biosciences). 
7.3.2 General protocol for detection by fluorophore-coupled antibody 
After blocking (section 7.2) membranes were incubated with the primary antibody which was 
diluted at a concentration specified by manufacturer in LICOR blocking buffer with 0.1% Tween-20 
avoiding light, and incubated (1 at room temperature, or overnight at 4°C). The membrane was 
washed PBST (5 times, for 5 min/time) while shaking. The membrane was incubated with the 
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secondary HRP-labelled antibody (LICOR blocking buffer with 0.1% Tween-20, 1 h, room 
temperature) while shaking. Prior to development the membrane was washed again with PBST (3 
time, 5 min/time) and PBS (1 time, 10 min/time). Membranes were scanned using Odyssey Infrared 
Imaging System LI-COR, (Biosciences). 
7.4  Detection of ERK phosphorylation via immunoblotting in NET formation  
Neutrophils were seeded in 6-well at plate flat bottom 1 x106 cells and were activated with EGF or 
PMA in presence of inhibitors and controls without for 90 min at 37°C at 5% CO2. The supernatant 
was removed, followed by addition of protease inhibitors to the samples following procedure in 
section 6.1.4.1. An equal amount of protein in each sample was separated (11% SDS/PAGE) and 
transferred to PVDF membrane. Membranes were blocked (5% skim milk/TBST) and probed with 
monoclonal mouse anti-p-ERK-1 and 2 (Sigma) and a polyclonal, rabbit anti-total ERK (Sigma). 
Membranes followed the general protocol on section 7.3.1.  
 
8 Target identification methods 
 
Protein target identification experiments consist of fishing for the protein by immobilizing the 
compound via a linker on to solid support (i.e. NHS beads). This enables to isolation of protein-
compound complexes and identification of protein targets using mass spectroscopy. 
8.1  Pulldown Experiments 
8.1.1 Pulldown using biotinylated probes 
Homogenized streptavidin magnetic beads (500 µL) were collected in a siliconized tube and washed 
with PBS (500 µl, 2min, room temperature). The biotinylated compound was diluted in PBS (500 µL, 
10 µM). Compound was added to the beads and incubated (30min, room temperature, gentle 
rotation). After the incubation, beads were collected with magnetic separator and washed with PBS 
(500 µL). Cell lysate obtained in section 6.1.3 (500 µL, 1 mg/ml) was added to the beads and 
incubated (1 h, 4°C, gentle rotation). The beads were washed with lysis buffer containing 75mM 
MgCl2 without β-mercaptoethanol (2 times, 10 min/time, gently rotation)  followed by additional 
washings with PBS (2 times, 10 min/time, gently rotation). This removes unspecific binders. For 
direct mass spectroscopy analysis, beads were collected and resuspendend in PBS (500 µL) and 
given to Monika Schmid directly. For in solution trypsin digestion the protocol in section 8.2.2 was 
followed. Alternatively, the beads were boiled in SDS loading buffer (50 µL, 95oC, 5 min, shaking) to 
release proteins from the solid support. The supernatant was collected in a new siliconized tube. In 
a Criterion precast gel 4-20% Gel (Biorad) SDS-PAGE, 40-45µl of the protein in SDS buffer were 
loaded on the gel and electrophoresis was performed. Gels were digested as described in section 
8.2.1. 
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8.1.2 Pulldown using probes with free amine  
Homogenized NHS magnetic beads (25 µL) were collected in a siliconized tube. Beads were 
collected with a magnetic separator and they were equilibrated with equilibration buffer (500µL, ice-
cold 1 mM HCl, section 1.4). After removal of the equilibration buffer, the probe was coupled in 
coupling buffer (500µl, 10 µM probe, in 0.15M triethanolamine, 0.5M NaCl, pH. 8.3) and incubated 
(1h, room temperature, gentle rotation). After the incubation, beads were collected followed by 
blocking with blocking buffer A (500µL, 0.5M ethanolamine, 0.5M NaCl, pH = 8.3). Upon removal of 
buffer A, beads were washed with blocking buffer B (500µL, 0.1M sodium acetate, 0.5M NaCl, pH = 
4.0). These washing steps (alternating blocking buffer A and B) were performed 3 more times. 
During the second addition of blocking buffer A beads were incubated (15min, slow rotation). After 
the last addition of blocking buffer B, beads were washed with binding buffer (500µL, 50mM TRIS, 
150mM NaCl, pH.= 7.5). After the washing, cell lysate obtained in section 6.1.3 (500 µL, 1 mg/ml) 
was added to the beads and incubated (1 h, 4°C, gentle rotation). The beads were washed with 
lysis buffer containing 75mM MgCl2 without β-mercaptoethanol (2 times, 10 min/time, gently 
rotation)  followed by additional washings with PBS (2 times, 10 min/time, gently rotation). For direct 
mass spectroscopy analysis, beads were collected and resuspendend in PBS (500 µL) and given to 
Monika Schmid directly. For in solution trypsin digestion the protocol in section 8.2.2 was followed.  
Alternatively, the beads were boiled in SDS loading buffer (50 µL, 95oC, 5 min, shaking) to release 
proteins from the solid support. The supernatant was collected in a new siliconized tube. In a 
Criterion precast gel 4-20% Gel (Biorad) SDS-PAGE, 40-45µl of the protein in SDS buffer were 
loaded on the gel and electrophoresis was performed. Gels were digested as described in section 
8.2.1. 
8.1.3 Pulldown using of photochemically-bound compound beads  
The functionalization of the beads has been performed via immobilization using photo-crosslinking. 
These beads were made by Tobias Zimmermann at the RIKEN Global Research Cluster in Wako, 
Japan. following the established protocol developed by Osada and colleagues (Kanoh et al., 2003). 
In a siliconized tube, homogenized beads (200 µL) were collected and washed with PBS (500 µL). It 
is important to note that these beads are not magnetic, in every step beads are allowed to settle and 
the buffers are carefully removed. After the removal of PBS, Cell lysate obtained in section 6.1.3 
(500 µL, 1 mg/ml) was added to the beads and incubated (1 h, 4°C, gentle rotation). The beads 
were washed with lysis buffer containing 75mM MgCl2 without β-mercaptoethanol (2 times, 10 
min/time, gently rotation)  followed by additional washings with PBS (2 times, 10 min/time, gently 
rotation). For direct mass spectroscopy analysis, beads were collected and resuspendend in PBS 
(500 µL) and given to Monika Schmid directly. For in solution trypsin digestion  the protocol in 
section 8.2.2 was followed. Alternatively, the beads were boiled in SDS loading buffer (50 µL, 95oC, 
5 min, shaking) to release proteins from the solid support. The supernatant was collected in a new 
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siliconized tube. In a Criterion precast gel 4-20% Gel (Biorad) SDS-PAGE, 40-45µl of the protein in 
SDS buffer were loaded on the gel and electrophoresis was performed. Gels were digested as 
described in section 8.2.1. 
8.2 Protein digestion methods for mass spectrometry analysis 
8.2.1  SDS gel trypsin digestion 
After the electrophoresis, the gel is placed in a Coomassie staining solution for proteomics (section 
1.4) and gently shaking (overnight, room temperature). The gel was destained with water until the 
background was clear. An image was collected of the Coomassie stained gel. Gel was cut in 10-15 
consecutive pieces (approximately 2mm in size) using a clean scalpel and placed into a siliconized 
tube. Gel pieces were covered with wash solution 1 (200 µL, 25 mM NH4HCO3 with acetonitrile in 
ratio 3:1, section 1.4) followed by incubation with shaking (30 min, 450 rpm, 37 °C). The washing 
solution was replaced with wash solution 2 (200 µL, 25 mM NH4HCO3 with acetonitrile in ratio 1:1 
section 1.4) and samples were shaken (30 min, 450 rpm, 37 °C). If necessary, the washing steps 
were repeated until the spots were completely destained. The following step was the reduction of 
the disulfide bonds in the proteins with freshly prepared reducing solution (100 µL, 50 mM DTT in 
25 mM NH4HCO3, section 1.4) was added to the destained gel pieces and incubated with shaking 
(45min, 450 rpm, 37 °C). After the reduction solution was removed, the gel pieces were alkylated 
(100 µL, 55 mM iodacetamide in 25 mM NH4HCO3, section 1.4) incubated in the dark (1-2 h, room 
temperature). The alkylation solution was removed and the gel pieces were washed while shaking 
with wash solution 2 (2 x 15 min, 450 rpm, room temperature). The wash solution 2 was completely 
removed, followed by the addition of acetonitrile (30 µL, 10 min) under the hood while the proteins 
were dried and the acetonitrile was removed using vacuum concentrator. To trypsinate the proteins, 
trypsination solution (15-30 µL, Trypsin stock solution:25 mM NH4HCO3, 9:1) was added to the dried 
gel spots and incubated (15 min, room temperature) and additional buffer is added (25 µL, 25 mM 
NH4HCO3) was added to the spots and samples were incubated while shaking (overnight, 30 °C). 
The tubes were placed in iced ultra-sonic bath for 30 min to extract the peptides. The peptide 
solution was collected in a new siliconized tube and TFA (3-5 µL, 10%) was added. The extraction 
procedure was repeated. The solution was collected in the same tubes as before. The peptides 
were dried in a vacuum concentrator and submitted for LC-MS/MS analysis.  
 
8.2.2 In solution trypsin digestion and stage tip purification 
After the beads were collected in the pulldown experiment (section 8.1), E1 fresh buffer (100 µL, 
E1 = 1.1 µL DTT stock + 13.75 µL trypsin stock (5 µg/mL) + 1085.15 µL urea stock, section 1.4) 
was added to the beads and incubated (1 h, room temperature, 350 rpm). The supernatant was 
transferred to new siliconized tube. Beads were collected and E2 buffer was added (100 µL,  E2 = 
11 µL chloracetamide stock + 1089 µL urea stock) and incubated (2 min, room temperature, 350 
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rpm). The supernatants were collected and combined. The tubes were placed in a thermomixer and 
incubated (overnight, 350 rpm, 37°C to RT). The reaction was stopped with TFA (2 µL).  For the 
generation of STAGE tips, two C18 filter disks were placed in a small petri-dish and stored sealed to 
avoid contaminations (Wisniewski et al., 2009). Using a STAGE tip syringe the layer of C18 filter 
disks were punctured through. The material was transferred to a yellow tip (1-200 µL) and pressed 
into the tip as far as possible. The yellow tip was placed onto an adapter on the top of a 150 µL 
tube. The tips were activated MeOH (100 µL), followed by an equilibration step with buffer A (100 
µL, 2 times, buffer A  = 0.1% formic acid in water, section 1.4)  and centrifuged (3 min, 5000 rpm). 
The pulldown sample was loaded (100 µL) followed by short incubation (1 min) and centrifuged (5 
min, 5000 rpm).  The tips were washed by adding buffer A (100 µL) and centrifuged (10 min, 2500 
rpm). The peptides were eluted by adding buffer B (20 µL, 2 times, 1 min/time,   buffer B = 20 % 
H2O + 80 % acetonitrile + 0.1% formic acid, section 1.4) and centrifuging (3 min, 5000 rpm). The 
peptides were dried in a vacuum concentrator and submitted for LC-MS/MS analysis. 
8.2.3 Mass spectrometry analysis  
Proteins enriched during the pulldowns were identified by means of mass spectrometry at two mass 
spectrometry facilities: Mass Spectrometry at the Max Planck Institute in Dortmund supervised by 
Petra Janning and Core Facility for Protein analysis at the Max Planck Institute for Infection Biology 
operated by Monika Schmid. For comparative purposes, Monika Schmid and Petra Janning 
coordinated their protocols.  
Samples were subjected to analysis using GC-MS/MS at the MPI for Infection Biology performed by 
Monika Schmid. Alternatively, samples were subjected to analysis using LC-MS/MS at the MPI of 
Molecular Physiology supervised by Dr. Petra Janning. 
8.3 Target validation experiment 
8.3.1 Protein binding of RAC2 detection via immunobloting  
The pulldown experiments using beads was performed as described in sections 8.1.  Cell lysates 
were collected according to section 6.1.3 and HL60 section 6.1.5, or pure RAC2 protein were used 
to perform the pulldown. Once the SDS is gels is done the RAC2 antibody (Millipore), at 
concentration indicated by manufacturer, immunoblot is performed following protocol from section 
7.3. The membranes were developed using chemiluminescence procedure and femto detection was 
usually required. 
 
9 In silico target prediction  
9.1 Similarity ensemble approach (SEA) 
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The Similarity ensemble approach (SEA, http://sea.bkslab.org) relates proteins to their ligands 
based on their chemical similarity. It is collaboration project by the Keiser and Shoichet groups. The 
tetraisoquinolines were subjected to this analysis (Keiser et al., 2007).  
9.2 Flexible alignment with Molecular Operating Environment (MOE) 
Flexible alignment for tetrahydroisoquinolines were subjected to alignments with known antagonist 
of GPCRs, i.e. Seratindol known 5-HT2 and dopamine, adregenic receptor binder,  performed with 
Molecular Operating Environment (MOE) Software Package. 
 
10 GPCR screening 
Based on the in-silico predictions, GPCR were suggested as a potential targets for the 
tetrahydroisoquinolines. After careful consideration a list GPCR of potential targets was generated 
and the most potent compound T1 was subjected to GPCR screening at the company CEREP. The 
purpose of this study was to test T1 in binding and cellular and nuclear receptor functional assays.  
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11 Synthetic Chemistry 
11.1 Synthesis of probes P3, P4 and P5 
 
 
 
Scheme 1: Synthesis of probes P3, P4, and P5. 
 
 
All chemicals were obtained from Acros, Aldrich, Alfa Aesar or Merck and were used without further 
purification. Solvents were used as received. 1H and 13C NMR spectra were recorded on a Varian 
Mercury 400- or a Bruker DRX 500 NMR spectrometer. Chemical shifts are reported in δ values 
relative to residual solvent peaks (Abbreviations: s: singlet, bs: broad singlet, bd: broad doublet, d: 
doublet, dd: doublet of doublets, dt: doublet of triplets, t: triplet, q: quartet, m: multiplet). Column 
chromatography was performed using silica gel for chromatography (0.035-0.070 mm, 60A) 
purchased from Acros Organic. Compounds on TLC were visualized by UV and/or basic KMnO4 
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staining. High resolution mass spectra (HR-MS, 70 eV) were measured on a Thermo Orbitrap, 
coupled to a Thermo Accela nano-HPLC machine, using electron spray ionization (ESI). Analytical 
HPLC-MS data were recorded on an Agilent HPLC (1100 series) coupled to a Finnigan LCQ ESI 
spectrometer, using a Nucleodur C18 gravity column, ID 4 mm, length 125 mm, particle size 3 μm 
from Macherey-Nagel. A gradient was applied beginning at 10% acetonitrile and ending at 90% 
after 15 min, followed by 3 min at 90% acetonitrile; finally, the column was washed for 5 min with 
100% acetonitrile. The column was equilibrated for 3 min with 10% acetonitrile. All RP-HPLC 
solvents contained TFA (0.1% v/v). Preparative HPLC purifications were performed with an Agilent 
1100 series instrument, connected to an Agilent MSD VL mass spectrometer andequipped with a 
fraction collector. All RP-HPLC solvents contained TFA (0.1% v/v) and products with basic amines 
were isolated as a TFA salt. 
 
 
 
 
 
 
tert-butyl 1-((3-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)ethynyl)-7-methoxy-3,4-
dihydroisoquinoline-2(1H)-carboxylate (2) 70 mg (0.24 mmol) 1 was dissolved in 4 ml dry THF. 
113 mg (0.3 mmol) 8 in 2 ml THF, 70 µl (0.5 mmol) TEA and 4 mg (0.024 mmol) CuI were added 
and argon was bubbled through the solution for 5 minutes before adding 20 mg (0.024 mmol) 
Pd(PPh3)4 and the RM was stirred overnight at 65 ºC. The RM was concentrated and the product 
was purified over silica(cHex/EtOAc 7:3) obtaining 86 mg (66%) 2. 1H-NMR (400 MHz, CDCl3): δ 
7.15 (t, J = 7.9 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 7.6 Hz, 2H), 6.92 (s, 2H), 6.89 – 6.82 
(m, 4H), 6.78 (dd, J = 8.4, 2.6 Hz, 2H), 4.11 (dt, J = 11.1, 5.6 Hz, 10H), 3.87 – 3.81 (m, 4H), 3.80 (s, 
6H), 3.72 (dd, J = 5.9, 3.0 Hz, 4H), 3.67 (dd, J = 6.9, 3.7 Hz, 9H), 3.41 – 3.32 (m, 5H), 2.89 (s, 2H), 
2.73 (d, J = 15.7 Hz, 2H), 1.51 (s, 19H): 13C NMR (101 MHz, CDCl3): δ 171.26, 158.64, 158.36, 
130.17, 129.41, 124.74, 124.10, 117.57, 115.67, 114.12, 112.26, 88.73, 77.57, 77.25, 76.93, 71.04, 
70.31, 69.97, 67.71, 60.56, 55.59, 50.90, 28.67, 27.91, 27.13, 21.21, 14.39. ESI HRMS calculated 
for C29H37O6N4 [M+H]
+ = 537.27076. Mass found [M+H]+ = 537.27176. 
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2-(2-(2-(3-((7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-
yl)ethynyl)phenoxy)ethoxy)ethoxy)ethan-1-amine (P3) 60 mg (0.11 mmol) 2 was dissolved in 
THF and 30 mg (0.11 mmol) PPh3 was added. The RM was stirred overnight at RT. 50 µl water was 
added and the RM was stirred overnight. The RM was evaporated to dryness and the residue was 
dissolved in 2.5 ml DMF obtaining a 0.044M solution of the reduced azide. 1 ml of the solution was 
treated with 1 ml 2.0 M HCl in ether (2 mmol) and the RM was stirred overnight. The RM was 
evaporated to dryness and the product was purified using preparative HPLC obtaining 14 mg P3 
(61% yield) as a TFA salt. 1H NMR (400 MHz, CDCl3): δ 8.39 – 7.89 (m, 3H), 7.22 – 7.16 (m, 2H), 
7.08 (d, J = 8.6 Hz, 4H), 7.02 (d, J = 7.7 Hz, 2H), 6.96 (d, J = 2.5 Hz, 2H), 6.89 (d, J = 8.3 Hz, 2H), 
6.85 (dd, J = 8.5, 2.6 Hz, 2H), 5.50 (s, 2H), 4.17 – 4.05 (m, 4H), 3.79 (d, J = 8.2 Hz, 11H), 3.64 (dd, 
J = 12.5, 5.4 Hz, 18H), 3.42 (s, 3H), 3.02 (d, J = 15.5 Hz, 10H), 2.48 (s, 13H). 13C NMR (101 MHz, 
CDCl3): δ 159.25, 158.73, 130.40, 130.14, 129.83, 124.91, 123.25, 122.45, 118.94, 116.71, 115.77, 
112.40, 88.64, 82.46, 70.75, 70.24, 69.88, 67.67, 66.85, 55.86, 48.19, 40.52, 39.89, 24.72. ESI 
HRMS calculated for C24H31O4N2 [M+H]
+ = 411.22783. Mass found [M+H]+ = 411.22814. 
 
 
 
 
 
6-(3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)-N-(2-(2-(2-(3-((7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-
yl)ethynyl)phenoxy)ethoxy)ethoxy)ethyl)hexanamide (P5) 0.5 ml of a 0.044M solution of Boc 
protected P3 in DMF was treated with 15 mg (0.025 mmol) bodipy-OSu and 5 µl (0.036 mmol) TEA. 
The RM was stirred overnight in a dark reaction vial. 250 µl 2M HCl in ether (0.5 mmol) added and 
the RM was stirred overnight at RT. The mixture was concentrated and taken up in methanol. The 
product was purified using preparative HPLC and 10 mg P5 (55 % yield) was obtained as a white 
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solid. ESI HRMS calculated for C44H55O6N5BF2 [M+H]
+ = 798.42080. Mass found [M+H]+ = 
798.42095. 
 
 
 
 
 
 
 
2-(2-(2-azidoethoxy)ethoxy)ethanol (7) 38.6 g (257 mmol) triethylene glycol (6) was dissolved in 
250 mL anhydrous THF under argon atmosphere and cooled to 0 0C. 5.0 mL methanesulfonyl 
chloride (64.4 mmol) and 9.0 mL TEA (64.4 mmol) were added dropwise. The RM was allowed to 
stir at room temperature overnight under an argon atmosphere. The reaction mixture was 
concentrated and the residue was dissolved in 250 mL dry ethanol. 20.9 g sodium azide (322.0 
mmol) was added and the reaction mixture was heated to reflux for 6 hours. After cooling to room 
temperature the mixture was concentrated and dissolved in water. The product was extracted with 
DCM (3x), and the combined organic fractions were dried over magnesium sulfate, filtered, and 
concentrated to yield 5.1 g 7 as a sticky oil (45% yield from methanesulfonyl chloride). Rf = 0.20 
(100% EtOAc); 1H-NMR(400 MHz, CDCl3) δ: 3.77 (t, J = 5.8 Hz, 2H), 3.72 – 3.66 (m, 6H), 3.64 (t, J 
= 5.8 Hz, 2H), 3.39 (t, J = 5.0 Hz, 2H), 1.57 (s, 1H).  
 
 
 
 
 
 
2-(2-(2-(3-((6,7-dimethoxy-1,2,3,4-1-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-3-iodobenzene (8) 
2.0 g (11.4 mmol) 7, 2.1 g (11.4 mmol) tosyl chloride were dissolved in 10 mL pyridine. The RM was 
stirred overnight at RT under argon. The RM was poured into sat. NaHCO3(aq) (60 mL) and was 
extracted with EtOAc (3x 50 mL). The combined EtOAc was dried over MgSO4(s) and evaporated. 
The residue was dissolved in 20 mL DMF and 2.8 g 3-iodophenol (12.5 mmol), 4.1 g cesium 
carbonate (12.5 mmol) and 0.36 g potassium iodide (2.3 mmol) were added. The RM was stirred for 
8 hours at RT. The RM was diluted with EtOAc (150 mL) and washed with sat. NaHCO3(aq) (100 
mL). The EtOAc was dried over MgSO4(s) and evaporated to dryness. The residue was purified 
over silica (cHex/EtOAc 7:3) obtaining 2.0 g (46 % yield) 8. 
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1-ethynyl-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (4) 300 mg iodine salt 3 (0.99 
mmol) was dissolved in 3 mL dry THF under argon. The RM was cooled to 0oC and 5.9 mL 0.5 M 
ethynyl magnesiumbromide solution (2.97 mmol) was added dropwise. The RM was stirred 30 min. 
and allowed to reach RT. The RM was diluted with EtOAc (20 mL) and washed with sat. 
NaHCO3(aq) (50 mL). The EtOAc was dried over MgSO4(s) and evaporated to dryness obtaining 
147 mg (73 % yield) 4. 
 
 
 
2-(2-(2-(3-((7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-
yl)ethynyl)phenoxy)ethoxy)ethoxy)ethan-1-amine (P4) 24 mg (0.11mmol) 4 was dissolved in 1 
ml THF. 67 mg (0.15mmol) iodide in 0.5 ml THF, 31 µl (0.22 mmol) TEA and 2 mg (0.011 mmol) CuI 
were added and argon was bubbled through the solution before adding 12 mg (0.011mmol) 
Pd(PPh3)4 and the RM was stirred overnight at 65 
oC. The solution was treated with 1 ml 2.0 M HCl 
in ether (2 mmol) and the RM was stirred overnight. The RM was evaporated to dryness and the 
product was purified using preparative HPLC obtaining 14 mg P4 (30 % yield) as a TFA salt. 1H 
NMR (400 MHz, CDCl3): δ 8.25 – 7.94 (m, 15H), 7.20 (d, J = 8.1 Hz, 8H), 7.11 (d, J = 9.3 Hz, 7H), 
7.02 (d, J = 8.0 Hz, 14H), 6.94 (s, 8H), 6.89 (d, J = 6.4 Hz, 14H), 5.73 – 5.65 (m, 2H), 5.62 – 5.44 
(m, 6H), 4.11 (s, 16H), 3.80 (d, J = 7.6 Hz, 44H), 3.74 – 3.60 (m, 55H), 3.59 – 3.45 (m, 9H), 3.31 – 
3.14 (m, 11H), 3.09 (s, 23H), 3.02 (s, 20H).13C NMR (101 MHz, CDCl3): δ 159.54, 158.90, 130.63, 
130.13, 125.10, 122.14, 121.62, 118.47, 117.56, 116.34, 112.73, 70.74, 70.29, 69.88, 67.64, 66.88, 
55.85, 48.42, 40.03. ESI HRMS calculated for C25H33O4N2 [M+H]
+ = 425.24348. Mass found [M+H]+ 
= 425.24385. 
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